<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN"  "JATS-archivearticle1-3-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">106397</article-id><article-id pub-id-type="doi">10.7554/eLife.106397</article-id><article-id pub-id-type="doi" specific-use="version">10.7554/eLife.106397.3</article-id><article-version article-version-type="publication-state">version of record</article-version><article-categories><subj-group subj-group-type="display-channel"><subject>Tools and Resources</subject></subj-group><subj-group subj-group-type="heading"><subject>Biochemistry and Chemical Biology</subject></subj-group></article-categories><title-group><article-title>Deep learning reveals endogenous sterols as allosteric modulators of the GPCR–Gα interface</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Mohanty</surname><given-names>Sanjay Kumar</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-1375-2223</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Mittal</surname><given-names>Aayushi</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-1973-8553</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Farooqi</surname><given-names>Namra</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0009-0000-8650-0249</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Gaur</surname><given-names>Aakash</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Duari</surname><given-names>Subhadeep</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-9805-7635</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Solanki</surname><given-names>Saveena</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-1079-9349</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Sharma</surname><given-names>Anmol Kumar</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0009-0007-2860-9407</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Arora</surname><given-names>Sakshi</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-7535-3597</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Kumar</surname><given-names>Suvendu</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-4405-8402</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Gautam</surname><given-names>Vishakha</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-4755-0291</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Dixit</surname><given-names>Nilesh Kumar</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Subramanian</surname><given-names>Karthika</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Ghosh</surname><given-names>Tarini Shankar</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Sengupta</surname><given-names>Debarka</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-6353-5411</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con14"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Gupta</surname><given-names>Shashi Kumar</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con15"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Murugan</surname><given-names>Arul Natarajan</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con16"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Sharma</surname><given-names>Deepak</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-1104-575X</contrib-id><email>deepaks@imtech.res.in</email><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con17"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Ahuja</surname><given-names>Gaurav</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-2837-9361</contrib-id><email>gaurav.ahuja@iiitd.ac.in</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con18"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03vfp4g33</institution-id><institution>Department of Computational Biology, Indraprastha Institute of Information Technology-Delhi (IIIT-Delhi)</institution></institution-wrap><addr-line><named-content content-type="city">New Delhi</named-content></addr-line><country>India</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/053rcsq61</institution-id><institution>Academy of Scientific and Innovative Research (AcSIR)</institution></institution-wrap><addr-line><named-content content-type="city">Ghaziabad</named-content></addr-line><country>India</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/055rjs771</institution-id><institution>CSIR-Institute of Microbial Technology, Sector-39A</institution></institution-wrap><addr-line><named-content content-type="city">Chandigarh</named-content></addr-line><country>India</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04t8qjg16</institution-id><institution>Pharmacology Division, CSIR-Central Drug Research Institute</institution></institution-wrap><addr-line><named-content content-type="city">Lucknow</named-content></addr-line><country>India</country></aff><aff id="aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03vfp4g33</institution-id><institution>Infosys Centre for AI, Indraprastha Institute of Information Technology-Delhi (IIIT-Delhi)</institution></institution-wrap><addr-line><named-content content-type="city">Delhi</named-content></addr-line><country>India</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Elgeti</surname><given-names>Matthias</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03s7gtk40</institution-id><institution>Leipzig University</institution></institution-wrap><country>Germany</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Cui</surname><given-names>Qiang</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05qwgg493</institution-id><institution>Boston University</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><author-notes><fn fn-type="con" id="equal-contrib1"><label>†</label><p>These authors contributed equally to this work</p></fn></author-notes><pub-date publication-format="electronic" date-type="publication"><day>08</day><month>12</month><year>2025</year></pub-date><volume>14</volume><elocation-id>RP106397</elocation-id><history><date date-type="sent-for-review" iso-8601-date="2025-02-18"><day>18</day><month>02</month><year>2025</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint.</event-desc><date date-type="preprint" iso-8601-date="2024-03-07"><day>07</day><month>03</month><year>2024</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2023.02.14.528587"/></event><event><event-desc>This manuscript was published as a reviewed preprint.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2025-05-30"><day>30</day><month>05</month><year>2025</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.106397.1"/></event><event><event-desc>The reviewed preprint was revised.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2025-10-30"><day>30</day><month>10</month><year>2025</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.106397.2"/></event></pub-history><permissions><copyright-statement>© 2025, Mohanty, Mittal, Farooqi et al</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Mohanty, Mittal, Farooqi et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-106397-v1.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-106397-figures-v1.pdf"/><abstract><p>Endogenous intracellular allosteric modulators of GPCRs remain largely unexplored, with limited binding and phenotype data available. This gap arises from the lack of robust computational methods for unbiased cavity identification, cavity-specific ligand design, synthesis, and validation across GPCR topology. Here, we developed Gcoupler, an AI-driven generalized computational toolkit that leverages an integrative approach combining de novo ligand design, statistical methods, Graph Neural Networks, and bioactivity-based ligand prioritization for rationally predicting high-affinity ligands. Using Gcoupler, we interrogated intracellular metabolites that target and regulate the GPCR–Gα interface (Ste2p–Gpa1p), affecting pheromone-induced programmed cell death in yeast. Our computational analysis, complemented by experimental validations, including genetic screening, multi-omics, site-directed mutagenesis, biochemical assays, and physiological readouts, identified endogenous hydrophobic metabolites, notably sterols, as direct intracellular allosteric modulators of Ste2p. Molecular simulations coupled with biochemical signaling assessment in site-directed Ste2p mutants further confirmed that metabolites binding to GPCR–Gα obstruct downstream signaling, possibly via a cohesive effect. Finally, by utilizing isoproterenol-induced, GPCR-mediated human and neonatal rat cardiac hypertrophy models, we observed that elevated metabolite levels attenuate hypertrophic response, reinforcing the evolutionary relevance of this mechanism.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>programmed cell death</kwd><kwd>deep learning</kwd><kwd>GPCR</kwd><kwd>hypertrophy</kwd><kwd>mating</kwd><kwd>yeast</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd><kwd>Rat</kwd><kwd><italic>S. cerevisiae</italic></kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03emtbt60</institution-id><institution>Department of Biotechnology, Ministry of Science and Technology, India</institution></institution-wrap></funding-source><award-id>BT/HRD/35/02/2006</award-id><principal-award-recipient><name><surname>Ahuja</surname><given-names>Gaurav</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03ffdsr55</institution-id><institution>Science and Engineering Research Board</institution></institution-wrap></funding-source><award-id>SRG/2020/000232</award-id><principal-award-recipient><name><surname>Ahuja</surname><given-names>Gaurav</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03emtbt60</institution-id><institution>Department of Science and Technology, Ministry of Science and Technology, India</institution></institution-wrap></funding-source><award-id>BT/RLF/re-entry/14/2019</award-id><principal-award-recipient><name><surname>Ahuja</surname><given-names>Gaurav</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution>IHUB Anubhuti</institution></institution-wrap></funding-source><award-id>IHUB Anubhuti/Project Grant/23</award-id><principal-award-recipient><name><surname>Ahuja</surname><given-names>Gaurav</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection, and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>An AI-driven computational toolkit, Gcoupler, integrates ligand design, statistical modeling, and graph neural networks to predict endogenous metabolites that allosterically modulate the GPCR–Gα interface and regulate downstream signaling.</meta-value></custom-meta><custom-meta specific-use="meta-only"><meta-name>publishing-route</meta-name><meta-value>prc</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>G-protein-coupled receptors (GPCRs) are critical regulators of cellular processes and thus represent prime drug targets (<xref ref-type="bibr" rid="bib85">Yang et al., 2021</xref>; <xref ref-type="bibr" rid="bib4">Alhosaini et al., 2021</xref>; <xref ref-type="bibr" rid="bib14">Calebiro et al., 2021</xref>). While traditional GPCR-targeted therapies focus on orthosteric sites, recent advances have revealed allosteric sites offering novel therapeutic avenues (<xref ref-type="bibr" rid="bib80">Wold and Zhou, 2018</xref>; <xref ref-type="bibr" rid="bib13">Bourque et al., 2022</xref>; <xref ref-type="bibr" rid="bib13">Bourque et al., 2022</xref>; <xref ref-type="bibr" rid="bib56">Rees et al., 2002</xref>; <xref ref-type="bibr" rid="bib42">Leach et al., 2007</xref>). Although exogenous synthetic allosteric modulators are known, endogenous counterparts remain poorly characterized (<xref ref-type="bibr" rid="bib75">van der Westhuizen et al., 2015</xref>; <xref ref-type="bibr" rid="bib68">Stornaiuolo et al., 2015</xref>; <xref ref-type="bibr" rid="bib21">Doller, 2017</xref>; <xref ref-type="bibr" rid="bib57">Reyes-Alcaraz et al., 2020</xref>; <xref ref-type="bibr" rid="bib90">Zhang et al., 2015</xref>; <xref ref-type="bibr" rid="bib52">O’Callaghan et al., 2012</xref>). Developing high-affinity endogenous modulators requires integrating structure-based design, artificial intelligence (AI), and assays, yet traditional approaches like SAR analysis are hampered by limited GPCR allosteric modulator data (<xref ref-type="bibr" rid="bib8">Basith et al., 2018</xref>; <xref ref-type="bibr" rid="bib28">Gupta et al., 2021</xref>). While experimental techniques like FRET and BRET can validate allosteric compounds, their use in high-throughput screening for novel intracellular modulators is challenging (<xref ref-type="bibr" rid="bib91">Zhou et al., 2021</xref>; <xref ref-type="bibr" rid="bib31">Hoffmann and Bünemann, 2010</xref>; <xref ref-type="bibr" rid="bib34">Jaeger et al., 2010</xref>). Identifying endogenous GPCR allosteric modulators is further complicated by factors like incomplete GPCR topology data (<xref ref-type="bibr" rid="bib19">Congreve et al., 2020</xref>) and vast chemical space (<xref ref-type="bibr" rid="bib72">Topiol, 2018a</xref>; <xref ref-type="bibr" rid="bib85">Yang et al., 2021</xref>). This necessitates a hybrid computational approach combining allosteric site prediction, de novo ligand synthesis, and efficient screening, potentially enhanced by AI. Existing de novo drug design tools often lack practical applicability for this purpose due to computational limitations and high technical demands (<xref ref-type="bibr" rid="bib66">Spiegel and Durrant, 2020</xref>; <xref ref-type="bibr" rid="bib62">Sicho et al., 2021</xref>; <xref ref-type="bibr" rid="bib44">Li et al., 2021</xref>; <xref ref-type="bibr" rid="bib12">Böhm, 1992</xref>; <xref ref-type="bibr" rid="bib50">Nishibata and Itai, 1991</xref>; <xref ref-type="bibr" rid="bib54">Pearlman and Murcko, 1993</xref>; <xref ref-type="bibr" rid="bib86">Yuan et al., 2011</xref>).</p><p>To overcome these challenges, we developed Gcoupler, a software suite (available as a Python package and Docker image) that integrates structural biology, statistical methods, and deep learning to identify GPCR allosteric modulators. We demonstrated the usability and applicability of Gcoupler in identifying novel endogenous modulators of GPCRs by exploiting the α-pheromone (α-factor)-induced mating or programmed cell death (PCD) pathway of <italic>Saccharomyces cerevisiae</italic>. Notably, it is well documented that the highly elevated, non-physiological levels of α-factor trigger PCD in less than half of the MATa population (<xref ref-type="bibr" rid="bib89">Zhang et al., 2006</xref>). Moreover, an equivalent concentration of α-factor triggers distinct PCD kinetics across distinct laboratory strains; for example, BY4741 is more resistant than the W303 strain (<xref ref-type="bibr" rid="bib64">Sokolov et al., 2020</xref>). We, therefore, hypothesized that a subset of pheromone-resistant cells might regulate the Ste2p-mediated PCD signaling via the endogenous intracellular metabolites by operating at the Ste2–Gα-binding interface. Using Gcoupler, we identified a subset of intracellular metabolites that could potentially bind to Ste2p (GPCR) at the Gpa1 (Gα)-binding interface and obstruct the downstream signaling. Our computational results further suggest that hydrophobic ligands such as sterols strengthen the Ste2p–Gpa1p binding and might trigger a cohesive response that potentially obstructs downstream signaling. Experimental evidence further supported these findings that the elevated intracellular levels of these metabolites rescue the pheromone-induced PCD. To evaluate the evolutionary conservation and possible clinically relevant translation of this mechanism, we tested these metabolites on human and rat isoproterenol-induced, GPCR-mediated cardiac hypertrophy model systems and observed attenuated response in the cardiomyocytes pretreated with GPCR–Gα-protein interface modulating metabolites.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Development and validation of Gcoupler</title><p>Designing novel target molecules by integrating the topological, chemical, and physical attributes of protein cavities necessitates advanced neural networks. While existing approaches like Bicyclic Generative Adversarial Networks (BicycleGANs) (<xref ref-type="bibr" rid="bib63">Skalic et al., 2019</xref>) and Recurrent Neural Networks (RNNs) (<xref ref-type="bibr" rid="bib83">Xu et al., 2021</xref>) have demonstrated potential, end-to-end standalone tools for GPCR-specific ligand design remain scarce. To address this, we developed the Gcoupler and provided it to the community as a Python Package and a Docker image. Gcoupler adopts an integrative approach utilizing structure-based, cavity-dependent de novo ligand design, robust statistical methods, and highly powerful Graph Neural Networks. Gcoupler consists of four interconnected modules, that is, Synthesizer, Authenticator, Generator, and BioRanker, that collectively impart a smoother, user-friendly, and minimalistic experience for the end-to-end de novo ligand design.</p><p>Synthesizer, the first module of Gcoupler, takes a protein structure as input in Protein Data Bank (PDB) format and identifies putative cavities across the protein surface, providing users with the flexibility to select cavities based on druggability scores or user-supplied critical residues. Since cavity-dependent molecule generation mainly depends on the chemical composition and geometric constraints of the cavity, it is, therefore, indispensable to select the cavity for the downstream steps considering its chemical nature (hydrophobicity/hydrophilicity) and functional relevance (proximity to the active site or residue composition), among others. Accounting for these, Gcoupler offers flexibility to the users to select either of its predicted cavities based on the user-supplied critical residue or by user-supplied cavity information (amino acids) using third-party software (e.g., Pocketome) (<xref ref-type="bibr" rid="bib29">Hedderich et al., 2022</xref>). To enhance user experience, Gcoupler computes and outputs all identified cavities along with their druggability scores using LigBuilder’s V3 (<xref ref-type="bibr" rid="bib87">Yuan et al., 2020</xref>) cavity module. Briefly, these druggability scores consider solvent accessibility, cavity exposure or burial, and detected pharmacophores and cavities, which are further prioritized based on this score. Post-cavity selection, the Synthesizer module generates cavity-specific ligands influenced by topology and pharmacophores, outputting SMILES, cavity coordinates, and other requisite files to downstream modules for further steps (<xref ref-type="fig" rid="fig1">Figure 1a</xref>). The chemical composition of the in silico synthesized ligands by the Synthesizer module is influenced by the cavity topology (3D) and its composition (pharmacophores). Noteworthy, the Synthesizer module of Gcoupler employs LigBuilder V3 (<xref ref-type="bibr" rid="bib87">Yuan et al., 2020</xref>), which utilizes the genetic algorithm for the in silico ligand synthesis. Notably, the fragment library of LigBuilder, comprising 177 distinct molecular fragments in Mol2 format, allows the selection of multiple seed structures and extensions that best complement the cavity pharmacophores throughout multiple iterative runs. For each run, once a seed structure is confirmed, Gcoupler employs a hybrid approach of the Growing and Linking modes of the LigBuilder build module, enabling the stepwise addition of small fragments to the seed structure within the binding pocket of the target GPCR to build synthetic ligands. Gcoupler generates 500 unique molecules by default, though it can also be user-defined. The Synthesizer module of Gcoupler enhances LigBuilder V3 practical applicability through automation, dynamic adaptability, and abstraction. This allows for more efficient and targeted ligand generation, even in challenging design scenarios for GPCR ligand design. However, it lacks user-defined library screening, proposes synthetically challenging molecules, and often requires post-processing to isolate High-Affinity Binders () from a broad affinity range of synthetically designed compounds.</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Development, benchmarking, and validation of Gcoupler computational framework.</title><p>(<bold>a</bold>) Schematic workflow depicting different modules of the Gcoupler package. Of note, Gcoupler possesses four major modules, that is, Synthesizer, Authenticator, Generator, and BioRanker. (<bold>b</bold>) AUC–ROC curves of the finally selected model for each of the indicated GPCRs. Note: Experimentally validated active ligands and decoys were used in the testing dataset. (<bold>c</bold>) Bar graphs depicting the sensitivities and specificities of the indicated GPCRs with experimentally validated active ligands and reported decoys. (<bold>d</bold>) The AUC–ROC curve indicates the model’s performance in the indicated conditions. (<bold>e</bold>) Bar graphs indicating the prediction probabilities for each experimentally validated ligand. (<bold>f</bold>) Schematic workflow illustrates the steps in measuring and comparing the structural conservation of the GPCR–Gα-protein interfaces across human GPCRs. (<bold>g</bold>) Snake plot depicting the standard human GPCR two-dimensional sequence level information. Conserved motifs of the GPCR–Gα-protein interfaces are depicted as WebLogo. Asterisks represent residues of conserved motifs present in the GPCRs–Gα-protein interfaces. Of note, the location of the motifs indicated in the exemplary GPCR snake plot is approximated. (<bold>h</bold>) Schematic workflow illustrates the steps in measuring and comparing the structural conservation of the GPCR–Gα-protein interfaces across human GPCRs. (<bold>i</bold>) Representative structures of the proteins depicting highly conserved (low root mean square deviation [RMSD]) and highly divergent (high RMSD) GPCR–Gα-protein interfaces. PDB accession numbers are indicated at the bottom. (<bold>j</bold>) Heatmap depicting the RMSD values obtained by comparing all the GPCR–Gα-protein interfaces of the available human GPCRs from the protein databank. Of note, the RMSD of the Gα–protein cavity was normalized with the RMSDs of the respective whole proteins across all pairwise comparisons. (<bold>k</bold>) Heatmap depicting the pairwise cosine similarities between the in silico synthesized ligands of the GPCR–Gα-protein interfaces of the available human GPCRs using Gcoupler. (<bold>l</bold>) Schematic diagram depicting the hypothesis that the intracellular metabolites could allosterically modulate the GPCR–Gα interaction.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-106397-fig1-v1.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Gcoupler benchmarking using experimentally validated orthosteric ligands of GPCRs.</title><p>(<bold>a</bold>) AUC–ROC curves depicting the optimal probability cutoff recommended by <italic>G</italic>-means and Youden <italic>J</italic> index algorithms, respectively. Notably, the optimal threshold is indicated by the black dot on the ROC curve. (<bold>b</bold>) Molecular representation depicting the indicated experimentally validated orthosteric sites of the AA2AR, ADRB1, ADRB2, CXCR4, and DRD3 receptors, with the zoom-in inlet on the right highlighting the ligand and the cavity topologies. (<bold>c</bold>) Overlapping density plots comparing the distributions of synthetic compounds predicted to target the indicated receptors into High-Affinity Binders (HABs) and Low-Affinity Binders (LABs) using the Authenticator module of the Gcoupler package. (<bold>d</bold>) Bar graphs indicating the performance of the indicated models made for the experimentally elucidated orthosteric sites of the indicated GPCRs, generated using the Gcoupler workflow. (<bold>e</bold>) Confusion matrices indicating the relative proportions of experimentally determined ligands and their respective decoys (randomly selected to match # of ligands for each receptor). Note that the number of active ligands and decoys is mentioned at the bottom.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-106397-fig1-figsupp1-v1.tif"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 2.</label><caption><title>Gcoupler benchmarking using experimentally validated allosteric ligands of GPCRs.</title><p>(<bold>a</bold>) Molecular representation of the β2AR, CCR2, and CCR9 receptors with highlighted experimentally validated intracellular allosteric cavity and ligand. (<bold>b</bold>) Overlapping density plots comparing the distributions of synthetic High-Affinity Binders (HABs) and Low-Affinity Binders (LABs) predicted to target the allosteric cavities of the indicated GPCRs using the Gcoupler package. (<bold>c</bold>) Bar graphs depicting the performance metrics of the indicated classification model generated using Gcoupler for the highlighted allosteric cavities of the indicated proteins.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-106397-fig1-figsupp2-v1.tif"/></fig><fig id="fig1s3" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 3.</label><caption><title>Run time comparison of Gcoupler and AutoDock.</title><p>(<bold>a</bold>) Flowchart depicting the entire workflow used to compute and compare the runtime using AutoDock and Gcoupler. Of note, the Synthesizer, Authenticator, and Generator module of Gcoupler are indicated alongside their key processes. (<bold>b</bold>) Ribbon diagram depicting the ADRA1A predicted structure using AlphaFold (ID: AF-P35348). (<bold>c</bold>) A waterfall chart depicts the timestamp information about the key steps involved in AutoDock. Time consumed at the indicated steps is mentioned in seconds and hours along the <italic>y</italic>-axis and above bars, respectively. (<bold>d</bold>) Waterfall chart depicting the timestamp information about the key steps involved in Gcoupler. Time consumed at the indicated steps is mentioned in seconds and hours along the <italic>y</italic>-axis and above bars, respectively. (<bold>e</bold>) Bar plot depicting the comparison between the total time consumed by the AutoDock and Gcoupler to predict the binding of experimentally validated ligands for ADRA1A (AF-P35348). (<bold>f</bold>) Box plot depicting the performance metrics of the 10-fold cross-validation of the training data obtained using Gcoupler. (<bold>g</bold>) Box plot depicting the performance metrics of the 10-fold cross-validation of the testing data obtained using Gcoupler. (<bold>h</bold>) Scatterplot depicting the relationship between AutoDock computed binding energies and Gcoupler computed prediction probabilities of the experimentally validated ligands of ADRA1A protein. (<bold>i</bold>) Density plot depicting the distribution of root mean square deviation (RMSD) between GPCR–Gα cavity across selected GPCRs–G-protein pairs. Of note, the RMSD of the Gα-protein cavity was normalized with the RMSDs of the respective whole proteins across all pairwise comparisons. (<bold>j</bold>) Heatmap depicting the RMSD values obtained by comparing all the GPCR–Gα-protein interfaces of the available human GPCRs from the protein data bank. (<bold>k</bold>) Heatmap depicting the RMSD values obtained by comparing the selected human GPCRs available in the protein data bank. (<bold>l</bold>) Density plot depicting the distribution of cosine similarities among the in silico synthesized ligands of the GPCR–Gα-protein interfaces of the available human GPCRs using Gcoupler.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-106397-fig1-figsupp3-v1.tif"/></fig></fig-group><p>To address this limitation, a second module was added to Gcoupler, termed Authenticator. This module processes output files from the Synthesizer module, conducting downstream validation steps and preparing results for constructing deep learning-based classification models (third module). The Authenticator requires input protein 3D structure in PDB format, cavity coordinates, and all silico-generated molecules from the Synthesizer module. Authenticator utilizes this information to further segregate the synthesized compounds into HABs and Low-Affinity Binders (LABs) by leveraging a structure-based virtual screening approach (AutoDock Vina) (<xref ref-type="bibr" rid="bib74">Trott and Olson, 2010</xref>) and statistically backed hypothesis testing for distribution comparisons (<xref ref-type="fig" rid="fig1">Figure 1a</xref>). The Authenticator module outputs the free binding energies of all the generated compounds, which further segregates the compounds into HABs and LABs by the statistical submodule while ensuring the optimal binding energy threshold and class balance. Of note, the Authenticator is also capable of leveraging the Empirical Cumulative Distribution Function (ECDF) for binding energy distribution comparisons of HABs and LABs and performs the Kolmogorov–Smirnov test (<xref ref-type="bibr" rid="bib10">Berger and Zhou, 2014</xref>), Epps–Singleton test (<xref ref-type="bibr" rid="bib27">Goerg and Kaiser, 2009</xref>), and Anderson–Darling test (<xref ref-type="bibr" rid="bib23">Engmann and Cousineau, 2011</xref>) for hypothesis testing. This expanded array of statistical tests allows users to employ methodologies that best suit their data distribution characteristics, ensuring robust and comprehensive analyses. Moreover, the Authenticator module incorporates a unique feature for decoy synthesis using HABs. This functionality enables the generation of a negative dataset in scenarios where the Synthesizer module fails to produce an optimal number of LABs. By synthesizing decoys from HABs, users can effectively balance their datasets, enhancing the reliability of downstream analyses. Lastly, the Authenticator module also accommodates user-supplied negative datasets as an alternative to LABs (<xref ref-type="bibr" rid="bib48">Mysinger et al., 2012</xref>). This feature provides users with the flexibility to incorporate external data sources, enabling robust prediction model building by the subsequent Generator module.</p><p>The Generator, the third module, employs state-of-the-art GNN models such as Graph Convolution Model (GCM), Graph Convolution Network (GCN), Attentive FP (AFP), and Graph Attention Network (GAT) to construct predictive classifiers using Authenticator-informed classes. These GNN algorithms are tailored to extract features from the graph structure of the compounds generated by the Synthesizer and apply them to the classification task by leveraging Authenticator-informed class information. For instance, the GCM assimilates features by analyzing neighboring nodes, while the GCN extracts features through a convolutional process. The AFP model focuses attention on specific graph segments, and the GAT employs attention mechanisms to learn node representations. By default, Generator tests all four models using standard hyperparameters provided by the DeepChem framework (<ext-link ext-link-type="uri" xlink:href="https://deepchem.io/">https://deepchem.io/</ext-link>), offering a baseline performance comparison across architectures. This includes pre-defined choices for node features, edge attributes, message-passing layers, pooling strategies, activation functions, and dropout values, ensuring reproducibility and consistency. All models are trained with binary cross-entropy loss and support default settings for early stopping, learning rate, and batch standardization where applicable. Gcoupler provides off-the-shelf hyperparameter tuning to ensure adequate training, which is essential for optimizing model performance. After selecting the best parameters and classification algorithm, Gcoupler further ensures the mitigation of overfitting and provides a more precise estimate of model performance through <italic>k</italic>-fold cross-validation. Notably, by default, Gcoupler employs threefold cross-validation, but users can adjust this parameter.</p><p>Finally, BioRanker, the last module, prioritizes ligands through statistical and bioactivity-based tools. The first level ranking offered by BioRanker is composed of a statistical tool that encompasses two distinct algorithms, namely <italic>G</italic>-means and Youden’s <italic>J</italic> statistics, to assist users in identifying the optimal probability threshold, thereby refining the selection of high-confidence hit compounds (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1a</xref>). Additionally, bioactivity embeddings computed via Signaturizer (<xref ref-type="bibr" rid="bib11">Bertoni et al., 2021</xref>) enable multi-activity-based ranking using a modified PageRank algorithm. Briefly, the bioactivity descriptors of the predicted compounds are projected onto various biological activity spaces, including Chemistry, Targets, Networks, Cells, and Clinics, by performing pairwise cosine similarity comparisons with HABs. The PageRank algorithm is then applied for activity-specific ranking and supports multi-activity-based ranking for sequential screening based on user-defined biological properties. BioRanker also offers flexibility through customizable probability thresholds, enabling stringent or relaxed selection of compounds. Users can also input SMILES representations for direct screening, bypassing prediction probabilities. Taken together, Gcoupler is a versatile platform supporting user-defined inputs, third-party tools for cavity selection, and customizable statistical analyses, enhancing its adaptability for diverse ligand design and screening tasks. This integrated framework streamlines cavity-specific ligand design, screening, and ranking, providing a comprehensive solution for GPCR-targeted drug discovery.</p><p>To evaluate Gcoupler’s performance, we tested its modules across five GPCRs (AA2AR, ADRB1, ADRB2, CXCR4, and DRD3) using experimentally validated ligands and matched decoys from the DUD-E dataset (<xref ref-type="bibr" rid="bib48">Mysinger et al., 2012</xref>). The DUD-E datasets contain five GPCRs alongside information about their cavity coordinates, positive ligands, and decoys (<ext-link ext-link-type="uri" xlink:href="https://dude.docking.org/subsets/gpcr">https://dude.docking.org/subsets/gpcr</ext-link>). We used these five GPCRs as independent samples to evaluate different modules and sub-modules of Gcoupler. We first checked whether the cavity search algorithm of Synthesizer could accurately detect a given orthosteric ligand-binding site for a GPCR. Gcoupler accurately identified orthosteric ligand-binding sites and additional allosteric cavities across all targets, validating its de novo cavity detection algorithm (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1b</xref>). We next asked whether Gcoupler could also synthesize molecules similar to the reported ligands for respective orthosteric sites based on the cavity’s physical, chemical, and geometric properties. For orthosteric sites, the Synthesizer module generated ~500 compounds per GPCR. Subsequently, as per the Gcoupler default workflow, the Authenticator module conducted a virtual screening of these newly synthesized compounds, segregating them into HABs and LABs. Although the Authenticator module provides flexibility in selecting an optimal threshold to distinguish HAB and LAB, we chose the default cutoff of –7 kcal/mol for AA2AR, CXCR4, and DRD3. For ADRB1 and ADRB2, we selected a threshold of –8 kcal/mol to minimize overlap in distributions and thus avoid class imbalance, a critical parameter that could influence the downstream model generation using the Generator module (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1c</xref>). Statistical validation confirmed significant separation between these groups (p &lt; 0.0001), enabling the Generator module to construct graph-based classification models with high values of AUC–ROC (&gt;0.95), sensitivity, and specificity (<xref ref-type="fig" rid="fig1">Figure 1b, c</xref>, <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1d, e</xref>). These models reliably distinguished ligands from decoys, demonstrating Gcoupler’s accuracy in identifying high-affinity ligands.</p><p>In addition to evaluating Gcoupler’s performance for the orthosteric sites of GPCRs, we also validated its capability to identify allosteric sites and their corresponding ligands. In this case, we first gathered information about the experimentally validated GPCR–ligand complexes sourced from the PDB database. We chose three GPCR–ligand complexes (β2AR-Cmpd-15PA, CCR2-CCR2-RA-[R], and CCR9-Vercirnon) from the PDB (<xref ref-type="bibr" rid="bib60">Shen et al., 2023</xref>). We removed the ligands from the PDB files and executed the standard Gcoupler workflow with default parameters. Gcoupler successfully identified allosteric binding sites and generated classification models for synthetic compounds with consistently high AUC–ROC values (&gt;0.95) (<xref ref-type="fig" rid="fig1">Figure 1d</xref>, <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2a–c</xref>). This high level of accuracy indicates the robustness of Gcoupler’s algorithms in distinguishing between true positives (allosteric ligands) and true negatives (non-binders). Projection of experimentally validated ligands onto these models further confirmed their predictive accuracy (<xref ref-type="fig" rid="fig1">Figure 1e</xref>), underscoring Gcoupler’s robustness and versatility for orthosteric and allosteric ligand discovery.</p><p>Next, to evaluate the efficiency of Gcoupler, we compared its run time with the biophysics-based gold standard molecular docking (AutoDock) (<xref ref-type="bibr" rid="bib47">Morris et al., 2009</xref>). To address the runtime efficiency, we first utilized the ChEMBL31 database (<xref ref-type="bibr" rid="bib24">Gaulton et al., 2012</xref>) to identify GPCRs with the highest number of reported experimentally validated agonists. We selected the alpha-1A adrenergic receptor (ADRA1A) since it qualifies for this criterion and contains 993 agonists (<xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3a, b</xref>). Methodologically, we followed the conventional steps of AutoDock Tools for molecular docking while keeping track of execution time for each step throughout the entire process until completion (<xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3a, c</xref>). In parallel, we applied the same timestamp procedure for Gcoupler, including its individual module sub-functions (<xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3a–d</xref>). Gcoupler was 13.5 times faster, leveraging its deep learning-based Generator module and AutoDock Vina’s efficiency. Both methods provided comparable predictions for active compounds, demonstrating Gcoupler’s speed and accuracy, making it ideal for large-scale ligand design and drug discovery (<xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3e–h</xref>).</p><p>Finally, we used Gcoupler to evaluate the ligand space conservation (functional conservation) of the GPCR–Gα interface. Specifically, we aimed to explore the possibility of direct small molecule binding to the GPCR–Gα interface to modulate downstream signaling pathways. We analyzed multiple human GPCR–Gα complexes from the PDB (<xref ref-type="fig" rid="fig1">Figure 1f</xref>, <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>), identified conserved motifs (DRY, CWxL, and NPxxY) and binding pockets through sequence and structural analyses (<xref ref-type="fig" rid="fig1">Figure 1g</xref>). To determine the topological similarity of the GPCR–Gα-protein interface, we undertook a detailed structural analysis across a wide array of GPCR–Gα-protein complexes. This analysis involved identifying and extracting the cavities present within each complex. By focusing on these critical regions, we aimed to assess the degree of structural conservation and quantify it through normalized root mean square deviation (RMSD) values. Specifically, the normalized RMSD values, which provide a measure of the average distance between atoms of superimposed proteins, indicated a high degree of similarity. The mean RMSD value was found to be 1.47 Å, while the median RMSD value was even lower at 0.86 Å. These values suggest that the overall topology of the GPCR–Gα interface is well conserved across different complexes, highlighting the robustness of this interaction site (<xref ref-type="fig" rid="fig1">Figure 1h–j</xref>, <xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3i–k</xref>, <xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>). Finally, to test whether this topological and sequence conservation also impacts the ligand profiles that could potentially bind to this interface, we performed the Gcoupler workflow on all 66 GPCRs and synthesized ~50 unique ligands per GPCR (<xref ref-type="fig" rid="fig1">Figure 1h</xref>). We next computed and compared the physicochemical properties (calculated using Mordred; <xref ref-type="bibr" rid="bib46">Moriwaki et al., 2018</xref>) of these synthesized ligands and observed high cosine similarity, which further supports the functional conservation of the GPCR–Gα interface (<xref ref-type="fig" rid="fig1">Figure 1h, k</xref>, <xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3l</xref>, <xref ref-type="supplementary-material" rid="supp3">Supplementary file 3</xref>). In summary, we used Gcoupler to systematically evaluate and analyze the ligand profiles of the GPCR–Gα-protein interface and observed a higher degree of sequence, topological, and functional conservation.</p></sec><sec id="s2-2"><title>Gcoupler reveals endogenous, intracellular Ste2p allosteric modulators</title><p>We next utilized Gcoupler to test the hypothesis that the intracellular metabolites could potentially and directly regulate the GPCR signaling by directly interacting with the GPCR–Gα-protein interaction interface (<xref ref-type="fig" rid="fig1">Figure 1l</xref>). To test this hypothesis, we utilized a well-characterized yeast mating pathway mediated via the Ste2p–Gpa1p interface (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1a</xref>). We used Gcoupler to screen for such metabolites against the Yeast Metabolome Database (YMDB) (<xref ref-type="bibr" rid="bib35">Jewison et al., 2012</xref>). We utilized the recently elucidated cryo-EM structure of the Ste2 protein (<xref ref-type="bibr" rid="bib77">Velazhahan et al., 2021</xref>) and performed a small-scale molecular dynamics (MD) simulation by using a yeast phospholipid composition-based lipid bilayer environment (<xref ref-type="bibr" rid="bib39">Kaneko et al., 1976</xref>), and subjected the simulated stable structure to the Gcoupler workflow (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1b–i</xref>). This led to the identification of 17 potential surface cavities on Ste2p. Careful interrogation of the structurally supported Ste2p–Gpa1p interface revealed two distinct predicted cavities (annotated as IC4 (intracellular cavity 4) and IC5 (intracellular cavity 5)), collectively capturing &gt;95% of the interface regions (<xref ref-type="fig" rid="fig2">Figure 2a, b</xref>, <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1j–n</xref>). Conservation analysis of these cavities across 14 yeast species further confirmed their structural significance (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1o</xref>). We next synthesized ~500 in silico synthetic compounds for both IC4 and IC5, each by leveraging the Synthesizer module of Gcoupler. To test whether the chemical space of these in silico synthesized ligands is cavity-specific, we performed a stringent evaluation by comparing the chemical heterogeneity of the 100 randomly selected synthesized ligands, each from the pool of 500 for IC4 and IC5, with 100 de novo synthesized ligands for an extracellular cavity (EC1). Of note, EC1 does not harbor any overlapping residue with IC4 or IC5 and possesses distinct pharmacophore properties (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2a, d, e</xref>). Next, we computed the atom pair fingerprints and visualized the chemical heterogeneity in the low-dimensional space using 2D and 3D PCA (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2b, c</xref>). These results suggest that the Synthesizer module of Gcoupler generated cavity-specific ligands by leveraging both the cavity topology (3D) and its composition (pharmacophore). We further assessed the reproducibility of the Gcoupler by synthesizing 100 in silico compounds per run across five runs for the Ste2p IC4 cavity. Visualization of the chemical heterogeneity between the compounds generated via different runs in the low-dimensional space using 2D/3D PCA and pairwise Tanimoto Similarity using atom pair fingerprints suggests heterogeneous and overlapping chemical composition among the synthesized ligands across all five runs (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2f–h</xref>).</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Identification of endogenous, intracellular allosteric modulators of Ste2p using Gcoupler.</title><p>(<bold>a</bold>) Schematic diagram depicting the topology of all the cavities identified using the Synthesizer module of the Gcoupler Python package. Of note, the cavity nomenclature includes the cavity location, that is, EC (extracellular), IC (intracellular), and TM (transmembrane), succeeded by a numerical number. (<bold>b</bold>) Diagram depicting the three-dimensional view of the Ste2 protein, with highlighted Gα-protein-binding site (Gpa1) and the Gcoupler intracellular cavities (IC4 and IC5). The Venn diagram at the bottom depicts the percentage overlap at the amino acid levels between the Gα-binding site and predicted IC4 and IC5. (<bold>c</bold>) Schematic representation of the overall workflow used to predict the endogenous intracellular allosteric modulators of Ste2 receptor using Gcoupler and molecular docking technique. Of note, Yeast Metabolome Database (YMDB) metabolites were used as query compounds. (<bold>d</bold>) Overlapping density plots depicting and comparing the distributions of synthetic compounds predicted to target the IC4 and IC5 of the Ste2 receptor using the Gcoupler package. Of note, the Authenticator module of Gcoupler segregated the synthesized compound for each cavity (IC4 or IC5) into High-Affinity Binders (HABs) and Low-Affinity Binders (LABs). (<bold>e</bold>) AUC (area under the curve) plots representing the performance of the indicated models. Notably, the models were trained using the cavity-specific synthetic compounds generated using the Gcoupler package. (<bold>f</bold>) Scatter plots depicting the relationship (correlation) between the binding prediction probabilities using Gcoupler and binding free energies computed using molecular docking (AutoDock). (<bold>g</bold>) Scatterplot depicting the Pathway Over Representation Analysis (ORA) results of the endogenous metabolites that were predicted to bind to the GPCR–Gα-protein (Ste2p–Gpa1p) interface using both Gcoupler and molecular docking. (<bold>h</bold>) Alluvial plot showing five-level sub-activity spaces screening of the selected metabolites for IC4. (<bold>i</bold>) Schematic diagram depicting the workflow opted to narrow down on the single metabolic gene mutants. (<bold>j</bold>) Schematic diagram depicting the experimental design used to screen single metabolic gene mutants for α-factor-induced programmed cell death (PCD). Cell viability was assessed using a propidium iodide-based fluorometric assay. (<bold>k</bold>) Scatter plot depicting the impact of α-factor stimuli on cellular viability, assessed using propidium iodide-based fluorometric assay. The <italic>y</italic>-axis represents −log<sub>10</sub>(p-value) of the one-sample Student’s <italic>t</italic>-test between the normalized PI fluorescence of untreated and treated conditions. The <italic>x</italic>-axis represents the percentage inhibition or increase in cellular viability, estimated using a propidium iodide-based assay. The mutants reported to be involved in mating, PCD, or both are indicated in orange, green, and blue, respectively. The statistically non-significant mutants are indicated below the dashed line in black. (<bold>l</bold>) Heatmap depicting the relative enrichment/de-enrichment of differentially enriched metabolites (DEMs) in the indicated conditions. Of note, four biological replicates per condition were used in the untargeted metabolomics. (<bold>m</bold>) Venn diagram depicting the overlap between the predicted endogenous intracellular allosteric modulators of Ste2p and DEMs identified using untargeted metabolomics. (<bold>n</bold>) Mean-whisker plot depicting the relative abundance of ubiquinone 6 (CoQ6) and zymosterol (ZST) in the indicated conditions. Student’s <italic>t</italic>-test was used to compute statistical significance. Asterisks indicate statistical significance, whereas ns represents non-significance.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-106397-fig2-v1.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Ste2 protein cavities prediction using Gcoupler.</title><p>(<bold>a</bold>) Schematic diagram depicting the hypothesis that the intracellular yeast metabolites could allosterically modulate the GPCR–Gα-protein (Ste2p–Gpa1p) interface and, therefore, the Ste2p signaling pathway in yeast. (<bold>b</bold>) Overlapping Ste2p (GPCR) ribbon diagram depicting the structural similarity between the experimentally elucidated Ste2p structure before and after molecular dynamics simulation using GROMACS software. Root mean square deviation (RMSD) value is depicted at the bottom. (<bold>c</bold>) Flowchart depicting the key steps used for the molecular dynamics simulation of Ste2p using CHARMM-GUI and GROMACS software. (<bold>d</bold>) Line plot depicting the changes in the density (kg/m<sup>3</sup>) along the <italic>z</italic>-axis of the three-dimensional Ste2p structure. (<bold>e</bold>) Line plot depicting the decline in the potential (kJ/mol) over molecular dynamics simulation time in picoseconds (ps). (<bold>f</bold>) Line plot depicting the changes in the density (kg/m<sup>3</sup>) of the overall system over molecular dynamics simulation time in picoseconds (ps). (<bold>g</bold>) Line plots depicting the changes in the pressure (in bars) and temperature (in Kelvin) of the overall system during molecular dynamics simulation of Ste2 protein. (<bold>h</bold>) Line plot depicting the RMSD changes of the Ste2 protein during molecular dynamics simulation. Note that the RMSD values are indicated in nanometers (nm). (<bold>i</bold>) Ramachandran plot depicting the location of simulated Ste2 protein residues in the favorable and unfavorable regions. (<bold>j</bold>) Bar plot depicting the predicted cavity volumes (Å). (<bold>k</bold>) Scatterplot depicting the relationship between the cavity volume and surface area in the indicated cavities of the Ste2 protein. (<bold>l</bold>) Heatmap depicting the percentage of amino acids of the indicated cavities residing in the EC (extracellular), IC (intracellular), and TM (transmembrane) region of the Ste2 protein. (<bold>m</bold>) Scatterplot depicting the predicted drug score of the indicated cavities of the Ste2 protein. (<bold>n</bold>) Snake plot depicting the key amino acids of the Ste2 protein alongside their location within the indicated functional cavities. (<bold>o</bold>) Snake plot depicting the conservation of Ste2 protein at the amino acid level. Of note, Ste2 proteins from 15 related yeast species were used for computing the conservation score.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-106397-fig2-figsupp1-v1.tif"/></fig><fig id="fig2s2" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 2.</label><caption><title>Comparison of the chemical composition of cavity-specific ligands of Ste2 protein.</title><p>(<bold>a</bold>) Venn diagram depicting the number of overlapping amino acids constituting the extracellular cavity 1 (EC1), intracellular cavity 4 (IC4), and intracellular cavity 5 (IC5) of the Ste2p. (<bold>b</bold>) Two-dimensional and (<bold>c</bold>) three-dimensional principal component analysis plots depicting the segregation of in silico synthesized ligands for the indicated cavities via Gcoupler. Of note, atom pair fingerprints were used as features for this analysis. (<bold>d</bold>) Scatter plot depicting the relationship between the depth of the pharmacophore features and the neighboring grids. (<bold>e</bold>) Donut charts illustrating the properties of amino acids constituting the pharmacophore for each of the indicated cavities. (<bold>f</bold>) Two-dimensional and (<bold>g</bold>) three-dimensional principal component analysis plots depicting the chemical properties of in silico synthesized ligands from five independent runs on the IC4 of the Ste2p using the Gcoupler Synthesizer module. Of note, atom pair fingerprints were used as features for this analysis. (<bold>h</bold>) Heatmap depicting the Tanimoto Similarities scores between the synthesized ligands for IC4 of Ste2p across five independent runs using Gcoupler.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-106397-fig2-figsupp2-v1.tif"/></fig><fig id="fig2s3" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 3.</label><caption><title>Sanity check of Gcoupler predictions.</title><p>(<bold>a</bold>) Principal component analysis depicting chemical heterogeneity of synthetic compounds synthesized using Gcoupler across intracellular cavities (IC4 and IC5). Notably, the compounds were segregated into High-Affinity Binders (HABs) and Low-Affinity Binders (LABs) by the Authenticator module of the Gcoupler. (<bold>b</bold>) Heatmap depicting the chemical similarity of the de novo synthesized HAB (dark green) and LAB (light green) across intracellular cavities (IC4 and IC5) of the Ste2 protein. Tanimoto similarities were computed using Atomic fingerprints. (<bold>c</bold>) Heatmaps illustrating the relative enrichment of the indicated functional groups (RNH2: primary amine, R2NH: secondary amine, R3N: tertiary amine, ROPO3: monophosphate, ROH: alcohol, RCHO: aldehyde, RCOR: ketone, RCOOH: carboxylic acid, RCOOR: ester, ROR: ether, RCCH: terminal alkyne, RCN: nitrile) among the Gcoupler-based de novo synthesized binders of Ste2p receptor across IC4 and IC5. (<bold>d</bold>) Box plots depicting the model’s performances across the 10-fold cross-validation. The upper and lower box plots depict the performance metrics of models trained using the de novo ligands for intracellular cavities (IC4 and IC5), respectively, of the Ste2 protein. (<bold>e</bold>) Venn diagrams depicting the number of yeast metabolites from YMDB predicted to bind to the Ste2p–Gpa1p interface, predicted using Gcoupler and AutoDock. Of note, IC4 and IC5 represent intracellular cavities 4 and 5 of the Ste2 protein, respectively. (<bold>f</bold>) Principal component analysis depicting chemical heterogeneity of endogenous yeast metabolites predicted to bind to the intracellular cavities (IC4 and IC5) of the Ste2 protein. Notably, the compounds were segregated into High-Affinity Metabolites (HAMs) and Low-Affinity Metabolites (LAMs) by the Generator module of the Gcoupler. (<bold>g</bold>) Heatmap illustrating the relative enrichment of the indicated functional groups among the endogenous intracellular allosteric modulators (metabolites) of Ste2 receptor across IC4 and IC5. (<bold>h</bold>) Percentage stacked bar plot depicting the relative enrichment of the indicated functional groups of the HAMs and LAMs across intracellular cavities (IC4 and IC5) of the Ste2 protein. (<bold>i</bold>) Heatmap depicting PageRank score of the selected metabolites for IC4 and (<bold>j</bold>) IC5 with respect to different biological properties. (<bold>k</bold>) Box plots depicting the performance parameters of the indicated models generated using Gcoupler against the IC4 cavity of Ste2p. Note that the training and testing datasets were generated randomly (five iterations) from the in silico synthesized ligands from Gcoupler. (<bold>l</bold>) Scatter plots depicting the segregation of HAMs/LAMs (indicated in green and red) identified using the Gcoupler workflow with 100% training data. Of note, models trained on lesser training data size (25%, 50%, and 75% of HAB/LAB) severely failed to segregate HAMs and LAMs (along the <italic>y</italic>-axis). The <italic>x</italic>-axis represents the binding affinity calculated using IC4-specific docking using AutoDock. (<bold>m</bold>) Bar plots depicting the correlation values obtained between the Gcoupler prediction probabilities and AutoDock computed binding energies in the indicated training data size. (<bold>n</bold>) Box plots depicting the distributions for binding energies of the HAMs and LAMs computed using cavity-specific docking and full docking via Autodock for IC4 and IC5 of the Ste2p.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-106397-fig2-figsupp3-v1.tif"/></fig><fig id="fig2s4" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 4.</label><caption><title>Untargeted metabolomics and genetic screening suggest an interlink between metabolites and Ste2p-mediated programmed cell death (PCD).</title><p>(<bold>a</bold>) Screenshot of the central yeast metabolism from the Kyoto Encyclopedia of Genes and Genomes (KEGG) indicating the key metabolic pathways (highlighted in red) harboring metabolic intermediates predicted as High-Affinity Binders of GPCR–Gα-protein (Ste2p–Gpa1p) interface by Gcoupler. (<bold>b</bold>) Venn diagram depicting the percentage overlaps of the mating-related genes reported in the literature and those used in the screening. The <italic>STE2</italic> was the only common gene. (<bold>c</bold>) Heatmap depicting the growth curve profiles of the wild-type, single metabolic mutants, and <italic>ste2Δ</italic> under optimal growth conditions. (<bold>d</bold>) Schematic diagram depicting the experimental workflow of the untargeted metabolomics experiment. Notably, the experiment involves the usage of increasing doses of α-factor to induce PCD and to enrich the surviving cells selectively. (<bold>e</bold>) Box plot depicting the increase in the propidium iodide fluorescence upon the increasing concentration of α-factor treatment. Heat-killed (HK), untreated, and vehicle (DMSO-treated) were used as controls, whereas the increasing concentration of α-factor surviving wild-type cells was used as test conditions. The Mann–Whitney <italic>U</italic> test was used to calculate statistical significance. Asterisks indicate statistical significance, whereas ns represents non-significance. (<bold>f</bold>) Heatmap depicting the relative (de)enrichment of differentially enriched metabolites in the indicated conditions. Of note, four biological replicates per condition were used in the untargeted metabolomics. (<bold>g</bold>) Principal component analysis depicting the segregation of indicated samples based on their metabolomics profiles along the PC1, PC2, and PC3. (<bold>h</bold>) Correlation plot depicting Pearson’s correlation of the metabolome of the indicated samples. (<bold>i</bold>) Heatmap depicting the relative enrichment of all the detected metabolites in the indicated condition. HK, untreated, and vehicle (DMSO-treated) were used as controls, whereas the increasing concentration of α-factor surviving wild-type cells was used as test conditions. (<bold>j</bold>) Venn diagram indicating that 38 predicted intracellular allosteric modulators of Ste2p were identified in the untargeted metabolomics profiling. (<bold>k</bold>) Scatterplot depicting the Pathway Over Representation Analysis (ORA) results of the differentially enriched metabolites (treated vs. vehicle control) identified using untargeted metabolomics.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-106397-fig2-figsupp4-v1.tif"/></fig></fig-group><p>Post these performance/reproducibility checks of Gcoupler, we segregated the 500 in silico synthesized ligands for IC4 and IC5, each into HABs and LABs by the Authenticator module of Gcoupler. Notably, the estimated binding energy threshold was set at –7 kcal/mol, a widely accepted cutoff in virtual screening (<xref ref-type="bibr" rid="bib81">Wong et al., 2022</xref>; <xref ref-type="bibr" rid="bib3">Alanzi et al., 2024</xref>; <xref ref-type="fig" rid="fig2">Figure 2c, d</xref>). A deep investigation into these classified synthetic compounds showed a comparable similarity between the HABs and LABs of the aforementioned target cavities, respectively (<xref ref-type="fig" rid="fig2s3">Figure 2—figure supplement 3a–c</xref>). The Generator module built classification models by implementing four distinct Graph Neural Network algorithms. Comparing the model performance metrics suggests that AFP outperformed other algorithms for both cavities (<xref ref-type="fig" rid="fig2">Figure 2e</xref>, <xref ref-type="fig" rid="fig2s3">Figure 2—figure supplement 3d</xref>). Next, we screened yeast metabolites, compiled from YMDB, on the best-performing model (hyperparameter-tuned AFP model) and predicted metabolites that could potentially bind to the IC4 and IC5 of the Ste2p–Gpa1p interface with a binding probability cutoff of &gt;0.5 (<xref ref-type="fig" rid="fig2">Figure 2c</xref>). To further optimize the lead metabolite list, we parallelly performed the standard molecular docking using AutoDock with YMDB metabolites against IC4 and IC5 of Ste2p, respectively, and ultimately selected the consensus metabolites (binding energy ≤–7 kcal/mol and binding probability &gt;0.5) for the downstream analysis (<xref ref-type="fig" rid="fig2">Figure 2c</xref>, <xref ref-type="fig" rid="fig2s3">Figure 2—figure supplement 3e</xref>, <xref ref-type="supplementary-material" rid="supp4">Supplementary file 4</xref>). Of note, the consensus metabolites list was further segregated into HAMs (High-Affinity Metabolites) and LAMs (Low-Affinity Metabolites) based on the binding prediction probability (cutoff = 0.5). Comparative analysis of the binding prediction probabilities of Gcoupler and binding energies from Autodock of HAM and LAM revealed a significant negative correlation that further validates the authenticity of our novel approach (<xref ref-type="fig" rid="fig2">Figure 2f</xref>). Of note, as expected, HAMs and LAMs possess distinct atomic fingerprints, as indicated by the Principal Component Analysis (<xref ref-type="fig" rid="fig2s3">Figure 2—figure supplement 3f</xref>). Furthermore, HAMs and LAMs displayed distinct atomic fingerprints, with enriched functional groups, including R2NH, R3N, ROPO3, ROH, and ROR, observed in HAMs (<xref ref-type="fig" rid="fig2s3">Figure 2—figure supplement 3g, h</xref>). To gain the pathway-level information about these putative endogenous intracellular allosteric modulators of Ste2p, we performed pathway-level over-representation analysis (<xref ref-type="bibr" rid="bib17">Chong et al., 2018</xref>) and observed the selective enrichment of metabolites involved in the steroid, sesquiterpenoid, and triterpenoid biosynthesis and one-carbon pool by folate pathways (<xref ref-type="fig" rid="fig2">Figure 2g</xref>). BioRanker module further pinpointed sterols, including zymosterol (ZST), ubiquinone 6 (CoQ6), and lanosterol (LST), as top candidates, exhibiting high prediction probabilities (&gt;0.99) and structural similarity to HABs (<xref ref-type="fig" rid="fig2">Figure 2h</xref>, <xref ref-type="fig" rid="fig2s3">Figure 2—figure supplement 3i–j</xref>). To validate Gcoupler-identified allosteric modulators, we performed control analyses of the Authenticator and Generator modules along with blind docking of YMDB metabolites with Ste2p. In the former case, we removed the class information (HAB and LAB labels) from the in silico compounds synthesized for the IC4 cavity of the Ste2p, which resulted in a heterogeneous pool of chemical compounds. We next randomly split the training and testing data (five iterations) and build independent models. Our results suggest that compared to the Authenticator-guided data splitting (HAB and LAB), the random splitting resulted in poor model performances (<xref ref-type="fig" rid="fig2s3">Figure 2—figure supplement 3k</xref>), suggesting the robustness of the Authenticator module. Additionally, we also evaluated the impact of the size of the training data on the Generator model performance. To achieve this, we randomly selected 25%, 50%, 75%, and 100% of the in silico synthesized compounds of the Ste2p IC4 cavity and built models using default parameters. Our results revealed a significant increase in the model performance with increased training data size (<xref ref-type="fig" rid="fig2s3">Figure 2—figure supplement 3l, m</xref>). For the latter case, we performed blind docking by AutoDock for Ste2p with the YMDB metabolites and compared these results with the cavity-specific docking via AutoDock and Gcoupler predictions. As expected, in contrast to the cavity-specific Gcoupler and AutoDock, where we observed significant segregation of the HAM and LAM at –7 kcal/mol binding energy (BE) cutoff and 0.5 as the probability cutoff of Gcoupler, we failed to observe any striking differences for the HAM in the case of blind docking (<xref ref-type="fig" rid="fig2s3">Figure 2—figure supplement 3n</xref>). All these rigorous control analyses and blind docking validated the reliability of Gcoupler’s predictions, confirming its robustness in identifying cavity-specific modulators.</p><p>To experimentally validate the role of Gcoupler-predicted metabolites in Ste2p signaling, we performed a genetic screen of metabolic mutants. We first mapped the predicted allosteric-modulating metabolites to biochemical pathway databases (KEGG and MetaCyc) and identified the enzymes responsible for processing these metabolites (<xref ref-type="fig" rid="fig2">Figure 2i</xref>, <xref ref-type="fig" rid="fig2s4">Figure 2—figure supplement 4a</xref>, <xref ref-type="supplementary-material" rid="supp5">Supplementary file 5</xref>). Among the 53 single metabolic mutants (+<italic>ste2Δ</italic>) screened, only Ste2 was previously reported in KEGG pathways for altered mating response (<xref ref-type="fig" rid="fig2s4">Figure 2—figure supplement 4b</xref>). Next, we performed large-scale activity screening using α-factor-induced PCD assays with propidium iodide (PI), assuming that metabolic gene deletions would lead to intracellular accumulation of target metabolites. Briefly, selected single metabolic mutants (MATa) were grown under optimal conditions to late log phase (16 hr). Growth profile analysis revealed varied responses relative to wild-type, with most mutants exhibiting delayed growth kinetics (<xref ref-type="fig" rid="fig2s4">Figure 2—figure supplement 4c</xref>). Late log phase cells were subsequently treated with α-factor, and PCD induction was quantified using PI-based cell viability assays (<xref ref-type="fig" rid="fig2">Figure 2j</xref>). Notably, wild-type BY4741 strains showed significant PI fluorescence increase, indicating pheromone-induced PCD, and <italic>STE2</italic> knockout mutants (<italic>ste2Δ</italic>) showed no significant death as expected. Interestingly, most metabolic mutants (94.4%) resisted α-factor-induced cell death, with some displaying accelerated growth in the presence of α-factor, indicating crosstalk between central metabolism and Ste2 signaling (<xref ref-type="fig" rid="fig2">Figure 2k</xref>). These results indicate that a significant proportion of Gcoupler predicted metabolites could directly or indirectly influence the Ste2 signaling pathway, establishing a link between metabolism and Ste2 signaling.</p><p>To further investigate the metabolic pathways associated with PCD resistance, we performed high-resolution metabolomics on cells surviving α-factor treatment at varying concentrations (<xref ref-type="fig" rid="fig2s4">Figure 2—figure supplement 4d</xref>). Unbiased metabolome analysis revealed differentially enriched metabolites in the surviving population (<xref ref-type="fig" rid="fig2">Figure 2l</xref>, <xref ref-type="fig" rid="fig2s4">Figure 2—figure supplement 4e–i</xref>, <xref ref-type="supplementary-material" rid="supp6">Supplementary file 6</xref>). Cross-comparison analysis identified seven metabolites overlapping between Gcoupler predictions and survivor-enriched metabolites, with ubiquinone 6 (CoQ6) and zymosterol (ZST) showing prominent enrichment across all tested concentrations (<xref ref-type="fig" rid="fig2">Figure 2m, n</xref>, <xref ref-type="fig" rid="fig2s4">Figure 2—figure supplement 4j</xref>). Over-Representation Analysis of the differentially enriched metabolites suggests their involvement in glyoxylate and dicarboxylate metabolism, purine metabolism, and vitamin B6 metabolism, among others. (<xref ref-type="fig" rid="fig2s4">Figure 2—figure supplement 4k</xref>). Taken together, the findings from genetic screening and untargeted metabolomics hint toward the interplay between the central metabolism and Ste2 signaling, with computationally predicted metabolites like ZST and CoQ6 potentially conferring resistance to α-factor-induced PCD.</p></sec><sec id="s2-3"><title>Elevated endogenous metabolic levels selectively inhibit GPCR signaling</title><p>To evaluate the stability of the interactions of zymosterol (ZST), lanosterol (LST), and ubiquinone 6 (CoQ6) at the Ste2p–Gpa1p interface, we performed three independent replicates of MD simulations (short run of 100 ns) of the Ste2p–metabolite complex for both cavities (<xref ref-type="fig" rid="fig3">Figure 3a–c</xref>, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1a</xref>). MD simulation results suggest that the interactions between the metabolites and Ste2p at the Ste2p–Gpa1p interface are thermodynamically stable in almost all cases across both the cavities (IC4 and IC5), except for the ubiquinone 6 (CoQ6), which harbored a fluctuating RMSD over the simulation timeframe (<xref ref-type="fig" rid="fig3">Figure 3c</xref>). Notably, fluctuating RMSD is observed only in the case of IC5, while it is within the permissive range for IC4 (<xref ref-type="fig" rid="fig3">Figure 3c</xref>, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1b</xref>). We further evaluated IC4 by performing a longer simulation run for 550 ns with these three Ste2p–metabolite complexes and observed stable complexes in the case of zymosterol (ZST) and lanosterol (LST) while observing fluctuations in the ligand RMSD for ubiquinone 6 (CoQ6) post 100 ns (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1c</xref>), which may be a result of its greater conformational flexibility. To gain further insight into the contributing residues from the MD simulations, we performed a residue-wise decomposition analysis that provides information about the energy contributions from the different residues to total binding free energies (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2a</xref>). These results suggest that IC4 and IC5 specific residues predominantly contribute to the total binding free energies. Notably, the binding free energies are obtained as an average of over 500 configurations corresponding to the last 50 ns of the MD simulations.</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Elevated endogenous metabolite levels stabilize Ste2p–Gpa1p interactions and selectively inhibit GPCR signaling.</title><p>(<bold>a</bold>) Scheme representing the key steps opted for preparing Ste2p structure for downstream computational analysis. (<bold>b</bold>) Bar plots depicting the binding energies obtained by the docking of Ste2p and indicated metabolites across IC4 and IC5. (<bold>c</bold>) Line plots depicting the root mean square deviation (RMSD) changes over simulation timeframes from the three independent replicates of the indicated conditions in the indicated conditions. The spread of the data is indicated as standard deviation (SD). Notably, RMSD is provided in Angstroms (Å), whereas the simulation time is in nanoseconds (ns). (<bold>d</bold>) Workflow depicting the steps involved in Ste2p-miniG-protein docking using HADDOCK and PRODIGY web servers. (<bold>e</bold>) Bar plots depicting the fold change of the dissociation constant (<italic>K</italic><sub>d</sub>) in the indicated conditions. Notably, fold change was computed with respect to the wild-type condition (Ste2p-miniG-protein). Inlets represent molecular representations of Ste2p-miniG-protein and the highlighted interface residues. (<bold>f</bold>) The schematic diagram depicts the experimental workflow used to quantify α-factor-induced programmed cell death (PCD) using a propidium iodide-based cell viability fluorometric assay. Box plot on the right depicting the rescue from the α-factor-induced PCD in the indicated conditions as inferred using propidium iodide-based cell viability fluorometric assay (<italic>n</italic> = 9 or 10 biological replicates; heat-killed = 2). The <italic>y</italic>-axis represents the fold change of the propidium iodide fluorescence values with respect to their respective controls. Mann–Whitney <italic>U</italic> test was used to calculate statistical significance. Asterisks indicate statistical significance, whereas ns represents non-significance. (<bold>g</bold>) Schematic representation (left) of the experimental approach used to measure cell vitality and viability using microscopy-based FUN1 staining. Representative micrographs (right) depicting the FUN1 staining results in the indicated conditions, Scale 10 µm. Mean-whisker plot depicting the relative proportion of the vital and viable yeast cells observed using FUN1 staining in the indicated conditions (<italic>n</italic> = 3 biological replicates). A Student’s <italic>t</italic>-test was used to compute statistical significance. Asterisks indicate statistical significance, whereas ns represents non-significance. Error bars represent the standard error of the mean (SEM). (<bold>h</bold>) Schematic representation (left) of the experimental design for the mating assay (<italic>n</italic> = 3 biological replicates, each with three technical replicates). MATa yeast cells were pre-loaded with the metabolites and then mated with MATα cells to evaluate the mating efficiency. Representative micrographs in the middle qualitatively depict the mating efficiency in the indicated conditions. The bar plots on the right depict the mating efficiency (mean ± SEM) in the indicated conditions. Student’s <italic>t</italic>-test was used to compute statistical significance. Asterisks indicate statistical significance, whereas ns represents non-significance. (<bold>i</bold>) Schematic representation depicting the experimental design of phospho-MAPK activity-based Western blot. Bar plots depicting the p-Fus3 levels (mean ± SEM; n = 5–6 biological replicates after IQR-based outlier removal) in the indicated conditions. Error bars represent the standard error of the mean (SEM). A Student’s <italic>t</italic>-test was used to compute statistical significance. Asterisks indicate statistical significance, whereas ns represents non-significance. (<bold>j</bold>) Schematic representation (left) of the experimental approach used to measure the fluorescence in P<italic><sub>FUS1</sub></italic>-eGFP-CYC1 yeast cells. Representative micrographs (right) depicting the eGFP expression in the yeast cells in the indicated conditions. Scale 20 µm. Bar plot depicting the Corrected Total Cell Fluorescence (CTCF) value (mean ± SEM; n = 3 biological replicates) in the indicated conditions. A Student’s <italic>t</italic>-test was used to compute statistical significance. Asterisks indicate statistical significance, whereas ns represents non-significance.</p><p><supplementary-material id="fig3sdata1"><label>Figure 3—source data 1.</label><caption><title>PDF file containing original western blots of p-Fus3, Fus3, and Pgk1 displayed in <xref ref-type="fig" rid="fig3">Figure 3i</xref>.</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-106397-fig3-data1-v1.pdf"/></supplementary-material></p><p><supplementary-material id="fig3sdata2"><label>Figure 3—source data 2.</label><caption><title>Original files for western blot analysis of p-Fus3, Fus3, and Pgk1 displayed in <xref ref-type="fig" rid="fig3">Figure 3i</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-106397-fig3-data2-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-106397-fig3-v1.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>Docking and molecular dynamics (MD) simulations suggest the stability of the Ste2–metabolite complex.</title><p>(<bold>a</bold>) Ligplots depicting the interacting amino acid residues and atoms of the Ste2 protein and indicated metabolites for the intracellular cavities (IC4 and IC5). (<bold>b</bold>) Table indicating the Van der Waals (Δ<italic>E</italic><sub>vdw</sub>), electrostatic (Δ<italic>E</italic><sub>elec</sub>), polar solvation (Δ<italic>E</italic><sub>psolv</sub>), and non-polar solvation (Δ<italic>E</italic><sub>npsolv</sub>) energies along with net binding free energy (Δ<italic>G</italic><sub>bind</sub>) in kcal/mol of the three independent replicates of the indicated metabolites across intracellular cavities IC4 and IC5 of the Ste2p. Note the values in the table are provided as mean ± standard errors. (<bold>c</bold>) Line plot depicting the variation in the root mean square deviation (RMSD) of the indicated metabolites bound to the intracellular cavity 4 (IC4) at the GPCR-Gα interface of the Ste2p, obtained using longer MD simulation runs. Notably, RMSD is provided in Angstroms (Å), whereas the simulation time is in nanoseconds (ns).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-106397-fig3-figsupp1-v1.tif"/></fig><fig id="fig3s2" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 2.</label><caption><title>Divergent characteristics of site-directed missense mutants of <italic>STE2</italic> gene.</title><p>(<bold>a</bold>) Line plots depicting the total energy decomposition of the individual amino acids of the Ste2p (three independent replicates) computed using molecular dynamics (MD) simulations in IC4 (left) and IC5 (right). (<bold>b</bold>) Molecular representation of the Ste2 protein structures (blue) and the miniGpa1–proteins (cyan), with the highlighted interface residues (red and green) in the indicated conditions. (<bold>c</bold>) Scatterplot depicting the net binding free energy Δ<italic>G</italic> (kcal/mol) of the Ste2p (with and without indicated metabolites) with miniG-protein (<italic>y</italic>-axis) and α-factor (<italic>x</italic>-axis). (<bold>d</bold>) Bar plot depicting root mean square deviation (RMSD) values of the Ste2 protein with indicated metabolite across intracellular cavities IC4 and IC5.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-106397-fig3-figsupp2-v1.tif"/></fig><fig id="fig3s3" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 3.</label><caption><title>Exogenous supplementation of selective metabolites rescues α-factor-mediated programmed cell death (PCD).</title><p>(<bold>a</bold>) Growth curve profiles of the wild-type (control), <italic>ste2Δ</italic>, and wild-type yeast pre-treated with the indicated metabolites. (<bold>b</bold>) Schematic diagram (left) depicting the workflow opted to monitor α-factor-induced PCD in the wild-type yeast cells pre-loaded for 24 hr with ubiquinone 6 (CoQ6), zymosterol (ZST), and lanosterol (LST) at three different concentrations. Bean plots on the right depict the changes in the α-factor-mediated PCD in the indicated conditions. Notably, cell viability was assessed by computing the area under the curve (AUC) of the growth kinetics. The Mann–Whitney <italic>U</italic> test was used to calculate statistical significance. Asterisks indicate statistical significance, whereas ns represents non-significance. (<bold>c</bold>) Bean plot depicting the fold change in the α-factor-mediated programmed cell death, assessed using the propidium iodide-mediated programmed cell death in the indicated conditions. The Mann–Whitney <italic>U</italic> test was used to calculate statistical significance. Asterisks indicate statistical significance, whereas ns represents non-significance. (<bold>d</bold>) Representative micrographs (left) depicting the growth of the cells (mating response) pretreated with indicated metabolites in the indicated single dropout medium (SC-Lys and SC-Met). Quantifications of the mating response with respect to the SC-Met control are indicated as a bar graph (mean ± SEM) on the right (<italic>n</italic> = 3 biological replicates, each with three technical replicates). The Student’s <italic>t</italic>-test was used to compute the statistical significance. Asterisks indicate statistical significance, whereas ns represents non-significance.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-106397-fig3-figsupp3-v1.tif"/></fig></fig-group><p>To gain deeper insight into the mode of action of these metabolites in inhibiting Ste2p signaling, we first analyzed their impact at the orthosteric site, that is, α-factor binding. We performed protein-peptide docking of Ste2p and α-factor and observed that metabolite-binding at the Ste2p–Gpa1p interface favors the α-factor interaction, as inferred from the binding free energies Δ<italic>G</italic> (kcal/mol) (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2b, c</xref>). We also analyzed protein–protein interaction between the Ste2p (GPCR) and miniGpa1p (55) by selecting GPCR configurations with and without metabolite-induced altered cavity topologies (IC4 and IC5), respectively (frames output from the aforementioned Ste2p–metabolite complex simulations), and computed the dissociation constant (<italic>K</italic><sub>d</sub>), binding affinity (Δ<italic>G</italic>), and the structural changes in the overall Ste2p topology (<xref ref-type="fig" rid="fig3">Figure 3d, e</xref>, <xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2b–d</xref>). These computational analyses revealed that, in contrast to the metabolite-free Ste2p–Gpa1p interaction, referred to as the wild-type (WT) condition, the <italic>K</italic><sub>d</sub> value is many-fold lower in the presence of metabolites, indicating a cohesive response induced by these metabolites. A multi-fold lower <italic>K</italic><sub>d</sub> value further indicates and potentially explains that the metabolite binding favors the Ste2p (GPCR) and miniGpa1–protein interaction and enables the establishment of a stable complex that might influence the shielding of the effector-regulating domains of the Gpa1p or influence its binding with the Ste4p (Gβ)–Ste18p (Gγ) complex.</p><p>We next asked whether the observed resistance toward α-factor-induced PCD in single metabolic mutants might be the direct consequence of the identified metabolites or a pleiotropic response due to an altered genome. To test this, we exogenously supplemented wild-type yeast with zymosterol (ZST), ubiquinone 6 (CoQ6), and lanosterol (LST). Yeast cells were pre-loaded with metabolites for 24 hr at concentrations (0.1, 1, and 10 μM) that did not significantly alter growth profiles, except for 10 μM lanosterol, which showed mild perturbation (<xref ref-type="fig" rid="fig3s3">Figure 3—figure supplement 3a</xref>), thereby ensuring the physiological relevance of our experimental conditions. Following pre-treatment, cells exhibited marked rescue from α-factor-induced PCD across multiple assays, including growth kinetics, PI-based viability, and FUN1 measurements (<xref ref-type="fig" rid="fig3">Figure 3f, g</xref>, <xref ref-type="fig" rid="fig3s3">Figure 3—figure supplement 3b, c</xref>). This protective effect was specific to α-factor-induced PCD, as metabolite-treated cells remained sensitive to acetic acid-induced death, suggesting that it is likely due to modulation of the Ste2p–Gpa1p interface and not a consequence of an altered response (<xref ref-type="fig" rid="fig3">Figure 3g</xref>). Next, we probed whether the observed modulation of Ste2 signaling also applies to the natural yeast mating behavior. We investigated this by performing a mating assay, which also revealed a decline in Ste2 signaling in metabolite-pre-loaded cells, suggesting the interlink between these metabolites and Ste2p signaling. Notably, in the case of CoQ6, we failed to observe any significant decline in the mating response, consistent with its instability observed in MD simulations (<xref ref-type="fig" rid="fig3">Figure 3h</xref>, <xref ref-type="fig" rid="fig3s3">Figure 3—figure supplement 3d</xref>).</p><p>Further, we evaluated the deactivation of the pathway at the MAPK signaling level by monitoring the Fus3 phosphorylation, where the α-factor-induced p-Fus3 levels were significantly suppressed by ZST and LST (<xref ref-type="fig" rid="fig3">Figure 3i</xref>) but not CoQ6 (data not shown). For final validation, we employed a P<italic><sub>FUS1</sub></italic>-eGFP-CYC1 transcriptional reporter system. Metabolite pretreatment significantly reduced eGFP-positive cells following α-factor stimulation compared to controls (<xref ref-type="fig" rid="fig3">Figure 3j</xref>), further demonstrating that the tested metabolites can inhibit α-factor-induced Ste2p signaling. These findings suggest endogenous metabolites as modulators of Ste2p signaling by stabilizing Ste2p–Gpa1p interactions.</p></sec><sec id="s2-4"><title>Site-directed <italic>Ste2</italic> mutants abrogate metabolite-mediated rescue phenotype</title><p>To gain a deeper understanding, we investigated the role of metabolite binding in modulating Ste2p–Gpa1p interaction dynamics and employed both computational and experimental approaches. First, we conducted in silico screening by generating site-directed mutants of Ste2p designed to alter metabolite binding, followed by docking with Gpa1p to assess the impact of these mutations. We selected mutation sites by analyzing non-covalent interactions in Ste2p–metabolite complexes (IC4 and IC5). We prioritized stronger hydrogen bonds over weaker hydrophobic interactions and pinpointed specific interaction sites for CoQ6 (S75, R233), ZST (L289), and LST (T155, V152, and I153). We finally applied a 2.7–3.3 Å ideal distance range for hydrogen bonds and selected mutants S75A for CoQ6, L289K for ZST, and T155D for LST. This filtering step eliminated unstable or distorted hydrogen bonds. These mutations significantly increased the dissociation constant (<italic>K</italic><sub>d</sub>) of the Ste2p–Gpa1p complex, indicating weakened interactions compared to wild-type Ste2p (<xref ref-type="fig" rid="fig4">Figure 4a, b</xref>, <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1a</xref>). This computational evidence supports the hypothesis that metabolite binding stabilizes the Ste2p–Gpa1p complex, facilitating the rescue response to α-factor-induced PCD.</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Site-directed Ste2p mutants disrupt metabolite-mediated rescue.</title><p>(<bold>a</bold>) Workflow depicting the steps involved in Ste2p-miniG-protein docking of the wild-type and site-directed Ste2p mutants. Notably, docking was performed using HADDOCK and PRODIGY web servers. (<bold>b</bold>) Bar plots depicting the dissociation constant (<italic>K</italic><sub>d</sub>) fold change in Ste2p site-directed mutants and wild-type. Notably, fold change was computed with respect to the metabolite-influenced wild-type condition (Ste2p-miniG-protein). (<bold>c</bold>) The schematic diagram depicts the experimental workflow used to quantify α-factor-induced programmed cell death in generated site-directed missense mutants (T155D, L289K, and S75A), alongside reconstituted wild-type <italic>STE2</italic> (rtWT), using a propidium iodide-based cell viability fluorometric assay. The box plot (left) depicts the increase in the relative proportion of dead cells upon α-factor exposure. Box plot (right) depicting the loss of rescue phenotype from the α-factor-induced programmed cell death in the indicated conditions when pre-loaded with metabolites as inferred using propidium iodide-based cell viability fluorometric assay. The <italic>y</italic>-axis represents the fold change of the propidium iodide fluorescence values with respect to their respective controls. The Mann–Whitney <italic>U</italic> test was used to calculate statistical significance. Asterisks indicate statistical significance, whereas ns represents non-significance. (<bold>d</bold>) Schematic representation (top) of the experimental approach used to measure cell vitality and viability using microscopy-based FUN1 staining. Representative micrographs (below) depicting the FUN1 staining results in the indicated conditions, Scale 10 µm. Mean-whisker plot depicting the relative proportion of the vital and viable yeast cells observed using FUN1 staining in the indicated conditions (<italic>n</italic> = 4 biological replicates). A Student’s <italic>t</italic>-test was used to compute statistical significance. Asterisks indicate statistical significance, whereas ns represents non-significance. Error bars represent the standard error of the mean (SEM). (<bold>e</bold>) Schematic representation (up) depicting the experimental design of phospho-MAPK activity-based Western blot. Bar plots (down) depicting the p-Fus3 levels (mean ± SEM) in the indicated conditions (n = 3 biological replicates). The <italic>y</italic>-axis represents the p-Fus3/Fus3 ratio for the stimulated condition normalized by its corresponding unstimulated sample. A Student’s <italic>t</italic>-test was used to compute statistical significance. Asterisks indicate statistical significance, whereas ns represents non-significance. (<bold>f</bold>) Schematic representation depicting the experimental design of RNA sequencing, featuring treatment duration and the sequencing parameters. (<bold>g</bold>) Heatmap depicting the expression of differentially expressed genes obtained from RNA sequencing in the indicated conditions. Notably, Control and LST represent yeast cells unloaded and pre-loaded with lanosterol, respectively. α-factor is represented as α, where plus and minus signs represent its presence and absence, respectively. (<bold>h</bold>) Schematic representation of the experimental workflow followed to deduce the impact of indicated metabolites treatment on isoproterenol (ISO)-induced, GPCR-mediated hypertrophy response in human (AC16) and neonatal rat cardiomyocytes. Notably, in the case of AC16 cells, wheat germ agglutinin (WGA) was used to stain the cardiomyocytes, whereas, for neonatal cardiomyocytes, alpha-sarcomeric actinin staining was used. (<bold>i</bold>) Micrographs depicting the human (above; green colored) and neonatal rat (below; red colored) cardiomyocytes in the indicated conditions. Scale 50 µm. (<bold>j</bold>) Box plots depicting the surface area of human (AC16) and neonatal rat cardiomyocytes in the indicated conditions. Statistical significance of indicated metabolites with untreated control and isoproterenol-treated conditions is indicated in green and gray text, respectively. Mann–Whitney <italic>U</italic> test with Bonferroni-corrected p-values was used to compute statistical significance.</p><p><supplementary-material id="fig4sdata1"><label>Figure 4—source data 1.</label><caption><title>PDF file containing original western blots of p-Fus3, Fus3, and Pgk1 displayed in <xref ref-type="fig" rid="fig4">Figure 4e</xref>.</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-106397-fig4-data1-v1.pdf"/></supplementary-material></p><p><supplementary-material id="fig4sdata2"><label>Figure 4—source data 2.</label><caption><title>Original files for western blot analysis of p-Fus3, Fus3, and Pgk1 displayed in <xref ref-type="fig" rid="fig4">Figure 4e</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-106397-fig4-data2-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-106397-fig4-v1.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Effects of Ste2 mutants on shmoo formation in response to α-factor.</title><p>(<bold>a</bold>) Ligplots depicting the interacting amino acid residues of the mutant Ste2 proteins (mutation site indicated) and atoms of indicated metabolites at the intracellular cavities (IC4 and IC5). (<bold>b</bold>) Growth curve profiles of the reconstituted wild-type (rtWT) and indicated missense site-directed mutants. (<bold>c</bold>) Schematic representation depicting the overall experimental workflow designed for the quantitative assessment of the shmoos formation upon α-factor treatment. (<bold>d</bold>) Micrographs depicting the phase contrast images of the rtWT cells, pretreated with the indicated metabolites, with and without α-factor treatment, Scale 10 µm. Mean-whisker plot (right) indicating the relative proportions of shmoos forming cells in the indicated conditions. (<bold>e</bold>) Micrographs depicting the phase contrast images of the indicated site-directed missense mutants of the <italic>STE2</italic> gene, pretreated with the indicated metabolites, with and without α-factor treatment, Scale 10 µm. Mean-whisker plot (right) indicating the relative proportions of shmoos forming cells in the indicated conditions. The Student’s <italic>t</italic>-test was used to compute the statistical significance of d and e. Asterisks indicate statistical significance, whereas ns represents non-significance. Error bars represent the standard error of the mean (SEM).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-106397-fig4-figsupp1-v1.tif"/></fig><fig id="fig4s2" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 2.</label><caption><title>RNA-sequencing unveils genes involved in attenuating α-factor-induced cell death response.</title><p>(<bold>a</bold>) A table highlighting the key differentially expressed genes in the indicated conditions reported to be involved in regulating yeast mating response. Arrowheads and their direction represent the direction of differential expression. (<bold>b</bold>) A table highlighting the key differentially expressed genes in the indicated conditions reported to be involved in regulating yeast programmed cell death (PCD)-like signaling response. Arrowheads and their direction represent the direction of differential expression. (<bold>c</bold>) <italic>M</italic>–<italic>D</italic> plots (left) from the NOIseq analysis highlighting the differentially expressed genes (colored) in the indicated conditions. Bar plots (middle) depicting the prominent Gene Ontologies in the indicated conditions. Venn diagram (right) depicting the overlaps between the differentially expressed genes and the genes used in biochemical assays. (<bold>d</bold>) Venn diagram depicting the overlap between the differentially expressed genes obtained from the RNA-Seq analysis and the yeast knockout library. (<bold>e</bold>) Growth curve profiles of the wild-type and indicated knockouts from the yeast knockout library. (<bold>f</bold>) Box plot depicting the relative proportion of dead cells upon α-factor exposure in the indicated knockouts, from the yeast knockout library as inferred using propidium iodide-based cell viability fluorometric assay (<italic>n</italic> = 12 biological replicates from 2 experiments). The <italic>y</italic>-axis represents the fold change of the propidium iodide fluorescence values with respect to their respective controls. The Mann–Whitney <italic>U</italic> test was used to calculate statistical significance. Asterisks indicate statistical significance, whereas ns represents non-significance.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-106397-fig4-figsupp2-v1.tif"/></fig><fig id="fig4s3" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 3.</label><caption><title>Evolutionary conservation of GPCR–Gα interface.</title><p>(<bold>a</bold>) Molecular representations depicting the topology of human and rat ADRB1 and ADRB2 receptors. GPCR–Gα interface cavities are color-coded at the intracellular sites. Of note, in the case of human ADRB1, the nomenclature of the two cavities detected at the interface includes ‘Cv’ (cavity) succeeded by the numerical number. (<bold>b</bold>) Bar plots depicting the binding energies obtained by the docking of Human ADRB1 (7BVQ), Human ADRB2 (5X7D), Rat ADRB1 (P18090), and Rat ADRB2 (P10608) with the indicated metabolites at the GPCR–Gα interfaces. (<bold>c</bold>) Table depicting the conservation of yeast Ste2p–metabolite (ZST, CoQ6, and LST) interacting residues in the adrenergic receptors from humans and rats. (<bold>d</bold>) The schematic workflow illustrates the steps involved in measuring and comparing the sequential and ligand-interaction conservation of GPCRs across six different species. (<bold>e</bold>) Donut charts illustrating the GPCR count across different species. (<bold>f</bold>) Phylogenetic tree representing 75 unique GPCRs from six species. (<bold>g</bold>) Empirical Cumulative Distribution Function (ECDF) plot depicting binding energy distribution of Gcoupler identified potential allosteric modulators along with five negative controls. (<bold>h</bold>) Heatmap depicting the pairwise <italic>d</italic>-values/p-values from the Kolmogorov–Smirnov statistical test under specified conditions. The lower triangle of the heatmap represents d-values, while the upper triangle shows p-values for the specified pair. The test provides two key outputs: the <italic>D</italic>-value, which represents the maximum difference between the cumulative distribution functions (CDFs) of the two groups, and the p-value, which indicates the statistical significance of the observed difference. Symbols *, **, ***, and **** refer to p-values &lt;0.05,&lt;0.01,&lt;0.001, and &lt;0.0001, respectively.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-106397-fig4-figsupp3-v1.tif"/></fig></fig-group><p>Next, we performed experimental validation by generating site-directed missense mutants targeting key binding residues at the Ste2p–Gpa1p interface and confirmed these computational predictions (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1b</xref>, <xref ref-type="supplementary-material" rid="supp13">Supplementary file 13</xref>). These mutants were expressed in a <italic>ste2Δ</italic> background, with the reconstituted wild-type <italic>STE2</italic> (rtWT) serving as a control. Using fluorometry-based cell death assays, it was assessed whether mutants retained the metabolite-mediated rescue response observed in wild-type cells. While rtWT exhibited significant cell death upon α-factor exposure that could be rescued by metabolite pretreatment, the T155D and L289K mutants showed no rescue response despite pretreatment with their respective metabolites (<xref ref-type="fig" rid="fig4">Figure 4c</xref>). This loss of rescue suggests direct metabolite regulation of Ste2p signaling at the intracellular Ste2p–Gpa1p interface. Notably, S75A mutants showed minimal α-factor responsiveness overall, likely due to significant structural disruptions affecting both pheromone sensitivity and metabolite binding. FUN1 staining assay and p-Fus3 signaling analysis by mapping MAPK pathway activation further supported these findings (<xref ref-type="fig" rid="fig4">Figure 4d, e</xref>). The lack of rescue highlights the direct role of metabolite binding at the Ste2p–Gpa1p interface in regulating downstream signaling. Interestingly, S75A mutants showed no α-factor-induced effects, likely due to significant structural disruptions. Shmoo formation assays further corroborated these findings, with no rescue effects observed in the mutants despite metabolite pre-loading (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1c–e</xref>).</p><p>To gain an unbiased view of the mode of action of these metabolites in attenuating Ste2p (GPCR)-mediated pheromone-induced cell death in yeast, we performed RNA sequencing on LST-pre-loaded and untreated (control) cells with and without α-factor exposure (<xref ref-type="fig" rid="fig4">Figure 4f</xref>). Transcriptomic analysis of control cells (without metabolite treatment) revealed significant expression changes in genes related to critical cellular processes upon α-factor exposure (<xref ref-type="fig" rid="fig4">Figure 4g</xref>, top panel; <xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2c</xref>). A more detailed and careful examination revealed differential expression of genes implicated in PCD and mating responses, including <italic>GSY1</italic>, whose downregulation was linked to α-factor resistance (<xref ref-type="fig" rid="fig4">Figure 4f, g</xref>, <xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2a–c</xref>, <xref ref-type="supplementary-material" rid="supp7 supp8 supp9 supp10">Supplementary files 7–10</xref>). LST treatment alone (without α-factor) also induced significant differential gene expression associated with cellular processing, validating its bioactivity (<xref ref-type="fig" rid="fig4">Figure 4g</xref>, middle panel). However, comparison of LST-pre-loaded versus control cells following α-factor treatment revealed no prominent mating or PCD-related genes among the differentially expressed genes (<xref ref-type="fig" rid="fig4">Figure 4g</xref>, lower panel); however, one cannot rule out the contribution of these genes in providing innate resistance to the α-factor. We tested the contribution of these genes in facilitating metabolite-mediated rescue phenotypes using the α-factor-induced cell-death assay on the knockouts of these differentially upregulated transcripts. Our results showed a significant loss of metabolite-mediated rescue phenotype in 6 out of 10 knockouts, with <italic>YCR095W-A</italic> displaying the most pronounced phenotype loss (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2d–f</xref>). These results collectively suggest that metabolite binding at the Ste2p–Gpa1p interface directly drives rescue responses, with secondary contributions from differentially expressed genes in attenuating α-factor-induced cell death.</p><p>Since our intensive computational interrogation of all the available human GPCR–Gα complexes revealed a higher degree of functional conservation (<xref ref-type="fig" rid="fig1">Figure 1k</xref>), we next explored whether intracellular allosteric modulators such as ubiquinone 6 (CoQ6), zymosterol (ZST), lanosterol (LST), fucosterol (FST), and ubiquinone 10 (CoQ10) modulate GPCR signaling in higher vertebrates such as human and rat beta 1/2-adrenergic receptors signaling. Briefly, by using Gcoupler, we identified the putative GPCR–Gα interface and performed molecular docking with the aforementioned metabolites. Docking results revealed a high binding affinity of these selected metabolites at the GPCR–Gα interface of adrenergic receptors, reminiscent of Ste2p–metabolite interactions (<xref ref-type="fig" rid="fig4s3">Figure 4—figure supplement 3a, b</xref>). Sequence conservation analysis of the GPCR–Gα interface across yeast Ste2p and adrenergic receptors in humans and rats further confirmed a high degree of evolutionary conservation at the metabolite-binding residues (<xref ref-type="fig" rid="fig4s3">Figure 4—figure supplement 3c</xref>). Finally, to test this functional relevance, we evaluated the effect of these metabolites on isoproterenol-induced adrenergic receptor-mediated cardiac hypertrophy in human AC16 cardiomyocytes and neonatal rat cardiomyocytes. Pre-loading cells with these metabolites significantly attenuated hypertrophic responses, as evidenced by reduced single-cell surface area in quantitative assessments (<xref ref-type="fig" rid="fig4">Figure 4h–j</xref>). Notably, to further evaluate the evolutionary conservation of this phenomenon, we also analyzed 75 unique GPCR–Gα complex structures from six species, selected from the PDB database. Dynamic docking was performed using five metabolites (CoQ6, ZST, LST, FST, and CoQ10) identified by Gcoupler as potential allosteric modulators and five negative controls predicted as poor binders. Results revealed significantly lower docking scores (&lt;−7 kcal/mol) for Gcoupler-recommended metabolites compared to negative controls, irrespective of GPCR type or species (<xref ref-type="fig" rid="fig4s3">Figure 4—figure supplement 3d–h</xref>). These findings demonstrate that intracellular metabolite modulation of GPCR activity is a conserved mechanism extending beyond yeast to higher vertebrates.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>Over the last few decades, extensive research has focused on identifying allosteric modulators of GPCRs due to their relevance in drug discovery (<xref ref-type="bibr" rid="bib42">Leach et al., 2007</xref>; <xref ref-type="bibr" rid="bib72">Topiol, 2018a</xref>). Most known modulators are exogenous and target extracellular sites, while intracellular allosteric sites, identified recently through structural biology, offer novel avenues for regulation (<xref ref-type="bibr" rid="bib14">Calebiro et al., 2021</xref>; <xref ref-type="bibr" rid="bib56">Rees et al., 2002</xref>; <xref ref-type="bibr" rid="bib80">Wold and Zhou, 2018</xref>; <xref ref-type="bibr" rid="bib42">Leach et al., 2007</xref>; <xref ref-type="bibr" rid="bib75">van der Westhuizen et al., 2015</xref>; <xref ref-type="bibr" rid="bib72">Topiol, 2018a</xref>). These sites, overlapping with G-protein and β-arrestin coupling regions, highlight the potential for intracellular allosteric modulation (<xref ref-type="bibr" rid="bib13">Bourque et al., 2022</xref>; <xref ref-type="bibr" rid="bib75">van der Westhuizen et al., 2015</xref>; <xref ref-type="bibr" rid="bib85">Yang et al., 2021</xref>). Intracellular modulators, including chemically diverse agents like auto-antibodies and sodium ions, remain poorly understood, emphasizing the need for systematic exploration of these sites (<xref ref-type="bibr" rid="bib80">Wold and Zhou, 2018</xref>; <xref ref-type="bibr" rid="bib13">Bourque et al., 2022</xref>; <xref ref-type="bibr" rid="bib56">Rees et al., 2002</xref>; <xref ref-type="bibr" rid="bib75">van der Westhuizen et al., 2015</xref>; <xref ref-type="bibr" rid="bib68">Stornaiuolo et al., 2015</xref>; <xref ref-type="bibr" rid="bib57">Reyes-Alcaraz et al., 2020</xref>; <xref ref-type="bibr" rid="bib49">Nachtergaele et al., 2012</xref>; <xref ref-type="bibr" rid="bib90">Zhang et al., 2015</xref>; <xref ref-type="bibr" rid="bib52">O’Callaghan et al., 2012</xref>). However, the lack of data on intracellular modulators limits the feasibility of conventional computational approaches (<xref ref-type="bibr" rid="bib8">Basith et al., 2018</xref>; <xref ref-type="bibr" rid="bib19">Congreve et al., 2020</xref>; <xref ref-type="bibr" rid="bib29">Hedderich et al., 2022</xref>; <xref ref-type="bibr" rid="bib16">Chatzigoulas and Cournia, 2021</xref>; <xref ref-type="bibr" rid="bib7">Bartuzi et al., 2018</xref>; <xref ref-type="bibr" rid="bib32">Hou et al., 2021</xref>; <xref ref-type="bibr" rid="bib73">Topiol, 2018b</xref>).</p><p>To address this gap, we developed Gcoupler, a computational framework integrating de novo cavity identification, ligand synthesis, statistical analysis, graph neural networks, and bioactivity-based ligand prioritization. Unlike existing tools, Gcoupler does not require cavity-specific experimentally validated compounds for model training. Gcoupler’s precision in cavity mapping, flexibility for user-defined queries, and ability to screen large chemical libraries make it a versatile and efficient tool. Additionally, Gcoupler’s generic design allows application beyond GPCRs, contrasting with existing platforms that often have limitations in modularity, precision, or open-source availability. Noteworthy, in contrast to other known allosteric sites identification tools for GPCRs, such as Allosite (<xref ref-type="bibr" rid="bib33">Huang et al., 2013</xref>), AllositePro (<xref ref-type="bibr" rid="bib65">Song et al., 2017</xref>), AlloReverse (<xref ref-type="bibr" rid="bib88">Zha et al., 2023</xref>), that largely leverage the ML-based models or require orthosteric ligand-bound structure as input, the cavity detection feature of Gcoupler (LigBuilderV3), a critical step for the entire workflow, is not limited to only the allosteric sites; instead, it identifies all possible cavity-like regions on the protein surface, which then get classified into druggable, undruggable, or amphibious based on their individual scoring and ligandability, thus making it unbiased and more specific toward query protein. Notably, the rationale for opting for LigBuilder V3 for cavity identification over similar tools such as Fpocket (<xref ref-type="bibr" rid="bib43">Le Guilloux et al., 2009</xref>) is that the former uses a hydrogen atom probe, moving along the protein surface grid of 0.5 Å for cavity detection, being much more precise in detecting cavity boundaries, in both breadth and depth mapping; in contrast, the latter considers clusters of alpha spheres (<xref ref-type="supplementary-material" rid="supp11">Supplementary file 11</xref>).</p><p>To date, only a few methods leverage generative AI models for cavity/pocket-based drug design. Gcoupler is an open-source, end-to-end platform integrating Ligand-Based Drug Design (LBDD) and Structure-Based Drug Design (SBDD) for drug design and large-scale screening. Unlike Pocket Crafter (<xref ref-type="bibr" rid="bib61">Shen et al., 2024</xref>), which requires proprietary tools (e.g., MOE QuickPrep) and lacks predictive model-building modules, Gcoupler offers comprehensive functionality. Similarly, DeepLigBuilder (<xref ref-type="bibr" rid="bib44">Li et al., 2021</xref>) and Schrodinger’s AutoDesigner are either closed source or limited in features compared to Gcoupler. Comparative analysis highlights Gcoupler’s unique advantages in precision, flexibility, and functionality (<xref ref-type="supplementary-material" rid="supp11">Supplementary file 11</xref>).</p><p>Using Gcoupler, we investigated the molecular basis of innate resistance to α-factor-induced PCD in yeast. Unlike humans, yeast possess only two GPCR systems, making their pheromone-sensing pathway ideal for focused study. Previous research predominantly identified downstream regulatory mechanisms (<xref ref-type="bibr" rid="bib77">Velazhahan et al., 2021</xref>; <xref ref-type="bibr" rid="bib64">Sokolov et al., 2020</xref>; <xref ref-type="bibr" rid="bib5">Alvaro and Thorner, 2016</xref>); however, our findings suggest an upstream, receptor-level regulation via endogenous intracellular metabolites. Computational and experimental evidence pinpointed specific metabolites binding to the Ste2p–miniGpa1 interface, modulating signaling. Site-directed mutagenesis confirmed the functional relevance of these metabolite-interacting residues. Of note, previous mutagenesis experiments also revealed multiple critical amino acid residues that overlap with IC4 and IC5, suggesting their functional relevance in Ste2p downstream signaling (<xref ref-type="supplementary-material" rid="supp12">Supplementary file 12</xref>). Despite these advances, certain limitations remain, including the potential pleiotropic effects in metabolic gene knockouts and challenges in replicating natural metabolite concentrations. Mechanistic insights into sterol biosynthesis mutants (<italic>ergΔ</italic>) revealed impaired mating responses due to heterogeneous defects, such as reduced sterol accumulation and shmoo formation, impaired membrane fusion, and decreased <italic>FUS1</italic> expression (<xref ref-type="bibr" rid="bib6">Bagnat and Simons, 2002</xref>; <xref ref-type="bibr" rid="bib36">Jin et al., 2008</xref>; <xref ref-type="bibr" rid="bib30">Heese-Peck et al., 2002</xref>; <xref ref-type="bibr" rid="bib2">Aguilar et al., 2010</xref>; <xref ref-type="bibr" rid="bib71">Tiedje et al., 2007</xref>). This highlights a novel role for sterols in GPCR regulation and their broader implications for yeast microbial factories and stress tolerance (<xref ref-type="bibr" rid="bib59">Shaw et al., 2019</xref>; <xref ref-type="bibr" rid="bib53">Ostrov et al., 2017</xref>). Sterols and other endogenous metabolites were shown to modulate GPCR activity by targeting conserved Gα-binding sites, reinforcing the evolutionary conservation of this mechanism across species, as demonstrated in human and rat hypertrophy models in this study.</p><p>In summary, our work uncovers a novel regulatory mechanism for GPCRs mediated by intracellular metabolites and presents a computational framework, Gcoupler, to explore unexplored allosteric sites. The proposed model suggests that selective metabolites binding to GPCR–Gα interfaces induce local conformational changes, stabilizing GPCR–G-protein complexes and potentially obstructing downstream signaling. Alternative mechanisms, such as orthosteric site modulation, kinase/arrestin interaction interference, or alterations in membrane dynamics, remain to be explored, warranting further investigation. A critical limitation of our study is the absence of direct binding assays to validate the interaction between the metabolites and Ste2p. While our results from genetic interventions, MD simulations, and docking studies strongly suggest that the metabolites interact with the Ste2p–Gpa1 interface, these findings remain indirect. Direct binding confirmation through techniques such as surface plasmon resonance, isothermal titration calorimetry, or co-crystallization would provide definitive evidence of this interaction. Addressing this limitation in future work would significantly strengthen our conclusions and provide deeper insights into the precise molecular mechanisms underlying the observed phenotypic effects. Another critical limitation of our findings is its reliance on tools like AutoDock and PRODIGY for preliminary binding affinity estimates, which lack the thermodynamic precision of advanced methods. Although calibrating docking scores with experimental data or using alchemical free energy calculations can improve accuracy, these methods are computationally expensive and require high-quality data, which is often unavailable. Gcoupler prioritizes speed, scalability, and accessibility, especially for data-sparse scenarios. By focusing on efficient, data-driven classification methods, it balances performance with practicality for large-scale screening. In this study, to address this limitation, we employed MD simulations with molecular mechanics-Generalizer Born surface area approach, incorporating factors like protein flexibility and solvation effects for more accurate Δ<italic>G</italic> calculations. While computationally intensive approaches were beyond this study’s scope, we ensured reported Δ<italic>G</italic> values reflected system conformational flexibility by basing them on pre-simulated docked structures from MD simulations. Further, our results suggest that the metabolite binds to the Ste2p–Gpa1 interface and modulates receptor activity upon pheromone stimulation, as supported by various assays. However, the precise sequence of interactions between Ste2p, the metabolite, and Gpa1 remains unexplored, as it requires sequential experiments beyond this study’s scope. Taken together, addressing these limitations in future work would significantly strengthen our conclusions and provide deeper insights into the precise molecular mechanisms underlying the observed phenotypic effects.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title>Backend code for the Gcoupler</title><p>The back-end code for Gcoupler is implemented entirely in Python (3.8) and comprises four modules: Synthesizer, Authenticator, Generator, and BioRanker. Synthesizer employs LigBuilder V3.0 (<xref ref-type="bibr" rid="bib87">Yuan et al., 2020</xref>) for de novo in silico ligand synthesis, identifying protein cavities likely to be active or allosteric sites using a hybrid GROW-LINK approach with a Genetic Algorithm. The module autonomously selects one cavity for ligand synthesis based on user-defined residue positions. Using the CAVITY function of LigBuilder (<xref ref-type="bibr" rid="bib86">Yuan et al., 2011</xref>), it classifies 3D grid points around the protein into occupied, vacant, and surface points and integrates geometric and physicochemical properties to identify binding sites (<xref ref-type="bibr" rid="bib18">Clark et al., 1989</xref>). Synthesizer outputs ligand structures in SMILES and PDBQT formats, alongside cavity grid coordinates for downstream modules. Authenticator validates the synthesized ligands using AutoDock Vina (1.2.3) for virtual screening (<xref ref-type="bibr" rid="bib74">Trott and Olson, 2010</xref>). Binding energy calculations classify ligands into HABs and LABs, preserving balance for subsequent deep learning analysis. The default energy threshold is set to –7 kcal/mol, but users can explore alternative cutoffs, visualize distributions, and perform statistical comparisons within the workflow. These steps ensure precise identification and prioritization of ligand candidates for further analysis. The Authenticator uses the Kolmogorov–Smirnov test (<xref ref-type="bibr" rid="bib10">Berger and Zhou, 2014</xref>), Anderson–Darling test (<xref ref-type="bibr" rid="bib23">Engmann and Cousineau, 2011</xref>), and Epps–Singleton test (<xref ref-type="bibr" rid="bib27">Goerg and Kaiser, 2009</xref>) for hypothesis testing for the comparison of the distributions. The Authenticator module visualizes ligand distributions using overlapping density plots and ECDF curves. If the default threshold fails to produce statistically meaningful separation, users can supply alternative negative datasets, such as decoys generated via Gcoupler’s inbuilt RDKit Chem module or custom datasets (<xref ref-type="bibr" rid="bib41">Landrum, 2023</xref>). The Generator module builds deep learning-based classification models using the DeepChem (2.6.1) library (<xref ref-type="bibr" rid="bib55">Ramsundar et al., 2019</xref>). It accepts HABs and LABs/decoys from the Authenticator module to train four graph-based models: GCM, GCN (<xref ref-type="bibr" rid="bib40">Kipf and Welling, 2016</xref>), AFP (<xref ref-type="bibr" rid="bib82">Xiong et al., 2020</xref>), and GAT (<xref ref-type="bibr" rid="bib78">Veličković et al., 2018</xref>). Class imbalance is addressed through upsampling techniques. The generator tests all models using default hyperparameters, returning performance metrics for user selection. Hyperparameters can be tuned via manual settings or using default values followed by <italic>k</italic>-fold cross-validation. The final optimized model, trained on the complete synthetic dataset (HAB + LAB/decoys), enables large-scale screening of user-supplied compounds based on their SMILES representations. The BioRanker module performs post-prediction analysis for functional activity-based compound screening. Positively predicted compounds are selected using a stringent probability threshold or adaptive methods such as <italic>G</italic>-means and Youden’s <italic>J</italic> statistic, which optimize sensitivity and specificity. The selected compounds are projected into biological activity spaces (Chemistry, Targets, Networks, Cells, and Clinics) by comparing their biological activity descriptor vectors with those of HABs using cosine similarity (<xref ref-type="bibr" rid="bib11">Bertoni et al., 2021</xref>). A modified PageRank algorithm ranks compounds based on activity-specific scores, with support for multi-activity ranking to refine results based on user-defined biological properties, ensuring precise and context-relevant compound prioritization.</p><p>Additional information about the backend code for Gcoupler, along with methodology for runtime analysis, sequence–structural–functional level analysis, MD simulation, molecular docking (AutoDock), functional enrichment analysis, and protein–protein docking, can be accessed in Appendix 1.</p></sec><sec id="s4-2"><title>Gcoupler benchmarking</title><p>To assess batch effects across Gcoupler runs for a specific cavity, we utilized the standard Gcoupler Docker image. Intracellular cavity 4 (IC4) of the Ste2 protein of yeast was used for benchmarking. A total of 100 molecules were in silico synthesized by the Synthesizer module of Gcoupler iteratively. Post-generation, atom pair fingerprints (ChemmineR; R package) were calculated for the synthesized molecules from each run, and the data was visualized using principal component analysis and pairwise comparison using Tanimoto Similarity (ChemmineR, R package).</p><p>For model benchmarking, Gcoupler was validated on GPCRs from the DUD-E dataset, alongside the information about the active ligands and their randomly selected number-matched decoys (<xref ref-type="bibr" rid="bib48">Mysinger et al., 2012</xref>). Additionally, Gcoupler’s performance in identifying experimentally elucidated allosteric sites and modulators was tested using PDB complexes obtained from the RCSB PDB database.</p></sec><sec id="s4-3"><title>Metabolomics</title><p>Wildtype (BY4741) and <italic>ste2Δ</italic> yeast strains were grown in YPD medium at 30°C, 150 rpm, through primary and secondary cultures (16 hr each). Equal cell numbers (1.5 ml) were aliquoted into a 96-well deep well plate. α-factor (Sigma-Aldrich) was added at final concentrations of 10, 20, 30, 40, and 50 μM (eight replicates each). DMSO served as the solvent control, while untreated WT and <italic>ste2Δ</italic> conditions received no treatment. Plates were incubated (30°C, 150 rpm, 4 hr) under a breathable membrane. A 50 μl aliquot was taken for PI (11195, SRL) assay as described in Appendix 1. Following the PI assay, four pooled replicates were pelleted (6000 rpm, 5 min, RT), treated with zymolyase (40 U/ml, 1X PBS, 30°C, 1 hr), washed with PBS, and metabolomics analysis was performed. Data analysis included peak normalization, omission of metabolites with constant or &gt;50% missing values, and kNN-based imputation (MetaboAnalyst). Data were interquartile range-filtered, and differentially enriched metabolites were identified by calculating log<sub>2</sub> fold change (|log<sub>2</sub>FC| ≥1, p &lt; 0.05 via Student’s <italic>t</italic>-test). Pathway Over-Representation Analysis was performed using MetaboAnalyst with hypergeometric or Fisher’s exact tests to assess pathway enrichment against background metabolite distributions. Further details about the methodology are available in Appendix 1.</p></sec><sec id="s4-4"><title>Genetic screening</title><p>Fifty-three knockout strains from the Yeast Deletion Collection, along with WT and <italic>ste2Δ</italic>, were treated with α-factor (30 μM), while DMSO served as the solvent control. Plates were incubated for 4 hr. A 50 μl aliquot was used to measure the PI-based cell viability assessment assay as described in Appendix 1. Fluorescence data were normalized to blank-adjusted OD<sub>600</sub>, followed by two additional rounds of normalization with unstained and HK controls. The percentage fold change for the treated group was calculated relative to the untreated group, and statistical significance was determined using a one-sample Student’s <italic>t</italic>-test. Further details about the methodology used are available in Appendix 1.</p></sec><sec id="s4-5"><title>Pre-loading of yeast cells with a metabolite</title><p>Yeast cells were cultured in YPD medium at 30°C, 200 rpm for 16 hr in primary and secondary cultures. Equal cell densities (5 μl) from secondary cultures were inoculated into 96-well plates containing 145 μl YPD with metabolites coenzyme Q6 (CoQ6, 900150O, Avanti Polar Lipids), zymosterol (ZST, 700068P, Avanti Polar Lipids), and lanosterol (LST, L5768, Sigma-Aldrich) at 0.1, 1, and 10 μM concentrations. Plates were incubated for 24 hr at 30°C, 200 rpm, with multiple biological replicates. Ethanol-treated wells served as solvent controls. For site-directed <italic>STE2</italic> mutants, the mutants were grown in YPD for primary and secondary cultures, but the metabolite pre-loading was performed in YPGR instead of YPD to induce Ste2 expression.</p><p>After pre-loading, the following assays were performed: growth kinetics, PI-based assay, FUN1 staining, mating assay, phospho-MAPK activity-based western blot, and transgenic reporter assay. The detailed protocol for each of these assays is available in Appendix 1.</p></sec><sec id="s4-6"><title>RNA-sequencing</title><p>Yeast cells (BY4741) were cultured in YPD medium at 30°C, 200 rpm, with or without lanosterol (LST, 1 μM) in biological duplicates. Cells were subsequently treated or untreated with α-factor (30 μM) for 2 hr. RNA was isolated following <xref ref-type="bibr" rid="bib45">Mittal et al., 2022</xref>. Sequencing quality was assessed using MultiFastQ, and paired-end reads were trimmed and aligned to the <italic>S. cerevisiae</italic> reference genome (ENSEMBL R64-1-1; GCA_000146045.2) using the Rsubread package (v2.6.4). Gene expression counts were generated via featureCounts and normalized using TMM (<xref ref-type="supplementary-material" rid="supp7">Supplementary file 7</xref>). Differential expression analysis was performed with NOISeq (v2.38.0) (<xref ref-type="supplementary-material" rid="supp8 supp9 supp10">Supplementary files 8–10</xref>). Functional enrichment was assessed using the Gene Ontology Term Finder (v0.86) from the <italic>Saccharomyces</italic> Genome Database. Raw FASTQ files and normalized expression data are available on Zenodo. Additional details are available in Appendix 1.</p></sec><sec id="s4-7"><title>Site-directed mutagenesis</title><p>The gene encoding wild-type <italic>STE2</italic> was PCR amplified from the genome of <italic>S. cerevisiae</italic> and further cloned into plasmid pRS304 under galactose-inducible <italic>GAL1</italic> promoter to generate plasmid pRS304-P<italic><sub>GAL1</sub></italic>-STE2-CYC1 using Gibson assembly (<xref ref-type="bibr" rid="bib26">Gibson et al., 2010</xref>; <xref ref-type="bibr" rid="bib25">Gibson et al., 2009</xref>). The mutants were generated by PCR amplifying the gene with primers consisting of respective mutations and cloned into plasmid pRS304 under <italic>GAL1</italic> promoter to generate pRS304-P<italic><sub>GAL1</sub></italic>-STE2 S75A-CYC1, pRS304-P<italic><sub>GAL1</sub></italic>-STE2 T155D-CYC1, and pRS304-P<italic><sub>GAL1</sub></italic>-STE2 L289K-CYC1. Wild-type (rtWT) and mutant <italic>STE2</italic> were integrated by digesting the pRS304 vector with restriction enzyme BstXI to generate a linearized plasmid and transformed into the <italic>S. cerevisiae</italic> BY4741 <italic>ste2Δ</italic> strain. Additional details about the methodology are available in <bold>Appendix 1</bold>.</p></sec><sec id="s4-8"><title>Cardiomyocyte hypertrophy models</title><p>Human AC16 cardiomyocytes were cultured in DMEM-F12 (Thermo Scientific) with 12.5% fetal bovine serum (FBS) at 37°C and 5% CO<sub>2</sub>. Cells were seeded in a 24-well plate for size measurements, treated after 24 hr with metabolites (CoQ6, ZST, LST, FST, and CoQ10) at 2.5 μM, and incubated overnight with 1% FBS. The medium was refreshed with fresh metabolites and isoproterenol (25 μM) for 48 hr. Cells were washed with PBS, fixed with 4% paraformaldehyde, and stained with wheat germ agglutinin (Thermo Scientific) and DAPI. Images were captured using a Leica DMI 6000 B microscope at 20× magnification, and cell area was measured using ImageJ. Neonatal rat cardiomyocytes were isolated from 1- to 3-day-old SD rat pups using Collagenase Type II. After heart explantation and digestion, the cells were centrifuged and pre-plated for 90 min to remove fibroblasts. The cardiomyocytes were seeded in a gelatin-coated 24-well plate, incubated overnight with 2.5 μM metabolites and 1% FBS, and then treated with metabolites (2.5 μM) and isoproterenol (10 μM) for 72 hr. Cells were fixed, stained with alpha-sarcomeric actinin and DAPI, and images were captured using a Leica DMI 6000 B at 20× magnification. Cell area was quantified using ImageJ. Additional details about the methodology are available in Appendix 1.</p></sec><sec id="s4-9"><title>Statistical analysis</title><p>Statistical analyses were performed using Past4 software or R Programming. The Mann–Whitney <italic>U</italic> test was applied to compare medians between two distributions (non-parametric), while Student’s <italic>t</italic>-test was used for pairwise comparisons of means. p-value correction was performed using the Bonferroni method when necessary. A significance threshold of 0.05 was set, with *, **, ***, and **** indicating p-values &lt;0.05, &lt;0.01, &lt;0.001, and &lt;0.0001, respectively.</p></sec><sec id="s4-10"><title>Materials availability</title><p>All yeast strains used in this study are available from the corresponding author upon reasonable request.</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Software, Formal analysis, Validation, Visualization, Methodology, Project administration, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Formal analysis, Validation, Visualization, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con3"><p>Data curation, Validation</p></fn><fn fn-type="con" id="con4"><p>Formal analysis</p></fn><fn fn-type="con" id="con5"><p>Formal analysis</p></fn><fn fn-type="con" id="con6"><p>Formal analysis</p></fn><fn fn-type="con" id="con7"><p>Formal analysis</p></fn><fn fn-type="con" id="con8"><p>Writing – review and editing</p></fn><fn fn-type="con" id="con9"><p>Formal analysis</p></fn><fn fn-type="con" id="con10"><p>Formal analysis</p></fn><fn fn-type="con" id="con11"><p>Formal analysis</p></fn><fn fn-type="con" id="con12"><p>Formal analysis</p></fn><fn fn-type="con" id="con13"><p>Formal analysis</p></fn><fn fn-type="con" id="con14"><p>Supervision</p></fn><fn fn-type="con" id="con15"><p>Formal analysis, Supervision, Validation, Methodology</p></fn><fn fn-type="con" id="con16"><p>Formal analysis, Supervision, Methodology</p></fn><fn fn-type="con" id="con17"><p>Conceptualization, Formal analysis, Supervision, Funding acquisition, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con18"><p>Conceptualization, Supervision, Funding acquisition, Methodology, Writing – original draft, Writing – review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>The local IAEC (Institutional Animal Ethics Committee) committee at CSIR-Central Drug Research Institute approved all the animal experiments (IAEC/2020/38) following the guidelines of the Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA), New Delhi, Government of India.</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>The table contains information about the structure of the human GPCR–Gα-protein complexes downloaded from the Protein Data Bank (PDB).</title><p>It also contains information about the PDB IDs, protein name, species information, whether it is used or not, UniProt IDs, and other information.</p></caption><media xlink:href="elife-106397-supp1-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="supp2"><label>Supplementary file 2.</label><caption><title>The table contains information about the normalized root mean square deviation (RMSD) of the pairwise comparison of the GPCR–Gα-protein interface (cavities) for the indicated GPCRs.</title></caption><media xlink:href="elife-106397-supp2-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="supp3"><label>Supplementary file 3.</label><caption><title>The table contains information about the chemical similarities of the de novo synthesized synthetic compounds of the indicated GPCR–Gα-protein interface (cavities).</title><p>Of note, the chemical similarity was computed using the Tanimoto coefficient on the Atomic fingerprints.</p></caption><media xlink:href="elife-106397-supp3-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="supp4"><label>Supplementary file 4.</label><caption><title>The table contains information about the YMDB metabolites predicted to bind at the intracellular cavities IC4 and IC5 of the Ste2 protein.</title><p>Of note, predictions were made using molecular docking and Gcoupler. It contains information about the YMDB ID, metabolite name, SMILES (Simplified Molecular Input Line Entry System), and cavity information. Of note, BE refers to binding energies, whereas probabilities were the outcome of Gcoupler.</p></caption><media xlink:href="elife-106397-supp4-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="supp5"><label>Supplementary file 5.</label><caption><title>The table contains information about the list of metabolite-gene pairs from the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway.</title></caption><media xlink:href="elife-106397-supp5-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="supp6"><label>Supplementary file 6.</label><caption><title>The table contains the results of the untargeted metabolomics.</title><p>Of note, the values represent normalized and imputed peak intensities of the indicated metabolites.</p></caption><media xlink:href="elife-106397-supp6-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="supp7"><label>Supplementary file 7.</label><caption><title>The table contains the TMM normalized read counts after RNA sequencing.</title></caption><media xlink:href="elife-106397-supp7-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="supp8"><label>Supplementary file 8.</label><caption><title>The table contains the list of differentially expressed genes (DEGs) of the Control groups, alongside the other standard output from the NOISeq analysis, such as M and D values, mean values of the two conditions, probability ranking, and other gene-associated features.</title></caption><media xlink:href="elife-106397-supp8-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="supp9"><label>Supplementary file 9.</label><caption><title>The table contains the list of differentially expressed genes (DEGs) of the Control versus LST group, alongside the other standard output from the NOISeq analysis, such as M and D values, mean values of the two conditions, probability ranking, and other gene-associated features.</title></caption><media xlink:href="elife-106397-supp9-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="supp10"><label>Supplementary file 10.</label><caption><title>The table contains the list of differentially expressed genes (DEGs) of the LST group, alongside the other standard output from the NOISeq analysis, such as M and D values, mean values of the two conditions, probability ranking, and other gene-associated features.</title></caption><media xlink:href="elife-106397-supp10-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="supp11"><label>Supplementary file 11.</label><caption><title>The table contains information about the comparison of de novo drug design and cavity detection tools.</title><p>Please note, SBDD refers to Structure-Based Drug Design, and LBDD refers to Ligand-Based Drug Design.</p></caption><media xlink:href="elife-106397-supp11-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="supp12"><label>Supplementary file 12.</label><caption><title>The table contains information about the known mutants from the literature that could modulate Ste2 signaling.</title><p>Of note, the table also contains information about the site of mutation, the nature of the mutation, its position within the intracellular cavities IC4 and IC5, its impact on the Ste2 signaling pathway, and references.</p></caption><media xlink:href="elife-106397-supp12-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="supp13"><label>Supplementary file 13.</label><caption><title>Details of the nucleotide and amino acid Multiple Sequence Alignments (MSAs) of the wild-type STE2 and the site-directed missense mutants of STE2.</title><p>Each row starts with the sequence identifier followed by the aligned sequence (in chunks) with the ending position of the aligned sequence provided at the end, separated by tabs. The mutation sites are highlighted in red (S75A), yellow (T155D), and blue (L289K).</p></caption><media xlink:href="elife-106397-supp13-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-106397-mdarchecklist1-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>The processed untargeted metabolomics data is provided as Supplementary Information. The raw RNA sequencing files are available at ArrayExpress under accession E-MTAB-12992. A Python package for Gcoupler is provided via pip <ext-link ext-link-type="uri" xlink:href="https://test.pypi.org/project/Gcoupler/">https://test.pypi.org/project/Gcoupler/</ext-link>. A dockerDocker container pre-compiled with Gcoupler and all of its dependencies can be found at <ext-link ext-link-type="uri" xlink:href="https://hub.docker.com/r/sanjayk741/gcoupler">https://hub.docker.com/r/sanjayk741/gcoupler</ext-link>. The source code of Gcoupler is available on the project GitHub page: <ext-link ext-link-type="uri" xlink:href="https://github.com/the-ahuja-lab/Gcoupler">https://github.com/the-ahuja-lab/Gcoupler</ext-link> (copy archived at Zenodo with DOI: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.5281/zenodo.7835335">https://doi.org/10.5281/zenodo.7835335</ext-link>), whereas the raw sequencing files can be accessed using DOI: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.5281/zenodo.7834294">https://doi.org/10.5281/zenodo.7834294</ext-link>.</p><p>The following datasets were generated:</p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset1"><person-group person-group-type="author"><name><surname>Ahuja</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2025">2025</year><data-title>RNA-seq of <italic>S. cerevisiae</italic> (BY4741) treated with Lanosterol against untreated controls in the presence and absence of alpha-factor</data-title><source>Array Express</source><pub-id pub-id-type="accession" xlink:href="https://www.ebi.ac.uk/biostudies/ArrayExpress/studies/E-MTAB-12992">E-MTAB-12992</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset2"><person-group person-group-type="author"><collab>the-ahuja-lab</collab></person-group><source>Zenodo</source><year iso-8601-date="2023">2023</year><data-title>Gcoupler supplement data</data-title><pub-id pub-id-type="doi">10.5281/zenodo.7834294</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset3"><person-group person-group-type="author"><collab>the-ahuja-lab</collab></person-group><year iso-8601-date="2023">2023</year><data-title>the-ahuja-lab/Gcoupler: Gcoupler</data-title><source>Zenodo</source><pub-id pub-id-type="doi">10.5281/zenodo.7835335</pub-id></element-citation></p></sec><ack id="ack"><title>Acknowledgements</title><p>The authors thank the IT-HelpDesk team of IIIT-Delhi for assisting with the computational resources. We thank all the members of the Ahuja lab for their intellectual contributions at various stages of this project. We thank Prof. G.P.S. Raghava for providing critical comments on our manuscript. We thank Dr. Arjun Ray for providing intellectual support. We also thank Dr. Martin Graef and Dr. Kaushik Chakraborty for sharing yeast strains and the NIPER Guwahati central facility for helping us with high-resolution metabolomics. The Ahuja lab is supported by the Ramalingaswami Re-entry Fellowship (BT/HRD/35/02/2006), a re-entry scheme of the Department of Biotechnology, Ministry of Science &amp; Technology, Government of India, Start-Up Research Grant (SRG/2020/000232) from the Science and Engineering Research Board, and a research grant from IHUB Anubhuti (Project Grant/23) and an intramural Start-up grant from Indraprastha Institute of Information Technology-Delhi. The INSPIRE faculty grant from the Department of Science &amp; Technology, India, funds the Sengupta lab. Gupta Lab is funded by the Ramalingaswami Re-entry Fellowship (BT/RLF/re-entry/14/2019) from the Department of Biotechnology, Government of India.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abraham</surname><given-names>MJ</given-names></name><name><surname>Murtola</surname><given-names>T</given-names></name><name><surname>Schulz</surname><given-names>R</given-names></name><name><surname>Páll</surname><given-names>S</given-names></name><name><surname>Smith</surname><given-names>JC</given-names></name><name><surname>Hess</surname><given-names>B</given-names></name><name><surname>Lindahl</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers</article-title><source>SoftwareX</source><volume>1–2</volume><fpage>19</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.1016/j.softx.2015.06.001</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aguilar</surname><given-names>PS</given-names></name><name><surname>Heiman</surname><given-names>MG</given-names></name><name><surname>Walther</surname><given-names>TC</given-names></name><name><surname>Engel</surname><given-names>A</given-names></name><name><surname>Schwudke</surname><given-names>D</given-names></name><name><surname>Gushwa</surname><given-names>N</given-names></name><name><surname>Kurzchalia</surname><given-names>T</given-names></name><name><surname>Walter</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Structure of sterol aliphatic chains affects yeast cell shape and cell fusion during mating</article-title><source>PNAS</source><volume>107</volume><fpage>4170</fpage><lpage>4175</lpage><pub-id pub-id-type="doi">10.1073/pnas.0914094107</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alanzi</surname><given-names>AR</given-names></name><name><surname>Moussa</surname><given-names>AY</given-names></name><name><surname>Alsalhi</surname><given-names>MS</given-names></name><name><surname>Nawaz</surname><given-names>T</given-names></name><name><surname>Ali</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Integration of pharmacophore-based virtual screening, molecular docking, ADMET analysis, and MD simulation for targeting EGFR: A comprehensive drug discovery study using commercial databases</article-title><source>PLOS ONE</source><volume>19</volume><elocation-id>e0311527</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0311527</pub-id><pub-id pub-id-type="pmid">39652601</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alhosaini</surname><given-names>K</given-names></name><name><surname>Azhar</surname><given-names>A</given-names></name><name><surname>Alonazi</surname><given-names>A</given-names></name><name><surname>Al-Zoghaibi</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>GPCRs: The most promiscuous druggable receptor of the mankind</article-title><source>Saudi Pharmaceutical Journal</source><volume>29</volume><fpage>539</fpage><lpage>551</lpage><pub-id pub-id-type="doi">10.1016/j.jsps.2021.04.015</pub-id><pub-id pub-id-type="pmid">34194261</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alvaro</surname><given-names>CG</given-names></name><name><surname>Thorner</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Heterotrimeric G protein-coupled receptor signaling in yeast mating pheromone response</article-title><source>The Journal of Biological Chemistry</source><volume>291</volume><fpage>7788</fpage><lpage>7795</lpage><pub-id pub-id-type="doi">10.1074/jbc.R116.714980</pub-id><pub-id pub-id-type="pmid">26907689</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bagnat</surname><given-names>M</given-names></name><name><surname>Simons</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Cell surface polarization during yeast mating</article-title><source>PNAS</source><volume>99</volume><fpage>14183</fpage><lpage>14188</lpage><pub-id pub-id-type="doi">10.1073/pnas.172517799</pub-id><pub-id pub-id-type="pmid">12374868</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bartuzi</surname><given-names>D</given-names></name><name><surname>Kaczor</surname><given-names>AA</given-names></name><name><surname>Matosiuk</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Opportunities and challenges in the discovery of allosteric modulators of GPCRs</article-title><source>Methods in Molecular Biology</source><volume>1705</volume><fpage>297</fpage><lpage>319</lpage><pub-id pub-id-type="doi">10.1007/978-1-4939-7465-8_13</pub-id><pub-id pub-id-type="pmid">29188568</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Basith</surname><given-names>S</given-names></name><name><surname>Cui</surname><given-names>M</given-names></name><name><surname>Macalino</surname><given-names>SJY</given-names></name><name><surname>Park</surname><given-names>J</given-names></name><name><surname>Clavio</surname><given-names>NAB</given-names></name><name><surname>Kang</surname><given-names>S</given-names></name><name><surname>Choi</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Exploring G protein-coupled receptors (GPCRs) ligand space via cheminformatics approaches: impact on rational drug design</article-title><source>Frontiers in Pharmacology</source><volume>9</volume><elocation-id>128</elocation-id><pub-id pub-id-type="doi">10.3389/fphar.2018.00128</pub-id><pub-id pub-id-type="pmid">29593527</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Battle</surname><given-names>GM</given-names></name></person-group><year iso-8601-date="2016">2016</year><source>PDBePISA: Identifying and Interpreting the Likely Biological Assemblies of a Protein Structure</source><publisher-name>Chemistry</publisher-name></element-citation></ref><ref id="bib10"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Berger</surname><given-names>VW</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2014">2014</year><source>Kolmogorov–Smirnov Test: Overview</source><publisher-name>Wiley StatsRef</publisher-name><pub-id pub-id-type="doi">10.1002/9781118445112</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bertoni</surname><given-names>M</given-names></name><name><surname>Duran-Frigola</surname><given-names>M</given-names></name><name><surname>Badia-I-Mompel</surname><given-names>P</given-names></name><name><surname>Pauls</surname><given-names>E</given-names></name><name><surname>Orozco-Ruiz</surname><given-names>M</given-names></name><name><surname>Guitart-Pla</surname><given-names>O</given-names></name><name><surname>Alcalde</surname><given-names>V</given-names></name><name><surname>Diaz</surname><given-names>VM</given-names></name><name><surname>Berenguer-Llergo</surname><given-names>A</given-names></name><name><surname>Brun-Heath</surname><given-names>I</given-names></name><name><surname>Villegas</surname><given-names>N</given-names></name><name><surname>de Herreros</surname><given-names>AG</given-names></name><name><surname>Aloy</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Bioactivity descriptors for uncharacterized chemical compounds</article-title><source>Nature Communications</source><volume>12</volume><elocation-id>3932</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-021-24150-4</pub-id><pub-id pub-id-type="pmid">34168145</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Böhm</surname><given-names>HJ</given-names></name></person-group><year iso-8601-date="1992">1992</year><article-title>The computer program LUDI: a new method for the de novo design of enzyme inhibitors</article-title><source>Journal of Computer-Aided Molecular Design</source><volume>6</volume><fpage>61</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.1007/BF00124387</pub-id><pub-id pub-id-type="pmid">1583540</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Bourque</surname><given-names>K</given-names></name><name><surname>Dallagnol</surname><given-names>JCC</given-names></name><name><surname>Nassour</surname><given-names>H</given-names></name><name><surname>Chatenet</surname><given-names>D</given-names></name><name><surname>Allen</surname><given-names>BG</given-names></name><name><surname>Hébert</surname><given-names>TE</given-names></name></person-group><year iso-8601-date="2022">2022</year><source>Exploring the Use of Intracellular and Extracellular Allosteric Modulators to Understand GPCR Signaling</source><publisher-name>Allosteric Modulation of G Protein-Coupled Receptors</publisher-name><pub-id pub-id-type="doi">10.1016/B978-0-12-819771-4.00008-7</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Calebiro</surname><given-names>D</given-names></name><name><surname>Koszegi</surname><given-names>Z</given-names></name><name><surname>Lanoiselée</surname><given-names>Y</given-names></name><name><surname>Miljus</surname><given-names>T</given-names></name><name><surname>O’Brien</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>G protein-coupled receptor-G protein interactions: a single-molecule perspective</article-title><source>Physiological Reviews</source><volume>101</volume><fpage>857</fpage><lpage>906</lpage><pub-id pub-id-type="doi">10.1152/physrev.00021.2020</pub-id><pub-id pub-id-type="pmid">33331229</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Case</surname><given-names>DA</given-names></name><name><surname>Cheatham</surname><given-names>TE</given-names><suffix>III</suffix></name><name><surname>Darden</surname><given-names>T</given-names></name><name><surname>Gohlke</surname><given-names>H</given-names></name><name><surname>Luo</surname><given-names>R</given-names></name><name><surname>Merz</surname><given-names>KM</given-names></name><name><surname>Onufriev</surname><given-names>A</given-names></name><name><surname>Simmerling</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Woods</surname><given-names>RJ</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>The Amber biomolecular simulation programs</article-title><source>Journal of Computational Chemistry</source><volume>26</volume><fpage>1668</fpage><lpage>1688</lpage><pub-id pub-id-type="doi">10.1002/jcc.20290</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chatzigoulas</surname><given-names>A</given-names></name><name><surname>Cournia</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Rational design of allosteric modulators: Challenges and successes</article-title><source>WIREs Computational Molecular Science</source><volume>11</volume><elocation-id>1529</elocation-id><pub-id pub-id-type="doi">10.1002/wcms.1529</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chong</surname><given-names>J</given-names></name><name><surname>Soufan</surname><given-names>O</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Caraus</surname><given-names>I</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Bourque</surname><given-names>G</given-names></name><name><surname>Wishart</surname><given-names>DS</given-names></name><name><surname>Xia</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>MetaboAnalyst 4.0: towards more transparent and integrative metabolomics analysis</article-title><source>Nucleic Acids Research</source><volume>46</volume><fpage>W486</fpage><lpage>W494</lpage><pub-id pub-id-type="doi">10.1093/nar/gky310</pub-id><pub-id pub-id-type="pmid">29762782</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clark</surname><given-names>M</given-names></name><name><surname>Cramer</surname><given-names>RD</given-names><suffix>III</suffix></name><name><surname>Van Opdenbosch</surname><given-names>N</given-names></name></person-group><year iso-8601-date="1989">1989</year><article-title>Validation of the general purpose tripos 5.2 force field</article-title><source>Journal of Computational Chemistry</source><volume>10</volume><fpage>982</fpage><lpage>1012</lpage><pub-id pub-id-type="doi">10.1002/jcc.540100804</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Congreve</surname><given-names>M</given-names></name><name><surname>de Graaf</surname><given-names>C</given-names></name><name><surname>Swain</surname><given-names>NA</given-names></name><name><surname>Tate</surname><given-names>CG</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Impact of GPCR structures on drug discovery</article-title><source>Cell</source><volume>181</volume><fpage>81</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.03.003</pub-id><pub-id pub-id-type="pmid">32243800</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Dallakyan</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2021">2021</year><source>MGLTools</source><publisher-name>Reference Source</publisher-name></element-citation></ref><ref id="bib21"><element-citation publication-type="confproc"><person-group person-group-type="author"><name><surname>Doller</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Endogenous Allosteric Modulators of G Protein-Coupled Receptors: Implications in Drug Design</article-title><conf-name>2017 Medicinal Chemistry Reviews</conf-name><pub-id pub-id-type="doi">10.29200/acsmedchemrev-v52.ch18</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Edgar</surname><given-names>RC</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>MUSCLE: multiple sequence alignment with high accuracy and high throughput</article-title><source>Nucleic Acids Research</source><volume>32</volume><fpage>1792</fpage><lpage>1797</lpage><pub-id pub-id-type="doi">10.1093/nar/gkh340</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Engmann</surname><given-names>S</given-names></name><name><surname>Cousineau</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Comparing distributions: the two-sample anderson-darling test as an alternative to the kolmogorov-smirnoff test</article-title><source>Journal of Applied Quantitative Methods</source><volume>6</volume><elocation-id>3</elocation-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gaulton</surname><given-names>A</given-names></name><name><surname>Bellis</surname><given-names>LJ</given-names></name><name><surname>Bento</surname><given-names>AP</given-names></name><name><surname>Chambers</surname><given-names>J</given-names></name><name><surname>Davies</surname><given-names>M</given-names></name><name><surname>Hersey</surname><given-names>A</given-names></name><name><surname>Light</surname><given-names>Y</given-names></name><name><surname>McGlinchey</surname><given-names>S</given-names></name><name><surname>Michalovich</surname><given-names>D</given-names></name><name><surname>Al-Lazikani</surname><given-names>B</given-names></name><name><surname>Overington</surname><given-names>JP</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>ChEMBL: a large-scale bioactivity database for drug discovery</article-title><source>Nucleic Acids Research</source><volume>40</volume><fpage>D1100</fpage><lpage>D1107</lpage><pub-id pub-id-type="doi">10.1093/nar/gkr777</pub-id><pub-id pub-id-type="pmid">21948594</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gibson</surname><given-names>DG</given-names></name><name><surname>Young</surname><given-names>L</given-names></name><name><surname>Chuang</surname><given-names>R-Y</given-names></name><name><surname>Venter</surname><given-names>JC</given-names></name><name><surname>Hutchison</surname><given-names>CA</given-names><suffix>III</suffix></name><name><surname>Smith</surname><given-names>HO</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Enzymatic assembly of DNA molecules up to several hundred kilobases</article-title><source>Nature Methods</source><volume>6</volume><fpage>343</fpage><lpage>345</lpage><pub-id pub-id-type="doi">10.1038/nmeth.1318</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gibson</surname><given-names>DG</given-names></name><name><surname>Glass</surname><given-names>JI</given-names></name><name><surname>Lartigue</surname><given-names>C</given-names></name><name><surname>Noskov</surname><given-names>VN</given-names></name><name><surname>Chuang</surname><given-names>RY</given-names></name><name><surname>Algire</surname><given-names>MA</given-names></name><name><surname>Benders</surname><given-names>GA</given-names></name><name><surname>Montague</surname><given-names>MG</given-names></name><name><surname>Ma</surname><given-names>L</given-names></name><name><surname>Moodie</surname><given-names>MM</given-names></name><name><surname>Merryman</surname><given-names>C</given-names></name><name><surname>Vashee</surname><given-names>S</given-names></name><name><surname>Krishnakumar</surname><given-names>R</given-names></name><name><surname>Assad-Garcia</surname><given-names>N</given-names></name><name><surname>Andrews-Pfannkoch</surname><given-names>C</given-names></name><name><surname>Denisova</surname><given-names>EA</given-names></name><name><surname>Young</surname><given-names>L</given-names></name><name><surname>Qi</surname><given-names>ZQ</given-names></name><name><surname>Segall-Shapiro</surname><given-names>TH</given-names></name><name><surname>Calvey</surname><given-names>CH</given-names></name><name><surname>Parmar</surname><given-names>PP</given-names></name><name><surname>Hutchison</surname><given-names>CA</given-names></name><name><surname>Smith</surname><given-names>HO</given-names></name><name><surname>Venter</surname><given-names>JC</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Creation of a bacterial cell controlled by a chemically synthesized genome</article-title><source>Science</source><volume>329</volume><fpage>52</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.1126/science.1190719</pub-id><pub-id pub-id-type="pmid">20488990</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goerg</surname><given-names>SJ</given-names></name><name><surname>Kaiser</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Nonparametric testing of distributions—the epps–singleton two-sample test using the empirical characteristic function</article-title><source>The Stata Journal</source><volume>9</volume><fpage>454</fpage><lpage>465</lpage><pub-id pub-id-type="doi">10.1177/1536867X0900900307</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>A</given-names></name><name><surname>Choudhary</surname><given-names>M</given-names></name><name><surname>Mohanty</surname><given-names>SK</given-names></name><name><surname>Mittal</surname><given-names>A</given-names></name><name><surname>Gupta</surname><given-names>K</given-names></name><name><surname>Arya</surname><given-names>A</given-names></name><name><surname>Kumar</surname><given-names>S</given-names></name><name><surname>Katyayan</surname><given-names>N</given-names></name><name><surname>Dixit</surname><given-names>NK</given-names></name><name><surname>Kalra</surname><given-names>S</given-names></name><name><surname>Goel</surname><given-names>M</given-names></name><name><surname>Sahni</surname><given-names>M</given-names></name><name><surname>Singhal</surname><given-names>V</given-names></name><name><surname>Mishra</surname><given-names>T</given-names></name><name><surname>Sengupta</surname><given-names>D</given-names></name><name><surname>Ahuja</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Machine-OlF-Action: a unified framework for developing and interpreting machine-learning models for chemosensory research</article-title><source>Bioinformatics</source><volume>37</volume><fpage>1769</fpage><lpage>1771</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btaa1104</pub-id><pub-id pub-id-type="pmid">33416866</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hedderich</surname><given-names>JB</given-names></name><name><surname>Persechino</surname><given-names>M</given-names></name><name><surname>Becker</surname><given-names>K</given-names></name><name><surname>Heydenreich</surname><given-names>FM</given-names></name><name><surname>Gutermuth</surname><given-names>T</given-names></name><name><surname>Bouvier</surname><given-names>M</given-names></name><name><surname>Bünemann</surname><given-names>M</given-names></name><name><surname>Kolb</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>The pocketome of G-protein-coupled receptors reveals previously untargeted allosteric sites</article-title><source>Nature Communications</source><volume>13</volume><elocation-id>2567</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-022-29609-6</pub-id><pub-id pub-id-type="pmid">35538063</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heese-Peck</surname><given-names>A</given-names></name><name><surname>Pichler</surname><given-names>H</given-names></name><name><surname>Zanolari</surname><given-names>B</given-names></name><name><surname>Watanabe</surname><given-names>R</given-names></name><name><surname>Daum</surname><given-names>G</given-names></name><name><surname>Riezman</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Multiple functions of sterols in yeast endocytosis</article-title><source>Molecular Biology of the Cell</source><volume>13</volume><fpage>2664</fpage><lpage>2680</lpage><pub-id pub-id-type="doi">10.1091/mbc.e02-04-0186</pub-id><pub-id pub-id-type="pmid">12181337</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Hoffmann</surname><given-names>C</given-names></name><name><surname>Bünemann</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2010">2010</year><chapter-title>Fluorescence and resonance energy transfer shine new light on GPCR function</chapter-title><person-group person-group-type="editor"><name><surname>Hoffmann</surname><given-names>C</given-names></name></person-group><source>GPCR Molecular Pharmacology and Drug Targeting: Shifting Paradigms and New Directions</source><publisher-name>Wiley</publisher-name><fpage>226</fpage><lpage>251</lpage><pub-id pub-id-type="doi">10.1002/9780470627327</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hou</surname><given-names>T</given-names></name><name><surname>Bian</surname><given-names>Y</given-names></name><name><surname>McGuire</surname><given-names>T</given-names></name><name><surname>Xie</surname><given-names>XQ</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Integrated multi-class classification and prediction of GPCR allosteric modulators by machine learning intelligence</article-title><source>Biomolecules</source><volume>11</volume><elocation-id>870</elocation-id><pub-id pub-id-type="doi">10.3390/biom11060870</pub-id><pub-id pub-id-type="pmid">34208096</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>W</given-names></name><name><surname>Lu</surname><given-names>S</given-names></name><name><surname>Huang</surname><given-names>Z</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Mou</surname><given-names>L</given-names></name><name><surname>Luo</surname><given-names>Y</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Hou</surname><given-names>T</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Allosite: a method for predicting allosteric sites</article-title><source>Bioinformatics</source><volume>29</volume><fpage>2357</fpage><lpage>2359</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btt399</pub-id><pub-id pub-id-type="pmid">23842804</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Jaeger</surname><given-names>WC</given-names></name><name><surname>Pfleger</surname><given-names>KDG</given-names></name><name><surname>Eidne</surname><given-names>KA</given-names></name></person-group><year iso-8601-date="2010">2010</year><chapter-title>Monitoring GPCR-protein complexes using bioluminescence resonance energy transfer</chapter-title><person-group person-group-type="editor"><name><surname>Poyner</surname><given-names>DR</given-names></name><name><surname>Wheatley</surname><given-names>M</given-names></name></person-group><source>G Protein-Coupled Receptors</source><publisher-name>wiley</publisher-name><fpage>111</fpage><lpage>132</lpage><pub-id pub-id-type="doi">10.1002/9780470749210</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jewison</surname><given-names>T</given-names></name><name><surname>Knox</surname><given-names>C</given-names></name><name><surname>Neveu</surname><given-names>V</given-names></name><name><surname>Djoumbou</surname><given-names>Y</given-names></name><name><surname>Guo</surname><given-names>AC</given-names></name><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>P</given-names></name><name><surname>Mandal</surname><given-names>R</given-names></name><name><surname>Krishnamurthy</surname><given-names>R</given-names></name><name><surname>Sinelnikov</surname><given-names>I</given-names></name><name><surname>Wilson</surname><given-names>M</given-names></name><name><surname>Wishart</surname><given-names>DS</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>YMDB: the yeast metabolome database</article-title><source>Nucleic Acids Research</source><volume>40</volume><fpage>D815</fpage><lpage>D820</lpage><pub-id pub-id-type="doi">10.1093/nar/gkr916</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>H</given-names></name><name><surname>McCaffery</surname><given-names>JM</given-names></name><name><surname>Grote</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Ergosterol promotes pheromone signaling and plasma membrane fusion in mating yeast</article-title><source>The Journal of Cell Biology</source><volume>180</volume><fpage>813</fpage><lpage>826</lpage><pub-id pub-id-type="doi">10.1083/jcb.200705076</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jo</surname><given-names>S</given-names></name><name><surname>Kim</surname><given-names>T</given-names></name><name><surname>Iyer</surname><given-names>VG</given-names></name><name><surname>Im</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>CHARMM-GUI: a web-based graphical user interface for CHARMM</article-title><source>Journal of Computational Chemistry</source><volume>29</volume><fpage>1859</fpage><lpage>1865</lpage><pub-id pub-id-type="doi">10.1002/jcc.20945</pub-id><pub-id pub-id-type="pmid">18351591</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jumper</surname><given-names>J</given-names></name><name><surname>Evans</surname><given-names>R</given-names></name><name><surname>Pritzel</surname><given-names>A</given-names></name><name><surname>Green</surname><given-names>T</given-names></name><name><surname>Figurnov</surname><given-names>M</given-names></name><name><surname>Ronneberger</surname><given-names>O</given-names></name><name><surname>Tunyasuvunakool</surname><given-names>K</given-names></name><name><surname>Bates</surname><given-names>R</given-names></name><name><surname>Žídek</surname><given-names>A</given-names></name><name><surname>Potapenko</surname><given-names>A</given-names></name><name><surname>Bridgland</surname><given-names>A</given-names></name><name><surname>Meyer</surname><given-names>C</given-names></name><name><surname>Kohl</surname><given-names>SAA</given-names></name><name><surname>Ballard</surname><given-names>AJ</given-names></name><name><surname>Cowie</surname><given-names>A</given-names></name><name><surname>Romera-Paredes</surname><given-names>B</given-names></name><name><surname>Nikolov</surname><given-names>S</given-names></name><name><surname>Jain</surname><given-names>R</given-names></name><name><surname>Adler</surname><given-names>J</given-names></name><name><surname>Back</surname><given-names>T</given-names></name><name><surname>Petersen</surname><given-names>S</given-names></name><name><surname>Reiman</surname><given-names>D</given-names></name><name><surname>Clancy</surname><given-names>E</given-names></name><name><surname>Zielinski</surname><given-names>M</given-names></name><name><surname>Steinegger</surname><given-names>M</given-names></name><name><surname>Pacholska</surname><given-names>M</given-names></name><name><surname>Berghammer</surname><given-names>T</given-names></name><name><surname>Bodenstein</surname><given-names>S</given-names></name><name><surname>Silver</surname><given-names>D</given-names></name><name><surname>Vinyals</surname><given-names>O</given-names></name><name><surname>Senior</surname><given-names>AW</given-names></name><name><surname>Kavukcuoglu</surname><given-names>K</given-names></name><name><surname>Kohli</surname><given-names>P</given-names></name><name><surname>Hassabis</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Highly accurate protein structure prediction with AlphaFold</article-title><source>Nature</source><volume>596</volume><fpage>583</fpage><lpage>589</lpage><pub-id pub-id-type="doi">10.1038/s41586-021-03819-2</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaneko</surname><given-names>H</given-names></name><name><surname>Hosohara</surname><given-names>M</given-names></name><name><surname>Tanaka</surname><given-names>M</given-names></name><name><surname>Itoh</surname><given-names>T</given-names></name></person-group><year iso-8601-date="1976">1976</year><article-title>Lipid composition of 30 species of yeast</article-title><source>Lipids</source><volume>11</volume><fpage>837</fpage><lpage>844</lpage><pub-id pub-id-type="doi">10.1007/BF02532989</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Kipf</surname><given-names>TN</given-names></name><name><surname>Welling</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Semi-supervised classification with graph convolutional networks</article-title><source>arXiv</source><ext-link ext-link-type="uri" xlink:href="http://arxiv.org/abs/1609.02907">http://arxiv.org/abs/1609.02907</ext-link></element-citation></ref><ref id="bib41"><element-citation publication-type="web"><person-group person-group-type="author"><name><surname>Landrum</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>RDKit: a software suite for cheminformatics, computational chemistry, and predictive modeling</article-title><ext-link ext-link-type="uri" xlink:href="http://www.rdkit.org/RDKit_Overview.pdf">http://www.rdkit.org/RDKit_Overview.pdf</ext-link><date-in-citation iso-8601-date="2023-08-11">August 11, 2023</date-in-citation></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leach</surname><given-names>K</given-names></name><name><surname>Sexton</surname><given-names>PM</given-names></name><name><surname>Christopoulos</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Allosteric GPCR modulators: taking advantage of permissive receptor pharmacology</article-title><source>Trends in Pharmacological Sciences</source><volume>28</volume><fpage>382</fpage><lpage>389</lpage><pub-id pub-id-type="doi">10.1016/j.tips.2007.06.004</pub-id><pub-id pub-id-type="pmid">17629965</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Le Guilloux</surname><given-names>V</given-names></name><name><surname>Schmidtke</surname><given-names>P</given-names></name><name><surname>Tuffery</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Fpocket: An open source platform for ligand pocket detection</article-title><source>BMC Bioinformatics</source><volume>10</volume><elocation-id>168</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2105-10-168</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Pei</surname><given-names>J</given-names></name><name><surname>Lai</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Structure-based <italic>de novo</italic> drug design using 3D deep generative models</article-title><source>Chemical Science</source><volume>12</volume><fpage>13664</fpage><lpage>13675</lpage><pub-id pub-id-type="doi">10.1039/d1sc04444c</pub-id><pub-id pub-id-type="pmid">34760151</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mittal</surname><given-names>A</given-names></name><name><surname>Mohanty</surname><given-names>SK</given-names></name><name><surname>Gautam</surname><given-names>V</given-names></name><name><surname>Arora</surname><given-names>S</given-names></name><name><surname>Saproo</surname><given-names>S</given-names></name><name><surname>Gupta</surname><given-names>R</given-names></name><name><surname>Sivakumar</surname><given-names>R</given-names></name><name><surname>Garg</surname><given-names>P</given-names></name><name><surname>Aggarwal</surname><given-names>A</given-names></name><name><surname>Raghavachary</surname><given-names>P</given-names></name><name><surname>Dixit</surname><given-names>NK</given-names></name><name><surname>Singh</surname><given-names>VP</given-names></name><name><surname>Mehta</surname><given-names>A</given-names></name><name><surname>Tayal</surname><given-names>J</given-names></name><name><surname>Naidu</surname><given-names>S</given-names></name><name><surname>Sengupta</surname><given-names>D</given-names></name><name><surname>Ahuja</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Artificial intelligence uncovers carcinogenic human metabolites</article-title><source>Nature Chemical Biology</source><volume>18</volume><fpage>1204</fpage><lpage>1213</lpage><pub-id pub-id-type="doi">10.1038/s41589-022-01110-7</pub-id><pub-id pub-id-type="pmid">35953549</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moriwaki</surname><given-names>H</given-names></name><name><surname>Tian</surname><given-names>Y-S</given-names></name><name><surname>Kawashita</surname><given-names>N</given-names></name><name><surname>Takagi</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Mordred: a molecular descriptor calculator</article-title><source>Journal of Cheminformatics</source><volume>10</volume><elocation-id>4</elocation-id><pub-id pub-id-type="doi">10.1186/s13321-018-0258-y</pub-id><pub-id pub-id-type="pmid">29411163</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morris</surname><given-names>GM</given-names></name><name><surname>Huey</surname><given-names>R</given-names></name><name><surname>Lindstrom</surname><given-names>W</given-names></name><name><surname>Sanner</surname><given-names>MF</given-names></name><name><surname>Belew</surname><given-names>RK</given-names></name><name><surname>Goodsell</surname><given-names>DS</given-names></name><name><surname>Olson</surname><given-names>AJ</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility</article-title><source>Journal of Computational Chemistry</source><volume>30</volume><fpage>2785</fpage><lpage>2791</lpage><pub-id pub-id-type="doi">10.1002/jcc.21256</pub-id><pub-id pub-id-type="pmid">19399780</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mysinger</surname><given-names>MM</given-names></name><name><surname>Carchia</surname><given-names>M</given-names></name><name><surname>Irwin</surname><given-names>JJ</given-names></name><name><surname>Shoichet</surname><given-names>BK</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Directory of useful decoys, enhanced (DUD-E): better ligands and decoys for better benchmarking</article-title><source>Journal of Medicinal Chemistry</source><volume>55</volume><fpage>6582</fpage><lpage>6594</lpage><pub-id pub-id-type="doi">10.1021/jm300687e</pub-id><pub-id pub-id-type="pmid">22716043</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nachtergaele</surname><given-names>S</given-names></name><name><surname>Mydock</surname><given-names>LK</given-names></name><name><surname>Krishnan</surname><given-names>K</given-names></name><name><surname>Rammohan</surname><given-names>J</given-names></name><name><surname>Schlesinger</surname><given-names>PH</given-names></name><name><surname>Covey</surname><given-names>DF</given-names></name><name><surname>Rohatgi</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Oxysterols are allosteric activators of the oncoprotein Smoothened</article-title><source>Nature Chemical Biology</source><volume>8</volume><fpage>211</fpage><lpage>220</lpage><pub-id pub-id-type="doi">10.1038/nchembio.765</pub-id><pub-id pub-id-type="pmid">22231273</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nishibata</surname><given-names>Y</given-names></name><name><surname>Itai</surname><given-names>A</given-names></name></person-group><year iso-8601-date="1991">1991</year><article-title>Automatic creation of drug candidate structures based on receptor structure starting point for artificial lead generation</article-title><source>Tetrahedron</source><volume>47</volume><fpage>8985</fpage><lpage>8990</lpage><pub-id pub-id-type="doi">10.1016/S0040-4020(01)86503-0</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O’Boyle</surname><given-names>NM</given-names></name><name><surname>Banck</surname><given-names>M</given-names></name><name><surname>James</surname><given-names>CA</given-names></name><name><surname>Morley</surname><given-names>C</given-names></name><name><surname>Vandermeersch</surname><given-names>T</given-names></name><name><surname>Hutchison</surname><given-names>GR</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Open Babel: An open chemical toolbox</article-title><source>Journal of Cheminformatics</source><volume>3</volume><elocation-id>33</elocation-id><pub-id pub-id-type="doi">10.1186/1758-2946-3-33</pub-id><pub-id pub-id-type="pmid">21982300</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O’Callaghan</surname><given-names>K</given-names></name><name><surname>Kuliopulos</surname><given-names>A</given-names></name><name><surname>Covic</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Turning receptors on and off with intracellular pepducins: new insights into G-protein-coupled receptor drug development</article-title><source>The Journal of Biological Chemistry</source><volume>287</volume><fpage>12787</fpage><lpage>12796</lpage><pub-id pub-id-type="doi">10.1074/jbc.R112.355461</pub-id><pub-id pub-id-type="pmid">22374997</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ostrov</surname><given-names>N</given-names></name><name><surname>Jimenez</surname><given-names>M</given-names></name><name><surname>Billerbeck</surname><given-names>S</given-names></name><name><surname>Brisbois</surname><given-names>J</given-names></name><name><surname>Matragrano</surname><given-names>J</given-names></name><name><surname>Ager</surname><given-names>A</given-names></name><name><surname>Cornish</surname><given-names>VW</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>A modular yeast biosensor for low-cost point-of-care pathogen detection</article-title><source>Science Advances</source><volume>3</volume><elocation-id>e1603221</elocation-id><pub-id pub-id-type="doi">10.1126/sciadv.1603221</pub-id><pub-id pub-id-type="pmid">28782007</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pearlman</surname><given-names>DA</given-names></name><name><surname>Murcko</surname><given-names>MA</given-names></name></person-group><year iso-8601-date="1993">1993</year><article-title>CONCEPTS: New dynamic algorithm for <italic>de novo</italic> drug suggestion</article-title><source>Journal of Computational Chemistry</source><volume>14</volume><fpage>1184</fpage><lpage>1193</lpage><pub-id pub-id-type="doi">10.1002/jcc.540141008</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Ramsundar</surname><given-names>B</given-names></name><name><surname>Eastman</surname><given-names>P</given-names></name><name><surname>Feinberg</surname><given-names>E</given-names></name><name><surname>Gomes</surname><given-names>J</given-names></name><name><surname>Leswing</surname><given-names>K</given-names></name><name><surname>Pappu</surname><given-names>A</given-names></name><name><surname>Wu</surname><given-names>M</given-names></name><name><surname>Pande</surname><given-names>V</given-names></name></person-group><year iso-8601-date="2019">2019</year><data-title>DeepChem: democratizing deep-learning for drug discovery, quantum chemistry</data-title><source>Materials Science and Biology</source><ext-link ext-link-type="uri" xlink:href="https://github.com/deepchem/deepchem">https://github.com/deepchem/deepchem</ext-link></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rees</surname><given-names>S</given-names></name><name><surname>Morrow</surname><given-names>D</given-names></name><name><surname>Kenakin</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>GPCR drug discovery through the exploitation of allosteric drug binding sites</article-title><source>Receptors &amp; Channels</source><volume>8</volume><fpage>261</fpage><lpage>268</lpage><pub-id pub-id-type="doi">10.3109/10606820214640</pub-id><pub-id pub-id-type="pmid">12690954</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reyes-Alcaraz</surname><given-names>A</given-names></name><name><surname>Garcia-Rojas</surname><given-names>EYL</given-names></name><name><surname>Bond</surname><given-names>RA</given-names></name><name><surname>McConnell</surname><given-names>BK</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Allosteric modulators for GPCRs as a therapeutic alternative with high potential in drug discovery</article-title><source>Molecular Pharmacology</source><volume>1</volume><elocation-id>91838</elocation-id><pub-id pub-id-type="doi">10.5772/intechopen.91838</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schindelin</surname><given-names>J</given-names></name><name><surname>Arganda-Carreras</surname><given-names>I</given-names></name><name><surname>Frise</surname><given-names>E</given-names></name><name><surname>Kaynig</surname><given-names>V</given-names></name><name><surname>Longair</surname><given-names>M</given-names></name><name><surname>Pietzsch</surname><given-names>T</given-names></name><name><surname>Preibisch</surname><given-names>S</given-names></name><name><surname>Rueden</surname><given-names>C</given-names></name><name><surname>Saalfeld</surname><given-names>S</given-names></name><name><surname>Schmid</surname><given-names>B</given-names></name><name><surname>Tinevez</surname><given-names>J-Y</given-names></name><name><surname>White</surname><given-names>DJ</given-names></name><name><surname>Hartenstein</surname><given-names>V</given-names></name><name><surname>Eliceiri</surname><given-names>K</given-names></name><name><surname>Tomancak</surname><given-names>P</given-names></name><name><surname>Cardona</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Fiji: an open-source platform for biological-image analysis</article-title><source>Nature Methods</source><volume>9</volume><fpage>676</fpage><lpage>682</lpage><pub-id pub-id-type="doi">10.1038/nmeth.2019</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shaw</surname><given-names>WM</given-names></name><name><surname>Yamauchi</surname><given-names>H</given-names></name><name><surname>Mead</surname><given-names>J</given-names></name><name><surname>Gowers</surname><given-names>G-OF</given-names></name><name><surname>Bell</surname><given-names>DJ</given-names></name><name><surname>Öling</surname><given-names>D</given-names></name><name><surname>Larsson</surname><given-names>N</given-names></name><name><surname>Wigglesworth</surname><given-names>M</given-names></name><name><surname>Ladds</surname><given-names>G</given-names></name><name><surname>Ellis</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Engineering a model cell for rational tuning of GPCR Signaling</article-title><source>Cell</source><volume>177</volume><fpage>782</fpage><lpage>796</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2019.02.023</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>S</given-names></name><name><surname>Zhao</surname><given-names>C</given-names></name><name><surname>Wu</surname><given-names>C</given-names></name><name><surname>Sun</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Yan</surname><given-names>W</given-names></name><name><surname>Shao</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Allosteric modulation of G protein-coupled receptor signaling</article-title><source>Frontiers in Endocrinology</source><volume>14</volume><elocation-id>1137604</elocation-id><pub-id pub-id-type="doi">10.3389/fendo.2023.1137604</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>L</given-names></name><name><surname>Fang</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Yang</surname><given-names>F</given-names></name><name><surname>Jenkins</surname><given-names>JL</given-names></name><name><surname>Kutchukian</surname><given-names>PS</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Pocket Crafter: a 3D generative modeling based workflow for the rapid generation of hit molecules in drug discovery</article-title><source>Journal of Cheminformatics</source><volume>16</volume><elocation-id>33</elocation-id><pub-id pub-id-type="doi">10.1186/s13321-024-00829-w</pub-id><pub-id pub-id-type="pmid">38515171</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sicho</surname><given-names>M</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Svozil</surname><given-names>D</given-names></name><name><surname>van Westen</surname><given-names>GJP</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>GenUI: interactive and extensible open source software platform for de novo molecular generation and cheminformatics</article-title><source>Journal of Cheminformatics</source><volume>13</volume><elocation-id>73</elocation-id><pub-id pub-id-type="doi">10.1186/s13321-021-00550-y</pub-id><pub-id pub-id-type="pmid">34563271</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Skalic</surname><given-names>M</given-names></name><name><surname>Sabbadin</surname><given-names>D</given-names></name><name><surname>Sattarov</surname><given-names>B</given-names></name><name><surname>Sciabola</surname><given-names>S</given-names></name><name><surname>De Fabritiis</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>From target to drug: generative modeling for the multimodal structure-based ligand design</article-title><source>Molecular Pharmaceutics</source><volume>16</volume><fpage>4282</fpage><lpage>4291</lpage><pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.9b00634</pub-id><pub-id pub-id-type="pmid">31437001</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sokolov</surname><given-names>SS</given-names></name><name><surname>Galkina</surname><given-names>KV</given-names></name><name><surname>Litvinova</surname><given-names>EA</given-names></name><name><surname>Knorre</surname><given-names>DA</given-names></name><name><surname>Severin</surname><given-names>FF</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>The role of LAM genes in the pheromone-induced cell death of <italic>S. cerevisiae</italic> yeast</article-title><source>Biochemistry</source><volume>85</volume><fpage>300</fpage><lpage>309</lpage><pub-id pub-id-type="doi">10.1134/S0006297920030050</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>K</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Huang</surname><given-names>W</given-names></name><name><surname>Lu</surname><given-names>S</given-names></name><name><surname>Shen</surname><given-names>Q</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Improved method for the identification and validation of allosteric sites</article-title><source>Journal of Chemical Information and Modeling</source><volume>57</volume><fpage>2358</fpage><lpage>2363</lpage><pub-id pub-id-type="doi">10.1021/acs.jcim.7b00014</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spiegel</surname><given-names>JO</given-names></name><name><surname>Durrant</surname><given-names>JD</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>AutoGrow4: an open-source genetic algorithm for de novo drug design and lead optimization</article-title><source>Journal of Cheminformatics</source><volume>12</volume><elocation-id>25</elocation-id><pub-id pub-id-type="doi">10.1186/s13321-020-00429-4</pub-id><pub-id pub-id-type="pmid">33431021</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sprenger</surname><given-names>KG</given-names></name><name><surname>Jaeger</surname><given-names>VW</given-names></name><name><surname>Pfaendtner</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>The general AMBER force field (GAFF) can accurately predict thermodynamic and transport properties of many ionic liquids</article-title><source>The Journal of Physical Chemistry. B</source><volume>119</volume><fpage>5882</fpage><lpage>5895</lpage><pub-id pub-id-type="doi">10.1021/acs.jpcb.5b00689</pub-id><pub-id pub-id-type="pmid">25853313</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stornaiuolo</surname><given-names>M</given-names></name><name><surname>Bruno</surname><given-names>A</given-names></name><name><surname>Botta</surname><given-names>L</given-names></name><name><surname>Regina</surname><given-names>GL</given-names></name><name><surname>Cosconati</surname><given-names>S</given-names></name><name><surname>Silvestri</surname><given-names>R</given-names></name><name><surname>Marinelli</surname><given-names>L</given-names></name><name><surname>Novellino</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Endogenous vs exogenous allosteric modulators in GPCRs: a dispute for shuttling CB1 among different membrane microenvironments</article-title><source>Scientific Reports</source><volume>5</volume><elocation-id>15453</elocation-id><pub-id pub-id-type="doi">10.1038/srep15453</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tarazona</surname><given-names>S</given-names></name><name><surname>Furió-Tarí</surname><given-names>P</given-names></name><name><surname>Turrà</surname><given-names>D</given-names></name><name><surname>Pietro</surname><given-names>AD</given-names></name><name><surname>Nueda</surname><given-names>MJ</given-names></name><name><surname>Ferrer</surname><given-names>A</given-names></name><name><surname>Conesa</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Data quality aware analysis of differential expression in RNA-seq with NOISeq R/Bioc package</article-title><source>Nucleic Acids Research</source><volume>43</volume><elocation-id>e140</elocation-id><pub-id pub-id-type="doi">10.1093/nar/gkv711</pub-id><pub-id pub-id-type="pmid">26184878</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tian</surname><given-names>C</given-names></name><name><surname>Kasavajhala</surname><given-names>K</given-names></name><name><surname>Belfon</surname><given-names>KAA</given-names></name><name><surname>Raguette</surname><given-names>L</given-names></name><name><surname>Huang</surname><given-names>H</given-names></name><name><surname>Migues</surname><given-names>AN</given-names></name><name><surname>Bickel</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Pincay</surname><given-names>J</given-names></name><name><surname>Wu</surname><given-names>Q</given-names></name><name><surname>Simmerling</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>ff19SB: amino-acid-specific protein backbone parameters trained against quantum mechanics energy surfaces in solution</article-title><source>Journal of Chemical Theory and Computation</source><volume>16</volume><fpage>528</fpage><lpage>552</lpage><pub-id pub-id-type="doi">10.1021/acs.jctc.9b00591</pub-id><pub-id pub-id-type="pmid">31714766</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tiedje</surname><given-names>C</given-names></name><name><surname>Holland</surname><given-names>DG</given-names></name><name><surname>Just</surname><given-names>U</given-names></name><name><surname>Höfken</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Proteins involved in sterol synthesis interact with Ste20 and regulate cell polarity</article-title><source>Journal of Cell Science</source><volume>120</volume><fpage>3613</fpage><lpage>3624</lpage><pub-id pub-id-type="doi">10.1242/jcs.009860</pub-id><pub-id pub-id-type="pmid">17895367</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Topiol</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2018">2018a</year><article-title>New opportunities for GPCR allosteric modulators</article-title><source>Future Medicinal Chemistry</source><volume>10</volume><fpage>707</fpage><lpage>710</lpage><pub-id pub-id-type="doi">10.4155/fmc-2017-0313</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Topiol</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2018">2018b</year><article-title>Current and future challenges in GPCR drug discovery</article-title><source>Methods in Molecular Biology</source><volume>1705</volume><fpage>1</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1007/978-1-4939-7465-8_1</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trott</surname><given-names>O</given-names></name><name><surname>Olson</surname><given-names>AJ</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading</article-title><source>Journal of Computational Chemistry</source><volume>31</volume><fpage>455</fpage><lpage>461</lpage><pub-id pub-id-type="doi">10.1002/jcc.21334</pub-id><pub-id pub-id-type="pmid">19499576</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van der Westhuizen</surname><given-names>ET</given-names></name><name><surname>Valant</surname><given-names>C</given-names></name><name><surname>Sexton</surname><given-names>PM</given-names></name><name><surname>Christopoulos</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Endogenous allosteric modulators of g protein–coupled receptors</article-title><source>The Journal of Pharmacology and Experimental Therapeutics</source><volume>353</volume><fpage>246</fpage><lpage>260</lpage><pub-id pub-id-type="doi">10.1124/jpet.114.221606</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Zundert</surname><given-names>GCP</given-names></name><name><surname>Rodrigues</surname><given-names>JPGL</given-names></name><name><surname>Trellet</surname><given-names>M</given-names></name><name><surname>Schmitz</surname><given-names>C</given-names></name><name><surname>Kastritis</surname><given-names>PL</given-names></name><name><surname>Karaca</surname><given-names>E</given-names></name><name><surname>Melquiond</surname><given-names>ASJ</given-names></name><name><surname>van Dijk</surname><given-names>M</given-names></name><name><surname>de Vries</surname><given-names>SJ</given-names></name><name><surname>Bonvin</surname><given-names>AMJJ</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>The HADDOCK2.2 web server: user-friendly integrative modeling of biomolecular complexes</article-title><source>Journal of Molecular Biology</source><volume>428</volume><fpage>720</fpage><lpage>725</lpage><pub-id pub-id-type="doi">10.1016/j.jmb.2015.09.014</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Velazhahan</surname><given-names>V</given-names></name><name><surname>Ma</surname><given-names>N</given-names></name><name><surname>Pándy-Szekeres</surname><given-names>G</given-names></name><name><surname>Kooistra</surname><given-names>AJ</given-names></name><name><surname>Lee</surname><given-names>Y</given-names></name><name><surname>Gloriam</surname><given-names>DE</given-names></name><name><surname>Vaidehi</surname><given-names>N</given-names></name><name><surname>Tate</surname><given-names>CG</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Structure of the class D GPCR Ste2 dimer coupled to two G proteins</article-title><source>Nature</source><volume>589</volume><fpage>148</fpage><lpage>153</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2994-1</pub-id><pub-id pub-id-type="pmid">33268889</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="confproc"><person-group person-group-type="author"><name><surname>Veličković</surname><given-names>P</given-names></name><name><surname>Cucurull</surname><given-names>G</given-names></name><name><surname>Casanova</surname><given-names>A</given-names></name><name><surname>Romero</surname><given-names>A</given-names></name><name><surname>Liò</surname><given-names>P</given-names></name><name><surname>Bengio</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Graph attention networks</article-title><conf-name>International Conference on Learning Representations</conf-name></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Yang</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Force field for water based on neural network</article-title><source>The Journal of Physical Chemistry Letters</source><volume>9</volume><fpage>3232</fpage><lpage>3240</lpage><pub-id pub-id-type="doi">10.1021/acs.jpclett.8b01131</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wold</surname><given-names>EA</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>GPCR allosteric modulators: mechanistic advantages and therapeutic applications</article-title><source>Current Topics in Medicinal Chemistry</source><volume>18</volume><fpage>2002</fpage><lpage>2006</lpage><pub-id pub-id-type="doi">10.2174/1568026619999190101151837</pub-id><pub-id pub-id-type="pmid">30621563</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>F</given-names></name><name><surname>Krishnan</surname><given-names>A</given-names></name><name><surname>Zheng</surname><given-names>EJ</given-names></name><name><surname>Stärk</surname><given-names>H</given-names></name><name><surname>Manson</surname><given-names>AL</given-names></name><name><surname>Earl</surname><given-names>AM</given-names></name><name><surname>Jaakkola</surname><given-names>T</given-names></name><name><surname>Collins</surname><given-names>JJ</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Benchmarking AlphaFold-enabled molecular docking predictions for antibiotic discovery</article-title><source>Molecular Systems Biology</source><volume>18</volume><elocation-id>e11081</elocation-id><pub-id pub-id-type="doi">10.15252/msb.202211081</pub-id><pub-id pub-id-type="pmid">36065847</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiong</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>D</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Zhong</surname><given-names>F</given-names></name><name><surname>Wan</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Luo</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>K</given-names></name><name><surname>Jiang</surname><given-names>H</given-names></name><name><surname>Zheng</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Pushing the boundaries of molecular representation for drug discovery with the graph attention mechanism</article-title><source>Journal of Medicinal Chemistry</source><volume>63</volume><fpage>8749</fpage><lpage>8760</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.9b00959</pub-id></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>M</given-names></name><name><surname>Ran</surname><given-names>T</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>De novo molecule design through the molecular generative model conditioned by 3D information of protein binding sites</article-title><source>Journal of Chemical Information and Modeling</source><volume>61</volume><fpage>3240</fpage><lpage>3254</lpage><pub-id pub-id-type="doi">10.1021/acs.jcim.0c01494</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xue</surname><given-names>LC</given-names></name><name><surname>Rodrigues</surname><given-names>JP</given-names></name><name><surname>Kastritis</surname><given-names>PL</given-names></name><name><surname>Bonvin</surname><given-names>AM</given-names></name><name><surname>Vangone</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>PRODIGY: a web server for predicting the binding affinity of protein-protein complexes</article-title><source>Bioinformatics</source><volume>32</volume><fpage>3676</fpage><lpage>3678</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btw514</pub-id><pub-id pub-id-type="pmid">27503228</pub-id></element-citation></ref><ref id="bib85"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>D</given-names></name><name><surname>Zhou</surname><given-names>Q</given-names></name><name><surname>Labroska</surname><given-names>V</given-names></name><name><surname>Qin</surname><given-names>S</given-names></name><name><surname>Darbalaei</surname><given-names>S</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Yuliantie</surname><given-names>E</given-names></name><name><surname>Xie</surname><given-names>L</given-names></name><name><surname>Tao</surname><given-names>H</given-names></name><name><surname>Cheng</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>Q</given-names></name><name><surname>Zhao</surname><given-names>S</given-names></name><name><surname>Shui</surname><given-names>W</given-names></name><name><surname>Jiang</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>M-W</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>G protein-coupled receptors: structure- and function-based drug discovery</article-title><source>Signal Transduction and Targeted Therapy</source><volume>6</volume><fpage>1</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1038/s41392-020-00435-w</pub-id></element-citation></ref><ref id="bib86"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yuan</surname><given-names>Y</given-names></name><name><surname>Pei</surname><given-names>J</given-names></name><name><surname>Lai</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>LigBuilder 2: a practical de novo drug design approach</article-title><source>Journal of Chemical Information and Modeling</source><volume>51</volume><fpage>1083</fpage><lpage>1091</lpage><pub-id pub-id-type="doi">10.1021/ci100350u</pub-id><pub-id pub-id-type="pmid">21513346</pub-id></element-citation></ref><ref id="bib87"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yuan</surname><given-names>Y</given-names></name><name><surname>Pei</surname><given-names>J</given-names></name><name><surname>Lai</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>LigBuilder V3: a multi-target de novo drug design approach</article-title><source>Frontiers in Chemistry</source><volume>8</volume><elocation-id>142</elocation-id><pub-id pub-id-type="doi">10.3389/fchem.2020.00142</pub-id></element-citation></ref><ref id="bib88"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zha</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Lin</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>T</given-names></name><name><surname>Wei</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Lu</surname><given-names>X</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Ni</surname><given-names>D</given-names></name><name><surname>Song</surname><given-names>K</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Lu</surname><given-names>X</given-names></name><name><surname>Lu</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>AlloReverse: multiscale understanding among hierarchical allosteric regulations</article-title><source>Nucleic Acids Research</source><volume>51</volume><fpage>W33</fpage><lpage>W38</lpage><pub-id pub-id-type="doi">10.1093/nar/gkad279</pub-id></element-citation></ref><ref id="bib89"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>N-N</given-names></name><name><surname>Dudgeon</surname><given-names>DD</given-names></name><name><surname>Paliwal</surname><given-names>S</given-names></name><name><surname>Levchenko</surname><given-names>A</given-names></name><name><surname>Grote</surname><given-names>E</given-names></name><name><surname>Cunningham</surname><given-names>KW</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Multiple signaling pathways regulate yeast cell death during the response to mating pheromones</article-title><source>Molecular Biology of the Cell</source><volume>17</volume><fpage>3409</fpage><lpage>3422</lpage><pub-id pub-id-type="doi">10.1091/mbc.e06-03-0177</pub-id><pub-id pub-id-type="pmid">16738305</pub-id></element-citation></ref><ref id="bib90"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>P</given-names></name><name><surname>Covic</surname><given-names>L</given-names></name><name><surname>Kuliopulos</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Pepducins and other lipidated peptides as mechanistic probes and therapeutics</article-title><source>Methods in Molecular Biology</source><volume>1324</volume><fpage>191</fpage><lpage>203</lpage><pub-id pub-id-type="doi">10.1007/978-1-4939-2806-4_13</pub-id><pub-id pub-id-type="pmid">26202271</pub-id></element-citation></ref><ref id="bib91"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Meng</surname><given-names>J</given-names></name><name><surname>Xu</surname><given-names>C</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Multiple GPCR functional assays based on resonance energy transfer sensors</article-title><source>Frontiers in Cell and Developmental Biology</source><volume>9</volume><elocation-id>611443</elocation-id><pub-id pub-id-type="doi">10.3389/fcell.2021.611443</pub-id><pub-id pub-id-type="pmid">34041234</pub-id></element-citation></ref></ref-list><app-group><app id="appendix-1"><title>Appendix 1</title><sec sec-type="appendix" id="s8"><title>Materials and methods</title><sec sec-type="appendix" id="s8-1"><title>Backend code for the Gcoupler</title><p>The back-end code for the Gcoupler is written entirely in Python (3.8). The Gcoupler workflow consists of four distinct modules, namely, Synthesizer, Authenticator, Generator, and BioRanker. The Synthesizer module leverages the LigBuilder V3.0 (<xref ref-type="bibr" rid="bib87">Yuan et al., 2020</xref>) to identify the putative cavities on the protein surface with the potential to be an active or an allosteric site and perform de novo in silico drug synthesis within the target cavity by following a hybrid approach of GROW and LINK method using Genetic Algorithm. Notably, among all the predicted cavities, the Synthesizer module pinpoints one cavity as the target for the subsequent in silico ligand synthesis process. The decision is autonomous in nature and is taken based on user-supplied residue-position pairs of interest. The Synthesizer module employs the CAVITY (a structure-based protein binding site detection program) function of LigBuilder V3 for cavity detection (<xref ref-type="bibr" rid="bib86">Yuan et al., 2011</xref>). It creates 3D grid points at a cushion of 0.5 Å to contain the whole protein. It uses a Tripos force field (<xref ref-type="bibr" rid="bib18">Clark et al., 1989</xref>) to categorize these points into three groups: ‘occupied grid points’, which contain protein atoms or lie within the range of solvent-accessible radii; ‘vacant grid points’, located outside the protein atoms; and ‘surface grid points’, positioned between the occupied and vacant grid points. Following this classification, a geometric approach is employed to identify potential sites accessible to ligands, also influenced by factors such as depth and volume. Finally, both geometric structural information and physical chemistry properties are utilized to pinpoint locations for ligand binding sites and to quantitatively assess the feasibility of drug binding within each potential site. Gcoupler identifies multiple potentially orthosteric and allosteric cavities across GPCR topological surfaces and allows users to select one of them (per run). Users are provided with three options to choose cavities in the Gcoupler: (1) one of the identified cavities from the Gcoupler, (2) providing key amino acids to receive cavity suggestions, or utilizing third-party tools for cavity identification and providing amino acid information. The synthesizer also performs in silico de novo synthesis of the active compounds within the target cavity, complementing the pharmacophores in the Cartesian space based on the target cavity. In summary, Synthesizer, the first module, generates and outputs the simplified molecular-input line-entry system (SMILES) and PDBQT files of the synthesized ligands along with cavity information in the form of grid coordinates, which is required as input by the next module.</p><p>Authenticator, the next module of Gcoupler, takes the PDBQT files and the cavity grid information generated using Synthesizer as input and further allows the segregation of these synthetic compounds based on their actual interaction at the molecular level. The Authenticator module leverages AutoDock Vina (1.2.3) python library for virtual screening (<xref ref-type="bibr" rid="bib74">Trott and Olson, 2010</xref>). The binding energies produced by the Authenticator module are further used to segregate the synthetic compounds into High-Affinity Binders (HABs) and Low-Affinity Binders (LABs) based on the distribution while preserving the class balance for the downstream deep learning steps. Of note, the default value of binding energy for the distribution split is set to –7 kcal/mol; however, the module provides enough flexibility to the users to try and test different cutoffs (loose to stringent) and can visualize the change in distribution and statistically compare the resulting distributions within the Gcoupler workflow.</p><p>The Authenticator uses the Kolmogorov–Smirnov test (<xref ref-type="bibr" rid="bib10">Berger and Zhou, 2014</xref>), Anderson–Darling test (<xref ref-type="bibr" rid="bib23">Engmann and Cousineau, 2011</xref>), and Epps–Singleton test (<xref ref-type="bibr" rid="bib27">Goerg and Kaiser, 2009</xref>) for hypothesis testing for the comparison of the distributions. The Authenticator module supports the graphical plots, such as overlapping density plots and Empirical Cumulative Distribution Function (ECDF), to visualize the distributions. In case either the Authenticator module fails to recognize the default cutoff as an optimal threshold for the distribution split or the user decides that the resulting distributions fail to obtain the statistical inference under any threshold of their choice, the module is also incorporated with the other options for providing negative datasets, such as decoys (Gcoupler inbuilt function using Chem module of RDKit Python package; <xref ref-type="bibr" rid="bib41">Landrum, 2023</xref>) and user-supplied negative datasets.</p><p>The third module of Gcoupler, known as Generator, leverages the DeepChem (2.6.1) (<xref ref-type="bibr" rid="bib55">Ramsundar et al., 2019</xref>) python library to build the Graph-Neural Networks supported classification models. The Generator takes the segregated HAB and LAB/decoys from the Authenticator module and uses these synthetic compounds to build prediction models. By default, the Generator module supports four different graph-based models, i.e., Graph Convolution Model (GCM), Graph Convolution Network (GCN) (<xref ref-type="bibr" rid="bib40">Kipf and Welling, 2016</xref>), Attentive FP (AFP) (<xref ref-type="bibr" rid="bib82">Xiong et al., 2020</xref>), and Graph Attention Network (GAT) (<xref ref-type="bibr" rid="bib78">Veličković et al., 2018</xref>), to generate classification models. Before the model-building step, the Generator module evaluates the class imbalance in the synthetic dataset and implements the upsampling techniques to counter it, if required. The Generator, by default, tests the preprocessed synthetic data on all four deep learning-based models under the default hyperparameters and returns models’ performance parameter list, allowing users to select the best-performing model for the downstream refinement process. Users can either manually set up the hyperparameter tuning grid parameters or opt for the recommended grid range along with the fold count for <italic>k</italic>-fold cross-validation to tune the selected model around the best hyperparameters and evaluate the stability of the said optimized parameters. In the final step, the Generator builds the resultant model with the best-performing hyperparameters by utilizing the complete synthetic compound library (HAB + LAB/decoys) for training, allowing large-scale screening of the user query compounds by using SMILES information.</p><p>The final module of Gcoupler, the BioRanker module, provides a framework for post-data analysis. It processes prediction outputs from the Generator module to conduct functional activity-based subsetting and screening of a query compound library. Initially, it employs a stringent prediction probability threshold to select positively predicted query compounds. Users can also choose the inbuilt function with <italic>G</italic>-means algorithm and Youden’s <italic>J</italic> statistics for more precise selection of query compounds to be processed. The geometric mean (<italic>G</italic>-mean) is the mathematical square root of the product of sensitivity and specificity, whereas Youden’s <italic>J</italic> statistic (sensitivity + specificity − 1) is defined as the distance between the ROC curve and the chance line. The optimal threshold is the one that maximizes the J Statistics. These selected compounds are then projected onto various biological activity spaces, including Chemistry, Targets, Networks, Cells, and Clinics, through pairwise cosine similarity comparisons between their biological activity descriptor vectors and those of synthetic HABs. Subsequently, a modified PageRank algorithm is utilized for activity-specific ranking of the query compounds. Additionally, the module supports multi-activity-based ranking, enabling sequential screening based on a user-defined list of biological properties, thus enhancing the precision and relevance of compound selection.</p></sec><sec sec-type="appendix" id="s8-2"><title>Runtime analysis</title><p>To showcase the speed and efficiency of our de novo coupled Deep Learning approach against conventional docking, we performed a comparative study involving analysis of the same query compound dataset against a single target of interest through both approaches. A system with 125 GB RAM, 16 Threads, and 8 CPU cores with no upgradation to the software or hardware within the duration of this analysis was used as the platform for this comparison. To compare the time complexity between Gcoupler and classical docking procedures using AutoDock (<xref ref-type="bibr" rid="bib47">Morris et al., 2009</xref>), we selected human alpha-1A adrenergic receptors (ADRA1A) as our GPCR of interest. Since the experimentally elucidated structure of ADRA1A is unknown, we used AlphaFold (<xref ref-type="bibr" rid="bib38">Jumper et al., 2021</xref>) predicted structure as our starting point. The ligand binding cavity at the extracellular site was determined using the LigBuilder V3.0 (<xref ref-type="bibr" rid="bib87">Yuan et al., 2020</xref>) cavity function. Moreover, we obtained the ADRA1A ligand information from the ChEMBL database (Version 31) corresponding to the accession ID: CHEMBL229 (<xref ref-type="bibr" rid="bib24">Gaulton et al., 2012</xref>). We obtained a total of 3684 bioactive compounds against ADRA1A; however, to ensure uniformity, we only selected those ligands (#933) that were annotated as ‘single protein format experiments’. Files preparation for AutoDock-based docking includes conversion of ligand SMILES to MOL2 using OpenBabel (2.4.1) (<xref ref-type="bibr" rid="bib51">O’Boyle et al., 2011</xref>), followed by conversion of MOL2 to PDBQT via MGLtools (1.5.6) (<xref ref-type="bibr" rid="bib20">Dallakyan, 2021</xref>), and receptor PDB to PDBQT using OpenBabel (2.4.1) (<xref ref-type="bibr" rid="bib51">O’Boyle et al., 2011</xref>). Noteworthily, the grid parameter calculations were manually performed, and docking was performed using AutoDock (4.2.6).</p><p>The Gcoupler workflow was performed using the steps above. To ensure uniformity of the target cavity between both approaches, the cavity information, along with the grid coordinate obtained during the initial steps of the AutoDock approach (<xref ref-type="bibr" rid="bib47">Morris et al., 2009</xref>), was reused by the Synthesizer and the Authenticator module for generating de novo ligands and their molecular interaction-based classification, respectively. The Authenticator module selected an optimal binding energy cutoff of –8 kcal/mol; however, we opted for decoys for the negative dataset generation due to severe class imbalance. Under default hyperparameters, AttentiveFP showed better overall performance scores among the four deep learning-based models tested. We used the AttentiveFP model with the following hyperparameters: {'num_layers': 2, 'num_timesteps': 2, 'graph_feat_size': 200, 'dropout': 0} after assessment with 10-fold cross-validation. The final model was generated using the complete HAB compound library as the positive and respective decoys dataset as a negative class for the model learning. Post-model generation, all 933 ligands were screened for their binding prediction probabilities.</p></sec><sec sec-type="appendix" id="s8-3"><title>Sequence–structural–functional level analysis</title><p>All the available, non-redundant 66 human GPCR–Gα complexes were downloaded from the RCSB PDB database (<ext-link ext-link-type="uri" xlink:href="https://www.rcsb.org/">https://www.rcsb.org/</ext-link>). The sequence level information for each of these GPCRs was obtained from the UniProt database (<ext-link ext-link-type="uri" xlink:href="https://www.uniprot.org">https://www.uniprot.org</ext-link>). Multiple Sequence Alignment (MSA) was performed to study the sequence level conservation, using the FASTA sequences of the GPCRs as input for the Multiple Sequence Comparison by Log-Expectation (MUSCLE) algorithm (<xref ref-type="bibr" rid="bib22">Edgar, 2004</xref>). MUSCLE uses the PAM substitution matrix and sum-of-pairs (SP) score for alignment scoring. The MUSCLE alignment output in CLW format was then subsequently used to compute amino acid level conservation using the WebLogo tool (<ext-link ext-link-type="uri" xlink:href="https://weblogo.berkeley.edu/logo.cgi">https://weblogo.berkeley.edu/logo.cgi</ext-link>). To identify conserved motifs native to the GPCR–Gα interface, residues at the GPCR–Gα interface for each GPCR–Gα complex were retrieved using EMBL-EBI developed PDBePISA tool and subsequently mapped on the WebLogos (<xref ref-type="bibr" rid="bib9">Battle, 2016</xref>). To test the structural level conservation, the pairwise similarity of the PDBePISA provided GPCR–Gα interfaces (cavity) of all 66 GPCRs was achieved using the normalized root mean square deviation (RMSD), calculated using the PyMOL software (<ext-link ext-link-type="uri" xlink:href="https://pymol.org/2/">https://pymol.org/2/</ext-link>). The RMSD values were normalized by dividing the cavity RMSD by their respective whole protein RMSD. Finally, to analyze the functional level conservation of the GPCR-Gα interfaces, we used the Gcoupler’s Synthesizer module to compute 50 synthetic ligands for each GPCR–Gα interface (cavity) and calculated their physicochemical properties (descriptors) using Mordred (<xref ref-type="bibr" rid="bib46">Moriwaki et al., 2018</xref>). For each GPCR–Gα-protein interface, we computed a single vector representing the aggregated physicochemical property of all the synthesized compounds for the given GPCR cavity and measured their similarities using the Cosine similarity.</p></sec><sec sec-type="appendix" id="s8-4"><title>Molecular dynamics simulation</title><p>The molecular dynamics simulation was performed using either GROMACS (<xref ref-type="bibr" rid="bib1">Abraham et al., 2015</xref>) or AMBER (<xref ref-type="bibr" rid="bib15">Case et al., 2005</xref>) software suite. For Ste2p, the experimentally elucidated structure with PDB ID: 7ad3 was downloaded from the RCSB PDB database (<xref ref-type="bibr" rid="bib77">Velazhahan et al., 2021</xref>). Since the available structure was provided for the dimer, PDB preprocessing steps were used to isolate a single chain (chain B) that refers to the GPCR. Embedding in the lipid bilayer representing yeast plasma membrane composition was performed using the CHARM-GUI (<xref ref-type="bibr" rid="bib37">Jo et al., 2008</xref>) and the simulations using GROMACS (<xref ref-type="bibr" rid="bib1">Abraham et al., 2015</xref>). Notably, we performed six rounds of equilibration with the membrane system and nine rounds of production runs of 5 ns each. We finally selected the last frame of the simulation step from the production run for further analysis. Protein–ligand complexes were prepared for the molecular dynamics simulations using AMBER software (<xref ref-type="bibr" rid="bib15">Case et al., 2005</xref>), as discussed above. Notably, we performed all analyses using the Ste2p monomers. The grid box center and several grids were chosen appropriately to restrict the conformational sampling within the specific binding site. By default, the software estimates docking energies for 250,000 conformations of the ligands within the binding sites and ranks them to find the top 10 binding modes. The best binding modes for the ligands in these two sites were analyzed. The subsequent molecular dynamics simulations were performed for the ligands in these two binding sites, and the input configuration is based on the aforementioned molecular docking study results. The charges for the ligands were computed using density functional theory calculations at the B3LYP/6–31+G* level of theory. We used a general amber force field (GAFF) to describe the molecular interactions (<xref ref-type="bibr" rid="bib67">Sprenger et al., 2015</xref>). For protein, we employed the FF19SB force field (<xref ref-type="bibr" rid="bib70">Tian et al., 2020</xref>), and for water, the TIP3P force field was used (<xref ref-type="bibr" rid="bib79">Wang and Yang, 2018</xref>). The Ste2p–ligand complexes were embedded in about 23,000 water molecules. The minimization run, simulation in the constant volume ensemble, and simulation in the isothermal-isobaric ensemble were carried out. The time step for integrating the equation of motion was 2 fs. Following the equilibration run, a time scale simulation was carried out for 100 ns (three replicates for IC4 and IC5) and 550 ns (one replicate for IC4 cavity only). All the Ste2p–ligand complex simulations were performed using Amber20 software (<xref ref-type="bibr" rid="bib15">Case et al., 2005</xref>). Various structural properties, such as RMSD and RMSF, were computed and analyzed. The binding free energies using molecular mechanics-Generalizer Born surface area approach (MM/GBSA) were computed for 1000 configurations picked up from the last 10 ns trajectory. The binding free energies computed using the molecular mechanics-generalized Born surface area approach are the quantitative measure of the binding preference of ligands to a specific target binding site. The values are obtained from the time average of different contributions such as van der Waals, electrostatic, polar, and non-polar solvation energies. When compared to molecular docking approaches, these binding free energies are obtained as an average over multiple protein–ligand configurations from MD simulations, and so are more reliable and accurate. In addition, many of the molecular docking simulations do not account for conformational flexibility. Still, in the MM/GBSA calculations, the effects of protein-conformational flexibility, segmental motion, and cavity breathing are also accounted for, making results more reliable compared to molecular docking-based binding affinities.</p></sec><sec sec-type="appendix" id="s8-5"><title>Molecular docking (AutoDock)</title><p>YMDB metabolites were downloaded from the YMDB database (Version 2.0) (<xref ref-type="bibr" rid="bib35">Jewison et al., 2012</xref>). Of note, we took the metabolites structure file (SDF format) provided on the YMDB database to extract 2D information of the metabolites, and to gain missing metadata, we intersected these metabolites with the YMDB full database and obtained a total of 1264 metabolites. When we finally converted these compounds into 3D structures for docking or into graphs for testing data for the DeepChem-based model, a fraction of these compounds failed to convert, and we finally selected a unique set of 1198 metabolites. The file preparation for the docking protocol involved converting the YMDB SMILES (1D) to MOL2 (3D) format. This was achieved using the OpenBabel software (2.4.1) (<xref ref-type="bibr" rid="bib51">O’Boyle et al., 2011</xref>). Further, the compounds from the MOL2 format were converted into dockable PDBQT format by following the MGLtools (1.5.6) ligand preparation procedure (<xref ref-type="bibr" rid="bib20">Dallakyan, 2021</xref>). Of note, the sub-processing steps include detecting the ligand center, selecting single bonds as torsion/rotatable bonds, etc. As discussed above, the receptor PDBs were also converted into PDBQT format using the OpenBabel software (<xref ref-type="bibr" rid="bib51">O’Boyle et al., 2011</xref>). AutoDock (4.2.6) (<xref ref-type="bibr" rid="bib47">Morris et al., 2009</xref>) was used for molecular docking by implementing a Genetic algorithm with the following parameters (population size = 150, maximum number of evaluations = 25,000,000, and maximum number of generations = 27,000). Notably, 10 complexes were generated per YMDB compound. The docking results, that is, extracting the lowest binding energy from each docked protein–ligand complex, were analyzed using the MGLtools (1.5.6) (<xref ref-type="bibr" rid="bib20">Dallakyan, 2021</xref>). Notably, the Δ<italic>G</italic> values were calculated on the pre-simulated stable docked structure. In the case of blind docking, the grid was made across the complete Ste2p structure and was docked using the aforementioned parameters with the YMDB metabolites.</p></sec><sec sec-type="appendix" id="s8-6"><title>Functional enrichment analysis</title><p>Functional enrichment analysis of the differentially enriched metabolites or the metabolites of interest was performed using MetaboAnalyst (<ext-link ext-link-type="uri" xlink:href="https://www.metaboanalyst.ca/">https://www.metaboanalyst.ca/</ext-link>) web server (<xref ref-type="bibr" rid="bib17">Chong et al., 2018</xref>). For the YMDB compound library, the union of the lead compounds identified for each target cavity (IC4 and IC5) was used as input. In the case of the untargeted metabolomics data, the differentially enriched metabolites between the α-factor treated and untreated conditions were used as input. The hypergeometric test was used for hypothesis testing and providing subsequent p-values for each resultant enrichment pathway.</p></sec><sec sec-type="appendix" id="s8-7"><title>Protein–protein docking</title><p>To determine the impact of metabolite binding on GPCR–Gα and GPCR–α-factor interaction, we performed Protein–Protein docking using the HADDOCK (High Ambiguity Driven protein–protein DOCKing) webserver (<xref ref-type="bibr" rid="bib76">van Zundert et al., 2016</xref>). HADDOCK is an innovative information-guided, flexible docking methodology for biomolecular complex modeling, uniquely utilizing ambiguous interaction restraints (AIRs) derived from identified or predicted protein interfaces, along with explicit distance restraints (e.g., MS cross-links) and diverse experimental data like NMR residual dipolar couplings, pseudo contact shifts, and cryo-EM maps, setting it apart from ab initio docking approaches. In the case of Ste2p-miniGpa1p or Ste2p–α-factor docking, the PDB chains of both proteins were extracted from the PDB complex (accession id: 7ad3) (<xref ref-type="bibr" rid="bib77">Velazhahan et al., 2021</xref>). Ste2p in the docked complex with the respective metabolites was simulated via the AMBER software suite (<xref ref-type="bibr" rid="bib15">Case et al., 2005</xref>). Post-simulation, the most stable conformation of protein-metabolite was taken, and the metabolite was manually removed to obtain a metabolite-influenced stable Ste2p structure. HADDOCK was subsequently used for the protein–protein docking between wild Ste2p or metabolite-influenced bound stable Ste2p against miniGpa1–protein or α-factor (extracted from PDB ID: 7ad3). The optimal representative complexes were obtained from the HADDOCK results (<xref ref-type="bibr" rid="bib76">van Zundert et al., 2016</xref>) and were used as input in PRODIGY (PROtein binDIng enerGY prediction) (<xref ref-type="bibr" rid="bib84">Xue et al., 2016</xref>) for <italic>K</italic><sub>d</sub> and ∆<italic>G</italic> calculations. PRODIGY is a web service that provides support for the prediction of binding affinity in biological complexes. Notably, the Δ<italic>G</italic> values were calculated on the pre-simulated stable docked structures.</p></sec><sec sec-type="appendix" id="s8-8"><title>Yeast strains</title><p>BY4741 (<italic>MATa his3Δ1 leu2Δ0 met15Δ ura3Δ</italic>) and <italic>ste2Δ</italic> (<italic>MATa ste2Δ::kanMX his3Δ1 leu2Δ ura3Δ met15Δ</italic>) strains of <italic>Saccharomyces cerevisiae</italic> were used in all the experiments. For the mating assay, BY4742 strain (<italic>MAT</italic>α <italic>his3Δ1 leu2Δ0 lys2Δ0 ura3Δ0</italic>) was also used. All the knockouts were obtained from the Yeast Deletion Collection (<italic>MATa xxx::kanMX his3Δ1 leu2Δ0 ura3Δ0 met15Δ0</italic>). Unless mentioned, the yeast was grown at 30°C at 200 rpm in yeast extract–peptone–dextrose (YPD) (1% yeast extract, 2% peptone, and 2% dextrose). Agar (1.5%) was additionally added to YPD to prepare plates. Both the site-directed yeast mutants (T155D, L289K, and S75A) as well as reconstituted <italic>STE2</italic> transgenes (rtWT) were grown in yeast extract–peptone–galactose-raffinose (YPGR; 1% yeast extract, 2% peptone, and 2% galactose, 2% raffinose).</p></sec><sec sec-type="appendix" id="s8-9"><title>Metabolomics</title><p>Wildtype (BY4741) and <italic>ste2Δ</italic> yeast strains were inoculated in the primary culture, followed by a secondary culture, in YPD medium at 30°C at 150 rpm for 16 hr each. 1.5 ml of the secondary cultures were aliquoted into a 96-well deep well plate to ensure an equal number of cells for both strains. α-factor (T6901, Sigma-Aldrich) was added to the wells to attain final concentrations of 10, 20, 30, 40, and 50 μM, with eight biological replicates each. DMSO (28580, SRL) (volume equivalent to the 30 μM α-factor sample) was added to the solvent control. DMSO or α-factor was not added to untreated (WT) and <italic>ste2Δ</italic> conditions. The plate was covered with a breathe-easy membrane (Z380059, Sigma-Aldrich) and incubated at 30°C at 150 rpm for 4 hr. After incubation, an aliquot of 50 μl was used to perform propidium iodide (PI) fluorometric assay as described in the later section.</p><p>Post PI-based cell viability assay, four biological replicates were created by pooling biological replicates. These were transferred to 1.5 ml microcentrifuge tubes and pelleted down at 6000 rpm for 5 min at room temperature (RT). The cell pellet was treated with zymolyase enzyme (L2524, Sigma-Aldrich) at a final concentration of 40 units/mL in 1X PBS and incubated at 30°C for 1 hr. Following this, the cells were washed with 1X PBS, and the cell pellet was stored at –80°C before metabolomics.</p><p>Metabolomics was performed on 1290 Infinity HPLC coupled with 6545 QTOF (Agilent Technologies, Santa Clara, CA, USA) equipped with dual ESI Source. The internal controls used in metabolomics include Jasmonic acid, Gibberellic acid, zeatin, Tryptophan 15N, Estrone D4, Arginine 15N, Thiamine D4, 15N5-8-OH-2-dG, 13C12 dityrosine, and 8-PGF2-D4. The protein precipitation method was used for the sample preparation. Briefly, 10 µl of a cocktail containing commercial stable isotopes internal standards were added, followed by the addition of chilled 750 µl methanol: water (4:1) and probe sonicated. Then, 450 µl of chilled chloroform was added and vortexed for 5 min, followed by adding 150 µl of chilled water, vortexed, and kept the sample at –20°C for 30 min. Next, samples were centrifuged at 5000 rpm at 4°C for 10 min to separate the methanol and chloroform layers. Both layers were collected and dried at 30°C using a vacuum concentrator and reconstituted in 100 µl methanol: water (1:1). Quality Control (QC) samples were injected between every five samples to check the drift in the instrument and to evaluate the signal repeatability. Pearson’s rank order showed that QCs (<italic>n</italic> = 6) were strongly correlated (<italic>r</italic> &gt; 0.9) with each other, suggesting variations were insignificant.</p><p>Data analysis of the metabolomics data includes peak normalization. Furthermore, the normalized peak intensities of all the samples’ replicates were merged, and the metabolites with a constant value or with more than 50% missing values were omitted. The missing values were imputed using the feature-based <italic>k</italic> nearest neighbors (kNN) via Metaboanalyst webserver. The data were filtered based on the interquartile range (IQR). To find the list of differentially enriched metabolites (DEMs), log<sub>2</sub> fold change (log<sub>2</sub>FC) values were calculated for each sample with respect to the solvent control, along with its statistical significance using Student’s <italic>t</italic>-test. The metabolites with |log<sub>2</sub>FC ≥1| and p-value &lt;0.05 were considered DEMs. Pathway Over Representation Analysis (ORA) was performed using MetaboAnalyst (<xref ref-type="bibr" rid="bib17">Chong et al., 2018</xref>). Note: ORA is a computational method used in metabolomics research to gain insights into the biological significance of a set of metabolites that exhibit changes under different experimental conditions or in response to a perturbation or those belonging to a particular group. This analysis is conducted using statistical tests such as hypergeometric tests or Fisher’s exact tests to determine if the observed number of metabolites in a given pathway is significantly higher than expected based on the background distribution of metabolites.</p></sec><sec sec-type="appendix" id="s8-10"><title>Genetic screening</title><p>Fifty-three knockout strains from the Yeast Deletion Collection, along with WT and <italic>ste2Δ</italic> strains, were grown in primary culture, followed by secondary culture, in YPD medium at 30°C at 150 rpm for 16 hr each. Ensuring an equal number of cells in all the strains, 5 μl of secondary culture was inoculated into 96-well plates containing 145 μl of YPD and grown for 16 hr at 30°C at 200 rpm with eight biological replicates. Afterward, α-factor was added to half the replicates at a final concentration of 30 μM. An equal volume of DMSO was added to the other half to serve as solvent control. The plates were incubated for another 4 hr. After incubation, a 50 μl aliquot was mixed with 50 μl of staining solution (PI (11195, SRL) in 1x PBS, freshly prepared) to attain a final PI concentration of 5 μg/ml in 96-well black plates. The plates were incubated in the dark for 15 min. Heat-killed (HK) cells were used as a positive control. The fluorescence was measured using Biotek Synergy HTX multi-mode reader at excitation and emission wavelengths of 530/25 nm and 590/25 nm, respectively. Another 50 μl aliquot from the original plates was used to measure OD<sub>600</sub> after 1:2 dilution with 1X PBS. The fluorescence values were first normalized for data analysis with the blank normalized OD<sub>600</sub> values of the respective well. These normalized fluorescence values were subjected to two more rounds of normalization, first with unstained cells followed by HK cells. Following this, percentage fold change was calculated for the treated group with respect to the untreated group. The p-value was computed using a one-sample Student’s <italic>t</italic>-test.</p></sec><sec sec-type="appendix" id="s8-11"><title>Pre-loading of yeast cells with metabolite</title><p>Yeast cells were cultured in YPD medium at 30°C, 200 rpm for 16 hr in primary and secondary cultures. Equal cell densities (5 μl) from secondary cultures were inoculated into 96-well plates containing 145 μl YPD with metabolites: coenzyme Q6 (CoQ6, 900150O, Avanti Polar Lipids), zymosterol (ZST, 700068P, Avanti Polar Lipids), and lanosterol (LST, L5768, Sigma-Aldrich) at 0.1, 1, and 10 μM concentrations. Plates were incubated for 24 hr at 30°C, 200 rpm, with multiple biological replicates. Ethanol-treated wells served as solvent controls.</p><p>Site-directed Ste2 mutants were grown in YPD for primary and secondary cultures, but metabolite pre-loading was performed in YPGR instead of YPD to induce Ste2 expression.</p></sec><sec sec-type="appendix" id="s8-12"><title>Cell viability assay using growth kinetics</title><p>Wildtype and <italic>ste2Δ</italic> yeast strains were grown and pre-loaded with ZST, LST, and CoQ6 at concentrations of 0.1, 1, and 10 μM. After pre-loading, 5 μl cultures from this plate were used as an inoculum for another 96-well plate containing 145 μl of YPD along with respective metabolites (CoQ6, ZST, and LST) at concentrations of 0.1, 1, and 10 μM each in the presence of 10 μM α-factor (T6901, Sigma-Aldrich) in the treated group and DMSO in the untreated group with multiple biological replicates. The plates were sealed with breathe-easy membranes to prevent evaporation. The growth kinetics was performed in a Biotek Synergy HTX multi-mode reader for 16.5 hr at 30°C under continuous orbital shaking at 559 CPM. Absorbance was measured at 600 nm every 30 min. The area under the curve (AUC) was calculated for each sample using the bayestestR package in R with default parameters and normalized using the OD<sub>600</sub> value at time <italic>t</italic> = 0.</p></sec><sec sec-type="appendix" id="s8-13"><title>Cell viability assay using PI</title><p>Wild-type and <italic>ste2Δ</italic> yeast strains were grown and pre-loaded with CoQ6, ZST, and LST at concentrations of 0.1, 1, and 10 μM for 24 hr. Following pre-loading, the α-factor was added to half the wells at a final concentration of 30 μM. An equal volume of DMSO was added to the other half to serve as solvent control. The plates were incubated for another 4 hr. After incubation, a 50 μl aliquot was mixed with 50 μl of staining solution (PI in 1X PBS, freshly prepared) to attain a final PI concentration of 5 μg/ml in 96 well-black plates. The plates were incubated in the dark for 15 min. HK cells were used as a positive control. The fluorescence was measured using Biotek Synergy HTX multi-mode reader at excitation and emission wavelengths of 530/25 nm and 590/25 nm, respectively. Another 50 μl aliquot from the original plate was used to measure OD<sub>600</sub> after 1:2 dilution with 1X PBS.</p><p>The fluorescence values were first normalized for data analysis with the blank normalized OD<sub>600</sub> values of the respective well. Cellular background fluorescence values of the unstained cells were subtracted from these normalized fluorescence values. Post this, the fold change between the untreated solvent control and the α-factor treated samples was computed by dividing the latter with the former. Mann–Whitney <italic>U</italic>-test was used to measure the statistical significance.</p><p>The assays for site-directed Ste2 mutants and differentially upregulated gene knockouts were performed and analyzed in the same way with the following modifications: the site-directed Ste2 mutants were grown in YPGR instead of YPD, and the knockouts were grown in the presence of 1 μM LST for pre-treatment before α-factor treatment.</p></sec><sec sec-type="appendix" id="s8-14"><title>Cell viability assay using FUN1 staining</title><p>Wildtype and <italic>ste2Δ</italic> yeast strains were pre-loaded with metabolites at 1 μM (ZST and LST) and 10 μM (CoQ6) concentrations and grown for 24 hr with nine biological replicates. An equal volume of ethanol was added to the control group to negate the effects of the solvent. Following this, α-factor was added to a third of the wells at a final concentration of 30 μM, acetic acid (85801, SRL) to another third at a final concentration of 199 mM, and DMSO to the remaining third to serve as solvent control. The plates were incubated for another 4 hr. Post-incubation, the cells were pelleted down and washed with 1X PBS to remove any media traces at 6000 rpm for 5 min at RT. The staining solution was freshly prepared in 1X GH solution (10 mM HEPES buffer, pH 7.2, 2% glucose) with FUN 1 Cell Stain (F7030, Invitrogen) at a final concentration of 5 μM. The samples were incubated in the dark for 30 min, centrifuged at 6000 rpm for 5 min, and the pellet resuspended in 25 μl of 1x GH solution. 5 μl of the sample was used for fluorescence microscopy (Nikon Eclipse Ci-L Fluorescence Microscope with Nikon DS-Qi2 camera). FITC and TRITC filters were used for measuring green and red fluorescence, respectively, with an exposure time of 1 s each. For each sample, the number of cells with red and green fluorescence, indicating cellular viability and vitality in each image, was counted using ImageJ and normalized with the total cell counts. The assay for site-directed Ste2 mutants was performed and analyzed similarly, with the only difference being that the yeast cells were pre-loaded with metabolites in YPGR instead of YPD.</p></sec><sec sec-type="appendix" id="s8-15"><title>Mating assay</title><p>BY4741 wild-type yeast strains were pre-loaded with metabolites at 1 μM (ZST and LST) and 10 μM (CoQ6) concentrations and grown for 24 hr with biological triplicates. After 24 hr, the cells were harvested, washed (6000 rpm, 5 min, RT) to remove metabolite traces, and resuspended in fresh YPD. Equalized volumes of treated MATa and untreated MATα cells (100 μl each) were mixed in 96-well plates, sealed with a breathable membrane, and incubated for 4 hr at 30°C, 200 rpm to allow mating. Post-mating, cells were washed with distilled water (6000 rpm, 5 min, RT), resuspended in 200 μl distilled water, and serially diluted (1:10). Diluted cultures (5 μl) were spotted on SC-Met (His, Leu, Ade, Ura, Lys), SC-Lys (His, Leu, Ade, Ura, Met), and SC-Met-Lys (His, Leu, Ade, Ura) agar plates (composition: 2% glucose, 2% agar, 20 mg/l histidine, 120 mg/l leucine, 60 mg/l lysine, 20 mg/l methionine, 20 mg/l uracil, and 20 mg/l adenine) in technical triplicates. Plates were incubated at 30°C for 2 days. After incubation, the colonies were counted in ImageJ in the 10<sup>4</sup> dilutions, which had the best resolution of colonies. Mating efficiency was calculated using the following formula:<disp-formula id="equ1"><alternatives><mml:math id="m1"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>M</mml:mi><mml:mi>a</mml:mi><mml:mi>t</mml:mi><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>g</mml:mi><mml:mspace width="thinmathspace"/><mml:mi>E</mml:mi><mml:mi>f</mml:mi><mml:mi>f</mml:mi><mml:mi>i</mml:mi><mml:mi>c</mml:mi><mml:mi>i</mml:mi><mml:mi>e</mml:mi><mml:mi>n</mml:mi><mml:mi>c</mml:mi><mml:mi>y</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mi>c</mml:mi><mml:mi>o</mml:mi><mml:mi>l</mml:mi><mml:mi>o</mml:mi><mml:mi>n</mml:mi><mml:mi>i</mml:mi><mml:mi>e</mml:mi><mml:mi>s</mml:mi><mml:mspace width="thinmathspace"/><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mspace width="thinmathspace"/><mml:mi>D</mml:mi><mml:mi>D</mml:mi><mml:mspace width="thinmathspace"/><mml:mo>×</mml:mo><mml:mspace width="thinmathspace"/><mml:mi>D</mml:mi><mml:mi>i</mml:mi><mml:mi>l</mml:mi><mml:mi>u</mml:mi><mml:mi>t</mml:mi><mml:mi>i</mml:mi><mml:mi>o</mml:mi><mml:mi>n</mml:mi><mml:mspace width="thinmathspace"/><mml:mi>F</mml:mi><mml:mi>a</mml:mi><mml:mi>c</mml:mi><mml:mi>t</mml:mi><mml:mi>o</mml:mi><mml:mi>r</mml:mi></mml:mrow><mml:mrow><mml:mi>c</mml:mi><mml:mi>o</mml:mi><mml:mi>l</mml:mi><mml:mi>o</mml:mi><mml:mi>n</mml:mi><mml:mi>i</mml:mi><mml:mi>e</mml:mi><mml:mi>s</mml:mi><mml:mspace width="thinmathspace"/><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mspace width="thinmathspace"/><mml:mi>S</mml:mi><mml:mi>D</mml:mi><mml:mspace width="thinmathspace"/><mml:mo>×</mml:mo><mml:mspace width="thinmathspace"/><mml:mi>D</mml:mi><mml:mi>i</mml:mi><mml:mi>l</mml:mi><mml:mi>u</mml:mi><mml:mi>t</mml:mi><mml:mi>i</mml:mi><mml:mi>o</mml:mi><mml:mi>n</mml:mi><mml:mspace width="thinmathspace"/><mml:mi>F</mml:mi><mml:mi>a</mml:mi><mml:mi>c</mml:mi><mml:mi>t</mml:mi><mml:mi>o</mml:mi><mml:mi>r</mml:mi></mml:mrow></mml:mfrac><mml:mo>×</mml:mo><mml:mn>100.</mml:mn></mml:mstyle></mml:mrow></mml:mstyle></mml:math><tex-math id="t1">\begin{document}$$\displaystyle Mating\, Efficiency = \frac{colonies\, in\, DD\, \times \, Dilution\, Factor}{colonies\, in\, SD\, \times \, Dilution\, Factor} \times 100.$$\end{document}</tex-math></alternatives></disp-formula></p><p>Here, SD is single dropout media (SC-Met for MATα, and SC-Lys for MATa), and DD is double dropout (SC-Met-Lys).</p></sec><sec sec-type="appendix" id="s8-16"><title>Phospho-MAPK activity-based western blot</title><p>The wild-type BY4741 strain was grown in primary culture, followed by secondary culture, in YPD medium at 30°C at 200 rpm for 16 hr each. 30 μl of secondary culture was inoculated into 1.5 ml of YPD with respective metabolites at concentrations of 1 μM (ZST and LST) and 10 μM (CoQ6) and grown for 24 hr at 30°C at 200 rpm with 6 biological replicates, with ethanol as solvent control. After incubation, the cells were treated with 3 μM of α-factor for 5 min with DMSO as solvent control. Post-incubation, the cells were harvested at 6000 rpm for 5 min at RT. The pellet was resuspended in 400 μl of chilled Lysis buffer (9.5 ml 1X PBS, 200 μl of Protease Inhibitor Cocktail, 200 μl of PMSF (20 mg/ml), 100 μl of 10% Triton X-100) with an equal volume of glass beads. The cells were homogenized for five cycles of 30 s at 3500 rpm, followed by 1-min incubation in ice each. The beads were allowed to settle down with a short spin, following which the lysate was transferred to a fresh vial. The lysate was centrifuged at 2000 rpm for 2 min at 4°C. Supernatants were then transferred to fresh vials, and 5 μl were used in a BCA Protein Assay (Thermo Scientific #23225) carried out according to the manufacturer’s instructions. Absorbance values were compared against bovine serum albumin standards. Lysates were normalized with lysis buffer to 470 μg/μl, mixed 1:4 with 4X Sample Loading buffer (2 ml 1 M Tris pH 6.8, 0.8 g SDS, 4 ml 100% glycerol, 0.4 ml β-mercaptoethanol, 1 ml 0.5 M EDTA, 8 mg bromophenol blue), and heated at 99°C for 10 min.</p><p>Ten milligrams of protein sample were loaded onto 12% SDS-PAGE gel and resolved in SDS electrophoresis buffer at 40 mA. The resolving gel was then transferred to methanol-activated PVDF membranes at 300 mA for 120 min in transfer buffer (3 g Tris, 14.4 g glycine, 200 methanol, 800 ml water) at 4°C. The membranes were placed in a blocking buffer (5% (wt/vol) BSA for p-Fus3 or 5% (wt/vol) skim milk in 1X TBST for rest) for 2 hr at room temperature, washed 3 × 5 min with 1X TBST, and then probed with antibodies to phospho-p44/42 (p-Fus3; Cell Signaling Technology Cat# 4370, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_2315112">AB_2315112</ext-link>, 1:2000), Fus3 (Cell Signaling Technology Cat# 9102, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_330744">AB_330744</ext-link>, 1:1000), or 3-Phosphoglycerate Kinase (Pgk1; Thermo Fisher Scientific Cat# 459250, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_2532235">AB_2532235</ext-link>, 1:5000) as a loading control in 5% BSA for 2 hr at room temperature with shaking. Blots were washed 3 × 5 min with 1X TBST and then incubated with horseradish peroxidase-conjugated goat anti-rabbit (Cell Signaling Technology Cat# 7074, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_2099233">AB_2099233</ext-link>, 1:5000), or horse anti-mouse (Cell Signaling Technology Cat# 7076, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_330924">AB_330924</ext-link>, 1:5000) secondary antibodies in 1X TBST for 2 hr at room temperature. Blots were washed 3 × 5 min with 1X TBST and imaged on a UVTech imaging system after incubation with Immobilon Forte Western HRP Substrate (Millipore #WBLUF0500). Phospho-Fus3 antibody was removed by treatment with mild Stripping Buffer (15 g glycine, 1 g SDS, 10 ml Tween20, pH 2.2, make up to 1 l with water) for 10 min at RT with shaking, discarding the buffer and reincubating for 10 min in fresh stripping buffer, then rinsed thoroughly with 1X TBST 5 × 5 min before blocking and re-probing with Fus3 antibody. Blots were stripped once again and re-probed for Pgk1 as a loading control.</p><p>ImageJ was used to perform the densitometric analysis of the blots. The raw densitometric values so obtained for p-Fus3 and Fus3 were normalized with the loading controls, and the p-Fus3/Fus3 ratio was calculated for each condition. For mutants, this ratio for the samples stimulated with α-factor was further normalized with their corresponding unstimulated solvent controls.</p></sec><sec sec-type="appendix" id="s8-17"><title>Transgenic reporter assay</title><p>The pRS306-P<italic><sub>FUS1</sub></italic>-eGFP-CYC1 plasmid was constructed by subcloning the eGFP gene under the control of the FUS1 promoter into pRS306 using Gibson assembly. The resulting plasmid was integrated at the <italic>URA3</italic> locus of the BY4741 strain, generating the genotype <italic>MATa his3Δ1 leu2Δ0 met15Δ0 ura3::pRS306-P<sub>FUS1</sub>-eGFP-CYC1</italic>.</p><table-wrap id="app1table1" position="float"><label>Appendix 1—table 1.</label><caption><title>The list of primers used in PCR amplification of indicated genes and plasmids for Gibson Assembly.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top">Primer name</th><th align="left" valign="top">Sequence (5′–3′)</th></tr></thead><tbody><tr><td align="left" valign="top">pFUS1 Forward</td><td align="left" valign="top"><named-content content-type="sequence">GTAAAACGACGGCCAGTGAGCTCAATCCTTCAATTTTTCTGGCAACTTTTCTC</named-content></td></tr><tr><td align="left" valign="top">pFUS1 Reverse</td><td align="left" valign="top"><named-content content-type="sequence">GCGTGACATAACTAATTACATGACTCGAGTTACTTGTACAGCTCGTCCATGCCG</named-content></td></tr><tr><td align="left" valign="top">eGFP Forward</td><td align="left" valign="top"><named-content content-type="sequence">CCATCAAGTTTCTGAAAATCAAAGGATCCATGAGTAAGGGCGAGGAGCTGTTCACCG</named-content></td></tr><tr><td align="left" valign="top">eGFP Reverse</td><td align="left" valign="top"><named-content content-type="sequence">GCGTGACATAACTAATTACATGACTCGAGTTACTTGTACAGCTCGTCCATGCCG</named-content></td></tr><tr><td align="left" valign="top">pRS306 Forward</td><td align="left" valign="top"><named-content content-type="sequence">CTCGAGTCATGTAATTAGTTATGTCACG</named-content></td></tr><tr><td align="left" valign="top">pRS306 Reverse</td><td align="left" valign="top"><named-content content-type="sequence">GAGCTCACTGGCCGTCGTTTTAC</named-content></td></tr></tbody></table></table-wrap><p>The transformed strain was cultured in SC-Ura medium (2% glucose, 200 mg/l histidine, 300 mg/l leucine, 400 mg/l methionine, 200 mg/l tryptophan, and 100 mg/l adenine) at 30°C, 200 rpm for 16 hr in both primary and secondary cultures. Equalized cell densities (5 μl) were inoculated into 96-well plates containing 145 μl SC-Ura medium with metabolites (ZST, LST: 1 μM; CoQ6: 10 μM) or ethanol (control) and incubated for 24 hr under identical conditions (three biological replicates). Following 24 hr, α-factor or DMSO (control) was added at a final concentration of 30 μM and incubated for a total of 1.5 hr. Toward the end of the incubation, PI (5 μg/ml) was added to co-stain for 15 min in the dark. Samples (10 μl) were analyzed using Nikon A1R Confocal/TIRF/FLIM microscopy. GFP (488 nm) and mCherry (561 nm) filters were used for measuring green and red fluorescence, respectively. The images were captured at a scan size of 1024 pixels, scan speed of ¼ frame/s, and line average at a count of 4, and the data analysis was performed using ImageJ (<xref ref-type="bibr" rid="bib58">Schindelin et al., 2012</xref>). Dead cells were excluded based on mCherry fluorescence intensity above 2500 intensity units, and cells with an area below 3 pixels were removed to reduce noise in the data. Corrected Total Cell Fluorescence (CTCF) was calculated from 500 randomly selected cells per condition.<disp-formula id="equ2"><alternatives><mml:math id="m2"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>C</mml:mi><mml:mi>T</mml:mi><mml:mi>C</mml:mi><mml:mi>F</mml:mi><mml:mo>=</mml:mo><mml:mi>I</mml:mi><mml:mi>n</mml:mi><mml:mi>t</mml:mi><mml:mi>D</mml:mi><mml:mi>e</mml:mi><mml:mi>n</mml:mi><mml:mi>s</mml:mi><mml:mspace width="thinmathspace"/><mml:mo>−</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>A</mml:mi><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>a</mml:mi><mml:mspace width="thinmathspace"/><mml:mi>o</mml:mi><mml:mi>f</mml:mi><mml:mspace width="thinmathspace"/><mml:mi>t</mml:mi><mml:mi>h</mml:mi><mml:mi>e</mml:mi><mml:mspace width="thinmathspace"/><mml:mi>s</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi><mml:mi>e</mml:mi><mml:mi>c</mml:mi><mml:mi>t</mml:mi><mml:mi>e</mml:mi><mml:mi>d</mml:mi><mml:mspace width="thinmathspace"/><mml:mi>c</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi><mml:mi>l</mml:mi><mml:mspace width="thinmathspace"/><mml:mo>∗</mml:mo><mml:mi>M</mml:mi><mml:mi>F</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>.</mml:mo></mml:mstyle></mml:mrow></mml:mstyle></mml:math><tex-math id="t2">\begin{document}$$\displaystyle CTCF = IntDens\, - \left (Area\, of\, the\, selected\, cell\, * MF\right).$$\end{document}</tex-math></alternatives></disp-formula></p><p>Here, IntDen is the Integrated Density of the selected cell, and MF is the Mean fluorescence of the background readings.</p></sec><sec sec-type="appendix" id="s8-18"><title>Site-directed mutagenesis</title><p>The gene encoding wild-type <italic>STE2</italic> was PCR amplified from the genome of <italic>Saccharomyces cerevisiae</italic> and further cloned into plasmid pRS304 under galactose-inducible <italic>GAL1</italic> promoter and CYC1 terminator to generate plasmid pRS304-P<italic><sub>GAL1</sub></italic>-STE2-CYC1 using Gibson assembly (<xref ref-type="bibr" rid="bib26">Gibson et al., 2010</xref>; <xref ref-type="bibr" rid="bib25">Gibson et al., 2009</xref>). The mutants were generated by PCR amplifying the gene with primers consisting of respective mutations and cloned into plasmid pRS304 under <italic>GAL1</italic> promoter to generate pRS304-P<italic><sub>GAL1</sub></italic>-STE2 S75A-CYC1, pRS304-P<italic><sub>GAL1</sub></italic>-STE2 T155D-CYC1, and pRS304-P<italic><sub>GAL1</sub></italic>-STE2 L289K-CYC1. Wild-type (rtWT) and mutant <italic>STE2</italic> were integrated by digesting the pRS304 vector with restriction enzyme BstXI to generate linearized plasmid and transformed into <italic>Saccharomyces cerevisiae</italic> BY4741 <italic>ste2Δ</italic> strain. The strains were confirmed for integration by isolating the genome and PCR amplification using locus-specific primers (<xref ref-type="table" rid="app1table2">Appendix 1—table 2</xref>). The following mutants were generated in this work:</p><list list-type="alpha-lower" id="list1"><list-item><p><italic>MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 ste2Δ::kanMX TRP1::P<sub>GAL1</sub>-STE2-CYC1</italic></p></list-item><list-item><p><italic>MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 ste2Δ::kanMX TRP1::P<sub>GAL1</sub>-STE2 S75A-CYC1</italic></p></list-item><list-item><p><italic>MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 ste2Δ::kanMX TRP1::P<sub>GAL1</sub>-STE2 T155D-CYC1</italic></p></list-item><list-item><p><italic>MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 ste2Δ::kanMX TRP1::P<sub>GAL1</sub>-STE2 L289K-CYC1</italic></p></list-item></list><table-wrap id="app1table2" position="float"><label>Appendix 1—table 2.</label><caption><title>The list of primers used in cloning and site-directed mutagenesis.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top">Primer name</th><th align="left" valign="top">Sequence (5′–3′)</th></tr></thead><tbody><tr><td align="left" valign="top">STE2 FWD overlap</td><td align="left" valign="top"><named-content content-type="sequence">CTTTAACGTCAAGGAGGGATCCATGTCTGATGCGGCTCCTTCATTG</named-content></td></tr><tr><td align="left" valign="top">SDM1 STE2 FWD</td><td align="left" valign="top"><named-content content-type="sequence">GTCATGTGGATGACATCGAGAGCTAGAAAAACGCCGATTT</named-content></td></tr><tr><td align="left" valign="top">SDM1 STE2 REV</td><td align="left" valign="top"><named-content content-type="sequence">AAATCGGCGTTTTTCTAGCTCTCGATGTCATCCACATGAC</named-content></td></tr><tr><td align="left" valign="top">SDM4 STE2 FWD</td><td align="left" valign="top"><named-content content-type="sequence">TTTCAGATAAAAGTTATTTTCGACGGCGACAACTTCAAAAGGATA</named-content></td></tr><tr><td align="left" valign="top">SDM4 STE2 REV</td><td align="left" valign="top"><named-content content-type="sequence">TATCCTTTTGAAGTTGTCGCCGTCGAAAATAACTTTTATCTGAAA</named-content></td></tr><tr><td align="left" valign="top">SDM5 STE2 FWD</td><td align="left" valign="top"><named-content content-type="sequence">ACATTACTTGCTGTATTGTCTAAACCATTATCATCAATGTGGGCC</named-content></td></tr><tr><td align="left" valign="top">SDM5 STE2 REV</td><td align="left" valign="top"><named-content content-type="sequence">GGCCCACATTGATGATAATGGTTTAGACAATACAGCAAGTAATGT</named-content></td></tr><tr><td align="left" valign="top">STE2 REV overlap</td><td align="left" valign="top"><named-content content-type="sequence">CATAACTAATTACATGACTCGAGTCATAAATTATTATTATCTTCAGTCCAGAACTTTCTG</named-content></td></tr><tr><td align="left" valign="top">CYC.F</td><td align="left" valign="top"><named-content content-type="sequence">ATAATAATTTATGACTCGAGTCATGTAATTAGTTATGTCACGCTTAC</named-content></td></tr><tr><td align="left" valign="top">GAL1 REV BAMHI</td><td align="left" valign="top"><named-content content-type="sequence">GCCGCATCAGACATGGATCCCTCCTTGACGTTAAAGTATAGAGG</named-content></td></tr></tbody></table></table-wrap></sec><sec sec-type="appendix" id="s8-19"><title>Cellular morphometric assay (shmoo formation)</title><p>The reconstituted <italic>STE2</italic> wild-type (rtWT) and mutants (T155D, L289K, and S75A) were grown in primary culture, followed by secondary culture, in YPGR medium at 30°C at 200 rpm for 16 hr each. Ensuring an equal number of cells for all, 5 μl of secondary culture was inoculated into a 96-well plate containing 145 μl of YPD in the presence or absence of respective metabolites at desired concentrations (T155D – 1 μM LST, L289K – 1 μM ZST, and S75A – 10 μM CoQ6) and grown for 24 hr at 30°C at 200 rpm with four biological replicates. An equal volume of ethanol was added to the control group to negate the effects of the solvent. After 24 hr, α-factor (T6901, Sigma-Aldrich) was added at a final concentration of 10 μM, with DMSO as solvent control, and incubated for 1 hr. Post-incubation, 5 μl of the sample was used for phase contrast microscopy (Nikon Eclipse Ci-L Fluorescence Microscope with Nikon DS-Qi2 camera). For each sample, the number of cells with shmoos was counted using ImageJ and normalized with the total cell counts.</p></sec><sec sec-type="appendix" id="s8-20"><title>RNA-sequencing</title><p>Yeast cells (BY4741) were grown at 30°C at 200 rpm in YPD medium in biological duplicates in the presence or absence of lanosterol (LST) at a final concentration of 1 μM, with ethanol as control. Post-metabolite loading, the cells were either treated or untreated with the α-factor at a final concentration of 30 μM for 2 hr at desired growth conditions. Following these steps, the cells were harvested, and RNA was isolated using the protocol described in <xref ref-type="bibr" rid="bib45">Mittal et al., 2022</xref>. Following sequencing, we conducted a quality control check with MultiFastQ. The paired-end sequencing reads were aligned to the yeast reference genome (ENSEMBL; R64-1-1; GCA_000146045.2) via the align function of the Rsubread package (v.2.6.4), generating aligned BAM files. Before mapping, read trimming was performed at both ends. An expression matrix was produced with the featureCounts function to contain raw read counts for each sample. The read count matrix was normalized using TMM (trimmed mean of M values) normalization (<xref ref-type="supplementary-material" rid="supp8">Supplementary file 8</xref>), and the differential gene expression analysis was performed using NOISeq (v2.38.0) (<xref ref-type="bibr" rid="bib69">Tarazona et al., 2015</xref>; <xref ref-type="supplementary-material" rid="supp10 supp9 supp11">Supplementary files 9–11</xref>). The functional gene ontology analysis was performed using the Gene Ontology Term Finder tool (Version 0.86) of the <italic>Saccharomyces</italic> Genome Database (<ext-link ext-link-type="uri" xlink:href="https://www.yeastgenome.org">https://www.yeastgenome.org</ext-link>). The normalized read count matrix and the raw FASTQ files are available at the Zenodo repository.</p></sec><sec sec-type="appendix" id="s8-21"><title>Cardiomyocyte hypertrophy models</title><p>Human cardiomyocyte cell line AC16 was cultured in DMEM-F12 (Thermo Scientific) with 12.5% fetal bovine serum (FBS; Thermo Scientific) at 37°C in the presence of 5% CO<sub>2</sub>. AC16 cells were seeded in a 24-well cell culture plate for cell size measurements. After 24 hr, cells were treated with metabolites CoQ6, ZST, LST, FST (F5379, Sigma-Aldrich), and CoQ10 (15039, SRL) at the final concentration of 2.5 μM in the presence of 1% FBS and incubated overnight. The next day, the medium was changed. Fresh metabolites were added at 2.5 μM final concentration and isoproterenol treatment at 25 μM concentration and incubated for 48 hr in the presence of 1% FBS. Next, cells were washed with 1X PBS, fixed with 4% paraformaldehyde, and stained with wheat germ agglutinin (Thermo Scientific) and DAPI. Images were taken by Leica DMI 6000 B (Leica Microsystems, USA) at 20X objective. Cell area was calculated by using ImageJ software.</p><p>Neonatal rat cardiomyocytes were isolated from 1- to 3-day-old SD rat pups using Collagenase Type II. Briefly, pups were sacrificed, hearts were explanted, washed in 1X PBS, and chopped into small pieces. Chopped heart pieces were digested with Collagenase Type II at 1 mg/ml (Thermo Scientific, USA) at 37°C. Digested cells are centrifuged, resuspended in a DMEM medium, and pre-plated for 90 min to remove fibroblasts. Cardiomyocytes containing supernatant were then collected and seeded in a gelatin-coated 24-well cell culture plate. After 48 hr, cells were washed with 1X PBS and incubated with metabolites at a concentration of 2.5 μM overnight in the presence of 1% FBS. The next day, the medium was changed, and cells were treated with metabolites (2.5 μM) and isoproterenol (10 μM) in the presence of 1% FBS. After 72 hr, cells were fixed and stained with alpha-sarcomeric actinin (#MA1-22863 Thermo Scientific, USA) and DAPI. Images were taken by Leica DMI 6000 B (Leica Microsystems, USA) at 20X objective. Cell area was calculated by using ImageJ software.</p><p>AC16 cells were provided by Dr. Regalla Kumar Swami, CSIR-CCMB, and primary cardiomyocytes were isolated from wild-type Sprague-Dawley (SD) rat pups (1–3 days old) male/female.</p></sec></sec></app></app-group></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.106397.3.sa0</article-id><title-group><article-title>eLife Assessment</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Elgeti</surname><given-names>Matthias</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution>Leipzig University</institution><country>Germany</country></aff></contrib></contrib-group><kwd-group kwd-group-type="evidence-strength"><kwd>Incomplete</kwd></kwd-group><kwd-group kwd-group-type="claim-importance"><kwd>Useful</kwd></kwd-group></front-stub><body><p>The authors present a set of wrappers around previously developed software and machine-learning toolkits, and demonstrate their use in identifying endogenous sterols binding to a GPCR. The resulting pipeline is potentially <bold>useful</bold> for molecular pharmacology researchers due to its accessibility and ease of use. However, the evidence supporting the GPCR-related findings remains <bold>incomplete</bold>, as the machine-learning model shows indications of overfitting, and no direct ligand-binding assays are provided for validation.</p></body></sub-article><sub-article article-type="referee-report" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.106397.3.sa1</article-id><title-group><article-title>Reviewer #1 (Public review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>This is a re-review following an author revision. I will go point-by-point in response to my original critiques and the authors' responses. I appreciate the authors taking the time to thoughtfully respond to the reviewer critiques.</p><p>Query 1. Based on the authors' description of their contribution to the algorithm design, it sounds like a hyperparameter search wrapped around existing software tools. I think that the use of their own language to describe these modules is confusing to potential users as well as unintentionally hides the contributions of the original LigBuilder developers. The authors should just explain the protocol plainly using language that refers specifically to the established software tools. Whether they use LigBuilder or something else, at the end of the day the description is a protocol for a specific use of an existing software rather than the creation of a new toolkit.</p><p>Query 2. I see. Correct me if I am mistaken, but it seems as though the authors are proposing using the Authenticator to identify the best distributions of compounds based on an in silico oracle (in this case, Vina score), and train to discriminate them. This is similar to training QSAR models to predict docking scores, such as in the manuscript I shared during the first round of review. In principle, one could perform this in successive rounds to create molecules that are increasingly composed of features that yield higher docking scores. This is an established idea that the authors demonstrate in a narrow context, but it also raises concern that one is just enriching for compounds with e.g., an abundance of hydrogen bond donors and acceptors. Regarding points (4) and (5), it is unclear to me how the authors perform train/test splits on unlabeled data with supervised machine learning approaches in this setting. This seems akin to a Y-scramble sanity check. Finally, regarding the discussion on the use of experimental data or FEP calculations for the determination of HABs and LABs, I appreciate the authors' point; however, the concern here is that in the absence of any true oracle the models will just learn to identify and/or generate compounds that exploit limitations of docking scores. Again, please correct me if I am mistaken. It is unclear to me how this advances previous literature in CADD outside of the specific context of incorporating some ideas into a GPCR-Gprotein framework.</p><p>Query 3. The authors mention that the hyperparameters for the ML models are just the package defaults in the absence of specification by the user. I would be helpful to know specifically what the the hyperparameters were for the benchmarks in this study; however, I think a deeper concern is still that these models are almost certainly far overparameterized given the limited training data used for the models. It is unclear why the authors did not just build a random forest classifier to discriminate their HABs and LABs using ligand- or protein-ligand interaction fingerprints or related ideas.</p><p>Query 4. It is good, and expected, that increasing the fraction of the training set size in a random split validation all the way to 100% would allow the model to perfectly discriminate HABs and LABs. This does not demonstrate that the model has significant enrichment in prospective screening, particularly compared to simpler methods. The concern remains that these models are overparameterized and insufficiently validated. The authors did not perform any scaffold splits or other out-of-distribution analysis.</p><p>Query 5. The authors contend that Gcoupler uniquely enables training models when data is scarce and ultra-large screening libraries are unavailable. Today, it is rather straightforward to dock a minimum of thousands of compounds. Using tools such as QuickVina2-GPU (<ext-link ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/10.1021/acs.jcim.2c01504">https://pubs.acs.org/doi/10.1021/acs.jcim.2c01504</ext-link>), it is possible to quite readily dock millions in a day with a single GPU and obtain the AutoDock Vina score. GPU-acclerated Vina has been combined with cavity detection tools likely multiple times, including here (<ext-link ext-link-type="uri" xlink:href="https://arxiv.org/abs/2506.20043">https://arxiv.org/abs/2506.20043</ext-link>). There are multiple cavity detection tools, including the ones the authors use in their protocol.</p><p>Query 6. The authors contend that the simulations are converged, but they elected not to demonstrate stability in the predicting MM/GBSA binding energies with block averaging across the trajectory. This could have been done through the existing trajectories without additional simulation.</p></body></sub-article><sub-article article-type="referee-report" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.106397.3.sa2</article-id><title-group><article-title>Reviewer #1 (Public review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>This is a re-review following an author revision. I will go point-by-point in response to my original critiques and the authors' responses. I appreciate the authors taking the time to thoughtfully respond to the reviewer critiques.</p><p>Query 1. Based on the authors' description of their contribution to the algorithm design, it sounds like a hyperparameter search wrapped around existing software tools. I think that the use of their own language to describe these modules is confusing to potential users as well as unintentionally hides the contributions of the original LigBuilder developers. The authors should just explain the protocol plainly using language that refers specifically to the established software tools. Whether they use LigBuilder or something else, at the end of the day the description is a protocol for a specific use of an existing software rather than the creation of a new toolkit.</p><p>Query 2. I see. Correct me if I am mistaken, but it seems as though the authors are proposing using the Authenticator to identify the best distributions of compounds based on an in silico oracle (in this case, Vina score), and train to discriminate them. This is similar to training QSAR models to predict docking scores, such as in the manuscript I shared during the first round of review. In principle, one could perform this in successive rounds to create molecules that are increasingly composed of features that yield higher docking scores. This is an established idea that the authors demonstrate in a narrow context, but it also raises concern that one is just enriching for compounds with e.g., an abundance of hydrogen bond donors and acceptors. Regarding points (4) and (5), it is unclear to me how the authors perform train/test splits on unlabeled data with supervised machine learning approaches in this setting. This seems akin to a Y-scramble sanity check. Finally, regarding the discussion on the use of experimental data or FEP calculations for the determination of HABs and LABs, I appreciate the authors' point; however, the concern here is that in the absence of any true oracle the models will just learn to identify and/or generate compounds that exploit limitations of docking scores. Again, please correct me if I am mistaken. It is unclear to me how this advances previous literature in CADD outside of the specific context of incorporating some ideas into a GPCR-Gprotein framework.</p><p>Query 3. The authors mention that the hyperparameters for the ML models are just the package defaults in the absence of specification by the user. I would be helpful to know specifically what the the hyperparameters were for the benchmarks in this study; however, I think a deeper concern is still that these models are almost certainly far overparameterized given the limited training data used for the models. It is unclear why the authors did not just build a random forest classifier to discriminate their HABs and LABs using ligand- or protein-ligand interaction fingerprints or related ideas.</p><p>Query 4. It is good, and expected, that increasing the fraction of the training set size in a random split validation all the way to 100% would allow the model to perfectly discriminate HABs and LABs. This does not demonstrate that the model has significant enrichment in prospective screening, particularly compared to simpler methods. The concern remains that these models are overparameterized and insufficiently validated. The authors did not perform any scaffold splits or other out-of-distribution analysis.</p><p>Query 5. The authors contend that Gcoupler uniquely enables training models when data is scarce and ultra-large screening libraries are unavailable. Today, it is rather straightforward to dock a minimum of thousands of compounds. Using tools such as QuickVina2-GPU (<ext-link ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/10.1021/acs.jcim.2c01504">https://pubs.acs.org/doi/10.1021/acs.jcim.2c01504</ext-link>), it is possible to quite readily dock millions in a day with a single GPU and obtain the AutoDock Vina score. GPU-acclerated Vina has been combined with cavity detection tools likely multiple times, including here (<ext-link ext-link-type="uri" xlink:href="https://arxiv.org/abs/2506.20043">https://arxiv.org/abs/2506.20043</ext-link>). There are multiple cavity detection tools, including the ones the authors use in their protocol.</p><p>Query 6. The authors contend that the simulations are converged, but they elected not to demonstrate stability in the predicting MM/GBSA binding energies with block averaging across the trajectory. This could have been done through the existing trajectories without additional simulation.</p></body></sub-article><sub-article article-type="author-comment" id="sa3"><front-stub><article-id pub-id-type="doi">10.7554/eLife.106397.3.sa3</article-id><title-group><article-title>Author response</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Mohanty</surname><given-names>Sanjay Kumar</given-names></name><role specific-use="author">Author</role><aff><institution>IIIT-Delhi</institution><addr-line><named-content content-type="city">New Delhi</named-content></addr-line><country>India</country></aff></contrib><contrib contrib-type="author"><name><surname>Mittal</surname><given-names>Aayushi</given-names></name><role specific-use="author">Author</role><aff><institution>IIIT-Delhi</institution><addr-line><named-content content-type="city">New Delhi</named-content></addr-line><country>India</country></aff></contrib><contrib contrib-type="author"><name><surname>Gaur</surname><given-names>Aakash</given-names></name><role specific-use="author">Author</role><aff><institution>CSIR-Central Drug Research Institute</institution><addr-line><named-content content-type="city">Lucknow</named-content></addr-line><country>India</country></aff></contrib><contrib contrib-type="author"><name><surname>Duari</surname><given-names>Subhadeep</given-names></name><role specific-use="author">Author</role><aff><institution>Indraprastha Institute of Information Technology Delhi</institution><addr-line><named-content content-type="city">New Delhi</named-content></addr-line><country>India</country></aff></contrib><contrib contrib-type="author"><name><surname>Solanki</surname><given-names>Saveena</given-names></name><role specific-use="author">Author</role><aff><institution>Indraprastha Institute of Information Technology Delhi</institution><addr-line><named-content content-type="city">New Delhi</named-content></addr-line><country>India</country></aff></contrib><contrib contrib-type="author"><name><surname>Sharma</surname><given-names>Anmol Kumar</given-names></name><role specific-use="author">Author</role><aff><institution>Indraprastha Institute of Information Technology Delhi</institution><addr-line><named-content content-type="city">New Delhi</named-content></addr-line><country>India</country></aff></contrib><contrib contrib-type="author"><name><surname>Arora</surname><given-names>Sakshi</given-names></name><role specific-use="author">Author</role><aff><institution>Indraprastha Institute of Information Technology Delhi</institution><addr-line><named-content content-type="city">New Delhi</named-content></addr-line><country>India</country></aff></contrib><contrib contrib-type="author"><name><surname>Kumar</surname><given-names>Suvendu</given-names></name><role specific-use="author">Author</role><aff><institution>Indraprastha Institute of Information Technology Delhi</institution><addr-line><named-content content-type="city">New Delhi</named-content></addr-line><country>India</country></aff></contrib><contrib contrib-type="author"><name><surname>Gautam</surname><given-names>Vishakha</given-names></name><role specific-use="author">Author</role><aff><institution>IIIT-Delhi</institution><addr-line><named-content content-type="city">New Delhi</named-content></addr-line><country>India</country></aff></contrib><contrib contrib-type="author"><name><surname>Dixit</surname><given-names>Nilesh Kumar</given-names></name><role specific-use="author">Author</role><aff><institution>Indraprastha Institute of Information Technology Delhi</institution><addr-line><named-content content-type="city">New Delhi</named-content></addr-line><country>India</country></aff></contrib><contrib contrib-type="author"><name><surname>Subramanian</surname><given-names>Karthika</given-names></name><role specific-use="author">Author</role><aff><institution>Indraprastha Institute of Information Technology Delhi</institution><addr-line><named-content content-type="city">New Delhi</named-content></addr-line><country>India</country></aff></contrib><contrib contrib-type="author"><name><surname>Ghosh</surname><given-names>Tarini Shankar</given-names></name><role specific-use="author">Author</role><aff><institution>Indraprastha Institute of Information Technology Delhi</institution><addr-line><named-content content-type="city">New Delhi</named-content></addr-line><country>India</country></aff></contrib><contrib contrib-type="author"><name><surname>Sengupta</surname><given-names>Debarka</given-names></name><role specific-use="author">Author</role><aff><institution>Indraprastha Institute of Information Technology Delhi</institution><addr-line><named-content content-type="city">Delhi</named-content></addr-line><country>India</country></aff></contrib><contrib contrib-type="author"><name><surname>Gupta</surname><given-names>Shashi Kumar</given-names></name><role specific-use="author">Author</role><aff><institution>Central Drug Research Institute</institution><addr-line><named-content content-type="city">Lucknow</named-content></addr-line><country>India</country></aff></contrib><contrib contrib-type="author"><name><surname>Murugan</surname><given-names>Arul Natarajan</given-names></name><role specific-use="author">Author</role><aff><institution>Indraprastha Institute of Information Technology Delhi</institution><addr-line><named-content content-type="city">New Delhi</named-content></addr-line><country>India</country></aff></contrib><contrib contrib-type="author"><name><surname>Sharma</surname><given-names>Deepak</given-names></name><role specific-use="author">Author</role><aff><institution>Institute of Microbial Technology</institution><addr-line><named-content content-type="city">Chandigarh</named-content></addr-line><country>India</country></aff></contrib><contrib contrib-type="author"><name><surname>Ahuja</surname><given-names>Gaurav</given-names></name><role specific-use="author">Author</role><aff><institution>Indraprastha Institute of Information Technology Delhi</institution><addr-line><named-content content-type="city">New Delhi</named-content></addr-line><country>India</country></aff></contrib></contrib-group></front-stub><body><p>The following is the authors’ response to the original reviews</p><disp-quote content-type="editor-comment"><p><bold>Public Reviews:</bold></p><p><bold>Reviewer #1 (Public review):</bold></p><p>Summary</p><p>Query: In this manuscript, the authors introduce Gcoupler, a Python-based computational pipeline designed to identify endogenous intracellular metabolites that function as allosteric modulators at the G protein-coupled receptor (GPCR) - Gα protein interface. Gcoupler is comprised of four modules:</p><p>I. Synthesizer - identifies protein cavities and generates synthetic ligands using LigBuilder3</p><p>II. Authenticator - classifies ligands into high-affinity binders (HABs) and low-affinity binders (LABs) based on AutoDock Vina binding energies</p><p>III. Generator - trains graph neural network (GNN) models (GCM, GCN, AFP, GAT) to predict binding affinity using synthetic ligands</p><p>IV. BioRanker - prioritizes ligands based on statistical and bioactivity data</p><p>The authors apply Gcoupler to study the Ste2p-Gpa1p interface in yeast, identifying sterols such as zymosterol (ZST) and lanosterol (LST) as modulators of GPCR signaling. Our review will focus on the computational aspects of the work. Overall, we found the Gcoupler approach interesting and potentially valuable, but we have several concerns with the methods and validation that need to be addressed prior to publication/dissemination.</p></disp-quote><p>We express our gratitude to Reviewer #1 for their concise summary and commendation of our work. We sincerely apologize for the lack of sufficient detail in summarizing the underlying methods employed in Gcoupler, as well as its subsequent experimental validations using yeast, human cell lines, and primary rat cardiomyocyte-based assays.</p><p>We wish to state that substantial improvements have been made in the revised manuscript, every section has been elaborated upon to enhance clarity. Please refer to the point-by-point response below and the revised manuscript.</p><disp-quote content-type="editor-comment"><p>Query: (1) The exact algorithmic advancement of the Synthesizer beyond being some type of application wrapper around LigBuilder is unclear. Is the grow-link approach mentioned in the methods already a component of LigBuilder, or is it custom? If it is custom, what does it do? Is the API for custom optimization routines new with the Synthesizer, or is this a component of LigBuilder? Is the genetic algorithm novel or already an existing software implementation? Is the cavity detection tool a component of LigBuilder or novel in some way? Is the fragment library utilized in the Synthesizer the default fragment library in LigBuilder, or has it been customized? Are there rules that dictate how molecule growth can occur? The scientific contribution of the Synthesizer is unclear. If there has not been any new methodological development, then it may be more appropriate to just refer to this part of the algorithm as an application layer for LigBuilder.</p></disp-quote><p>We appreciate Reviewer #1's constructive suggestion. We wish to emphasize that</p><p>(1) The LigBuilder software comprises various modules designed for distinct functions. The Synthesizer in Gcoupler strategically utilizes two of these modules: &quot;CAVITY&quot; for binding site detection and &quot;BUILD&quot; for de novo ligand design.</p><p>(2) While both modules are integral to LigBuilder, the Synthesizer plays a crucial role in enabling their targeted, automated, and context-aware application for GPCR drug discovery.</p><p>(3) The CAVITY module is a structure-based protein binding site detection program, which the Synthesizer employs for identifying ligand binding sites on the protein surface.</p><p>(4) The Synthesizer also leverages the BUILD module for constructing molecules tailored to the target protein, implementing a fragment-based design strategy using its integrated fragment library.</p><p>(5) The GROW and LINK methods represent two independent approaches encompassed within the aforementioned BUILD module.</p><fig id="sa3fig1" position="float"><label>Author response image 1.</label><caption><title>Schematic representation of the key strategy used in the Synthesizer module of Gcoupler.</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-106397-sa3-fig1-v1.tif"/></fig><p>Our manuscript details the &quot;grow-link&quot; hybrid approach, which was implemented using a genetic algorithm through the following stages:</p><p>(1) Initial population generation based on a seed structure via the GROW method.</p><p>(2) Selection of &quot;parent&quot; molecules from the current population for inclusion in the mating pool using the LINK method.</p><p>(3) Transfer of &quot;elite&quot; molecules from the current population to the new population.</p><p>(4) Population expansion through structural manipulations (mutation, deletion, and crossover) applied to molecules within the mating pool.</p><p>Please note, the outcome of this process is not fixed, as it is highly dependent on the target cavity topology and the constraint parameters employed for population evaluation. Synthesizer customizes generational cycles and optimization parameters based on cavity-specific constraints, with the objective of either generating a specified number of compounds or comprehensively exploring chemical diversity against a given cavity topology.</p><p>While these components are integral to LigBuilder, Synthesizer's innovation lies</p><p>(1) in its programmatic integration and dynamic adjustment of these modules.</p><p>(2) Synthesizer distinguishes itself not by reinventing these algorithms, but by their automated coordination, fine-tuning, and integration within a cavity-specific framework.</p><p>(3) It dynamically modifies generation parameters according to cavity topology and druggability constraints, a capability not inherently supported by LigBuilder.</p><p>(4) This renders Synthesizer particularly valuable in practical scenarios where manual optimization is either inefficient or impractical.</p><p>In summary, Synthesizer offers researchers a streamlined interface, abstracting the technical complexities of LigBuilder and thereby enabling more accessible and reproducible ligand generation pipelines, especially for individuals with limited experience in structural or cheminformatics tools.</p><disp-quote content-type="editor-comment"><p>Query: (2) The use of AutoDock Vina binding energy scores to classify ligands into HABs and LABs is problematic. AutoDock Vina's energy function is primarily tuned for pose prediction and displays highly system-dependent affinity ranking capabilities. Moreover, the HAB/LAB thresholds of -7 kcal/mol or -8 kcal/mol lack justification. Were these arbitrarily selected cutoffs, or was benchmarking performed to identify appropriate cutoffs? It seems like these thresholds should be determined by calibrating the docking scores with experimental binding data (e.g., known binders with measured affinities) or through re-scoring molecules with a rigorous alchemical free energy approach.</p></disp-quote><p>We again express our gratitude to Reviewer #1 for these inquiries. We sincerely apologize for the lack of sufficient detail in the original version of the manuscript. In the revised manuscript, we have ensured the inclusion of a detailed rationale for every threshold utilized to prioritize high-affinity binders. Please refer to the comprehensive explanation below, as well as the revised manuscript, for further details.</p><p>We would like to clarify that:</p><p>(1) The Authenticator module is not solely reliant on absolute binding energy values for classification. Instead, it calculates binding energies for all generated compounds and applies a statistical decision-making layer to define HAB and LAB classes.</p><p>(2) Rather than using fixed thresholds, the module employs distribution-based methods, such as the Empirical Cumulative Distribution Function (ECDF), to assess the overall energy landscape of the compound set. We then applied multiple statistical tests to evaluate the HAB and LAB distributions and determine an optimal, data-specific cutoff that balances class sizes and minimizes overlap.</p><p>(3) This adaptive approach avoids rigid thresholds and instead ensures context-sensitive classification, with safeguards in place to maintain adequate representation of both classes for downstream model training, and in this way, the framework prioritizes robust statistical reasoning over arbitrary energy cutoffs and aims to reduce the risks associated with direct reliance on Vina scores alone.</p><p>(4) To assess the necessity and effectiveness of the Authenticator module, we conducted a benchmarking analysis where we deliberately omitted the HAB and LAB class labels, treating the compound pool as a heterogeneous, unlabeled dataset. We then performed random train-test splits using the Synthesizer-generated compounds and trained independent models.</p><p>(5) The results from this approach demonstrated notably poorer model performance, indicating that arbitrary or unstructured data partitioning does not effectively capture the underlying affinity patterns. These experiments highlight the importance of using the statistical framework within the Authenticator module to establish meaningful, data-driven thresholds for distinguishing High- and Low-Affinity Binders. The cutoff values are thus not arbitrary but emerge from a systematic benchmarking and validation process tailored to each dataset.</p><p>Please note: While calibrating docking scores with experimental binding affinities or using rigorous methods like alchemical free energy calculations can improve precision, these approaches are often computationally intensive and reliant on the availability of high-quality experimental data, a major limitation in many real-world screening scenarios.</p><p>In summary, the primary goal of Gcoupler is to enable fast, scalable, and broadly accessible screening, particularly for cases where experimental data is sparse or unavailable. Incorporating such resource-heavy methods would not only significantly increase computational overhead but also undermine the framework’s intended usability and efficiency for large-scale applications. Instead, our workflow relies on statistically robust, data-driven classification methods that balance speed, generalizability, and practical feasibility.</p><disp-quote content-type="editor-comment"><p>Query: (3) Neither the Results nor Methods sections provide information on how the GNNs were trained in this study. Details such as node features, edge attributes, standardization, pooling, activation functions, layers, dropout, etc., should all be described in detail. The training protocol should also be described, including loss functions, independent monitoring and early stopping criteria, learning rate adjustments, etc.</p></disp-quote><p>We again thank Reviewer #1 for this suggestion. We would like to mention that in the revised manuscript, we have added all the requested details. Please refer to the points below for more information.</p><p>(1) The Generator module of Gcoupler is designed as a flexible and automated framework that leverages multiple Graph Neural Network architectures, including Graph Convolutional Model (GCM), Graph Convolutional Network (GCN), Attentive FP, and Graph Attention Network (GAT), to build classification models based on the synthetic ligand datasets produced earlier in the pipeline.</p><p>(2) By default, Generator tests all four models using standard hyperparameters provided by the DeepChem framework <ext-link ext-link-type="uri" xlink:href="https://deepchem.io/">(</ext-link><ext-link ext-link-type="uri" xlink:href="https://deepchem.io/">https://deepchem.io/</ext-link>), offering a baseline performance comparison across architectures. This includes pre-defined choices for node features, edge attributes, message-passing layers, pooling strategies, activation functions, and dropout values, ensuring reproducibility and consistency. All models are trained with binary cross-entropy loss and support default settings for early stopping, learning rate, and batch standardization where applicable.</p><p>(3) In addition, Generator supports model refinement through hyperparameter tuning and k-fold cross-validation (default: 3 folds). Users can either customize the hyperparameter grid or rely on Generator’s recommended parameter ranges to optimize model performance. This allows for robust model selection and stability assessment of tuned parameters.</p><p>(4) Finally, the trained models can be used to predict binding probabilities for user-supplied compounds, making it a comprehensive and user-adaptive tool for ligand screening.</p><p>Based on the reviewer #1 suggestion, we have now added a detailed description about the Generator module of Gcoupler, and also provided relevant citations regarding the DeepChem workflow.</p><disp-quote content-type="editor-comment"><p>Query: (4) GNN model training seems to occur on at most 500 molecules per training run? This is unclear from the manuscript. That is a very small number of training samples if true. Please clarify. How was upsampling performed? What were the HAB/LAB class distributions? In addition, it seems as though only synthetically generated molecules are used for training, and the task is to discriminate synthetic molecules based on their docking scores. Synthetic ligands generated by LigBuilder may occupy distinct chemical space, making classification trivial, particularly in the setting of a random split k-folds validation approach. In the absence of a leave-class-out validation, it is unclear if the model learns generalizable features or exploits clear chemical differences. Historically, it was inappropriate to evaluate ligand-based QSAR models on synthetic decoys such as the DUD-E sets - synthetic ligands can be much more easily distinguished by heavily parameterized ligand-based machine learning models than by physically constrained single-point docking score functions.</p></disp-quote><p>We thank reviewer #1 for these detailed technical queries. We would like to clarify that:</p><p>(1) The recommended minimum for the training set is 500 molecules, but users can add as many synthesized compounds as needed to thoroughly explore the chemical space related to the target cavity.</p><p>(2) Our systematic evaluation demonstrated that expanding the training set size consistently enhanced model performance, especially when compared to AutoDock docking scores. This observation underscores the framework's scalability and its ability to improve predictive accuracy with more training compounds.</p><p>(3) The Authenticator module initially categorizes all synthesized molecules into HAB and LAB classes. These labeled molecules are then utilized for training the Generator module. To tackle class imbalance, the class with fewer data points undergoes upsampling. This process aims to achieve an approximate 1:1 ratio between the two classes, thereby ensuring balanced learning during GNN model training.</p><p>(4) The Authenticator module's affinity scores are the primary determinant of the HAB/LAB class distribution, with a higher cutoff for HABs ensuring statistically significant class separation. This distribution is also indirectly shaped by the target cavity's topology and druggability, as the Synthesizer tends to produce more potent candidates for cavities with favorable binding characteristics.</p><p>(5) While it's true that synthetic ligands may occupy distinct chemical space, our benchmarking exploration for different sites on the same receptor still showed inter-cavity specificity along with intra-cavity diversity of the synthesized molecules.</p><p>(6) The utility of random k-fold validation shouldn't be dismissed outright; it provides a reasonable estimate of performance under practical settings where class boundaries are often unknown. Nonetheless, we agree that complementary validation strategies like leave-class-out could further strengthen the robustness assessment.</p><p>(7) We agree that using synthetic decoys like those from the DUD-E dataset can introduce bias in ligand-based QSAR model evaluations if not handled carefully. In our workflow, the inclusion of DUD-E compounds is entirely optional and only considered as a fallback, specifically in scenarios where the number of low-affinity binders (LABs) synthesized by the Synthesizer module is insufficient to proceed with model training.</p><p>(8) The primary approach relies on classifying generated compounds based on their derived affinity scores via the Authenticator module. However, in rare cases where this results in a heavily imbalanced dataset, DUD-E compounds are introduced not as part of the core benchmarking, but solely to maintain minimal class balance for initial model training. Even then, care is taken to interpret results with this limitation in mind. Ultimately, our framework is designed to prioritize data-driven generation of both HABs and LABs, minimizing reliance on synthetic decoys wherever possible.</p><fig id="sa3fig2" position="float"><label>Author response image 2.</label><caption><title>Scatter plots depicting the segregation of High/Low-Affinity Metabolites (HAM/LAM) (indicated in green and red) identified using Gcoupler workflow with 100% training data.</title><p>Notably, models trained on lesser training data size (25%, 50%, and 75% of HAB/LAB) severely failed to segregate HAM and LAM (along Y-axis). X-axis represents the binding affinity calculated using IC4-specific docking using AutoDock.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-106397-sa3-fig2-v1.tif"/></fig><p>Based on the reviewer #1’s suggestion, we have now added all these technical details in the revised version of the manuscript.</p><disp-quote content-type="editor-comment"><p>Query: (5) Training QSAR models on docking scores to accelerate virtual screening is not in itself novel (see here for a nice recent example: <ext-link ext-link-type="uri" xlink:href="https://www.nature.com/articles/s43588-025-00777-x">https://www.nature.com/articles/s43588-025-00777-x</ext-link>), but can be highly useful to focus structure-based analysis on the most promising areas of ligand chemical space; however, we are perplexed by the motivation here. If only a few hundred or a few thousand molecules are being sampled, why not just use AutoDock Vina? The models are trained to try to discriminate molecules by AutoDock Vina score rather than experimental affinity, so it seems like we would ideally just run Vina? Perhaps we are misunderstanding the scale of the screening that was done here. Please clarify the manuscript methods to help justify the approach.</p></disp-quote><p>We acknowledge the effectiveness of training QSAR models on docking scores for prioritizing chemical space, as demonstrated by the referenced study <ext-link ext-link-type="uri" xlink:href="https://www.nature.com/articles/s43588-025-00777-x">(</ext-link><ext-link ext-link-type="uri" xlink:href="https://www.nature.com/articles/s43588-025-00777-x">https://www.nature.com/articles/s43588-025-00777-x</ext-link>) on machine-learning-guided docking screen frameworks.</p><p>We would like to mention that:</p><p>(1) While such protocols often rely on extensive pre-docked datasets across numerous protein targets or utilize a highly skewed input distribution, training on as little as 1-10% of ligand-protein complexes and testing on the remainder in iterative cycles.</p><p>(2) While powerful for ultra-large libraries, this approach can introduce bias towards the limited training set and incur significant overhead in data curation, pre-computation, and infrastructure.</p><p>(3) In contrast, Gcoupler prioritizes flexibility and accessibility, especially when experimental data is scarce and large pre-docked libraries are unavailable. Instead of depending on fixed docking scores from external pipelines, Gcoupler integrates target-specific cavity detection, de novo compound generation, and model training into a self-contained, end-to-end framework. Its QSAR models are trained directly on contextually relevant compounds synthesized for a given binding site, employing a statistical classification strategy that avoids arbitrary thresholds or precomputed biases.</p><p>(4) Furthermore, Gcoupler is open-source, lightweight, and user-friendly, making it easily deployable without the need for extensive infrastructure or prior docking expertise. While not a complete replacement for full-scale docking in all use cases, Gcoupler aims to provide a streamlined and interpretable screening framework that supports both focused chemical design and broader chemical space exploration, without the computational burden associated with deep learning docking workflows.</p><p>(5) Practically, even with computational resources, manually running AutoDock Vina on millions of compounds presents challenges such as format conversion, binding site annotation, grid parameter tuning, and execution logistics, all typically requiring advanced structural bioinformatics expertise.</p><p>(6) Gcoupler's Authenticator module, however, streamlines this process. Users only need to input a list of SMILES and a receptor PDB structure, and the module automatically handles compound preparation, cavity mapping, parameter optimization, and high-throughput scoring. This automation reduces time and effort while democratizing access to structure-based screening workflows for users without specialized expertise.</p><p>Ultimately, Gcoupler's motivation is to make large-scale, structure-informed virtual screening both efficient and accessible. The model serves as a surrogate to filter and prioritize compounds before deeper docking or experimental validation, thereby accelerating targeted drug discovery.</p><disp-quote content-type="editor-comment"><p>Query: (6) The brevity of the MD simulations raises some concerns that the results may be over-interpreted. RMSD plots do not reliably compare the affinity behavior in this context because of the short timescales coupled with the dramatic topological differences between the ligands being compared; CoQ6 is long and highly flexible compared to ZST and LST. Convergence metrics, such as block averaging and time-dependent MM/GBSA energies, should be included over much longer timescales. For CoQ6, the authors may need to run multiple simulations of several microseconds, identify the longest-lived metastable states of CoQ6, and perform MM/GBSA energies for each state weighted by each state's probability.</p></disp-quote><p>We appreciate Reviewer #1's suggestion regarding simulation length, as it is indeed crucial for interpreting molecular dynamics (MD) outcomes. We would like to mention that:</p><p>(1) Our simulation strategy varied based on the analysis objective, ranging from short (~5 ns) runs for preliminary or receptor-only evaluations to intermediate (~100 ns) and extended (~550 ns) runs for receptor-ligand complex validation and stability assessment.</p><p>(2) Specifically, we conducted three independent 100 ns MD simulations for each receptor-metabolite complex in distinct cavities of interest. This allowed us to assess the reproducibility and persistence of binding interactions. To further support these observations, a longer 550 ns simulation was performed for the IC4 cavity, which reinforced the 100 ns findings by demonstrating sustained interaction stability over extended timescales.</p><p>(3) While we acknowledge that even longer simulations (e.g., in the microsecond range) could provide deeper insights into metastable state transitions, especially for highly flexible molecules like CoQ6, our current design balances computational feasibility with the goal of screening multiple cavities and ligands.</p><p>(4) In our current workflow, MM/GBSA binding free energies were calculated by extracting 1000 representative snapshots from the final 10 ns of each MD trajectory. These configurations were used to compute time-averaged binding energies, incorporating contributions from van der Waals, electrostatic, polar, and non-polar solvation terms. This approach offers a more reliable estimate of ligand binding affinity compared to single-point molecular docking, as it accounts for conformational flexibility and dynamic interactions within the binding cavity.</p><p>(5) Although we did not explicitly perform state-specific MM/GBSA calculations weighted by metastable state probabilities, our use of ensemble-averaged energy estimates from a thermally equilibrated segment of the trajectory captures many of the same benefits. We acknowledge, however, that a more rigorous decomposition based on metastable state analysis could offer finer resolution of binding behavior, particularly for highly flexible ligands like CoQ6, and we consider this a valuable direction for future refinement of the framework.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #2 (Public review):</bold></p><p>Summary:</p><p>Query: Mohanty et al. present a new deep learning method to identify intracellular allosteric modulators of GPCRs. This is an interesting field for e.g. the design of novel small molecule inhibitors of GPCR signalling. A key limitation, as mentioned by the authors, is the limited availability of data. The method presented, Gcoupler, aims to overcome these limitations, as shown by experimental validation of sterols in the inhibition of Ste2p, which has been shown to be relevant molecules in human and rat cardiac hypertrophy models. They have made their code available for download and installation, which can easily be followed to set up software on a local machine.</p><p>Strengths:</p><p>Clear GitHub repository</p><p>Extensive data on yeast systems</p></disp-quote><p>We sincerely thank Reviewer #2 for their thorough review, summary, and appreciation of our work. We highly value their comments and suggestions.</p><disp-quote content-type="editor-comment"><p>Weaknesses:</p><p>Query: No assay to directly determine the affinity of the compounds to the protein of interest.</p></disp-quote><p>We thank Reviewer #2 for raising these insightful questions. During the experimental design phase, we carefully accounted for validating the impact of metabolites in the rescue response by pheromone.</p><p>We would like to mention that we performed an array of methods to validate our hypothesis and observed similar rescue effects. These assays include:</p><p>a. Cell viability assay (FDA/PI Flourometry-based)</p><p>b. Cell growth assay</p><p>c. FUN1-based microscopy assessment</p><p>d. Shmoo formation assays</p><p>e. Mating assays</p><p>f. Site-directed mutagenesis-based loss of function</p><p>g. ransgenic reporter-based assay</p><p>h. MAPK signaling assessment using Western blot.</p><p>i. And via computational techniques.</p><p>Concerning the in vitro interaction studies of Ste2p and metabolites, we made significant efforts to purify Ste2p by incorporating a His tag at the N-terminal. Despite dedicated attempts over the past year, we were unsuccessful in purifying the protein, primarily due to our limited expertise in protein purification for this specific system. As a result, we opted for genetic-based interventions (e.g., point mutants), which provide a more physiological and comprehensive approach to demonstrating the interaction between Ste2p and the metabolites.</p><fig id="sa3fig3" position="float"><label>Author response image 3.</label><caption><p>(<bold>a</bold>) Affinity purification of Ste2p from <italic>Saccharomyces cerevisiae</italic>. Western blot analysis using anti-His antibody showing the distribution of Ste2p in various fractions during the affinity purification process. The fractions include pellet, supernatant, wash buffer, and sequential elution fractions (1–4). Wild-type and ste2Δ strains served as positive and negative controls, respectively. (<bold>b</bold>) Optimization of Ste2p extraction protocol. Ponceau staining (left) and Western blot analysis using anti-His antibody (right) showing Ste2p extraction efficiency. The conditions tested include lysis buffers containing different concentrations of CHAPS detergent (0.5%, 1%) and glycerol (10%, 20%).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-106397-sa3-fig3-v1.tif"/></fig><p>Furthermore, in addition to the clarification above, we have added the following statement in the discussion section to tone down our claims: “A critical limitation of our study is the absence of direct binding assays to validate the interaction between the metabolites and Ste2p. While our results from genetic interventions, molecular dynamics simulations, and docking studies strongly suggest that the metabolites interact with the Ste2p-Gpa1 interface, these findings remain indirect. Direct binding confirmation through techniques such as surface plasmon resonance, isothermal titration calorimetry, or co-crystallization would provide definitive evidence of this interaction. Addressing this limitation in future work would significantly strengthen our conclusions and provide deeper insights into the precise molecular mechanisms underlying the observed phenotypic effects.”</p><p>We request Reviewer #2 to kindly refer to the assays conducted on the point mutants created in this study, as these experiments offer robust evidence supporting our claims.</p><disp-quote content-type="editor-comment"><p>Query: In conclusion, the authors present an interesting new method to identify allosteric inhibitors of GPCRs, which can easily be employed by research labs. Whilst their efforts to characterize the compounds in yeast cells, in order to confirm their findings, it would be beneficial if the authors show their compounds are active in a simple binding assay.</p></disp-quote><p>We express our gratitude and sincere appreciation for the time and effort dedicated by Reviewer #2 in reviewing our manuscript. We are confident that our clarifications address the reviewer's concerns.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #3 (Public review):</bold></p><p>Summary:</p><p>Query: In this paper, the authors introduce the Gcoupler software, an open-source deep learning-based platform for structure-guided discovery of ligands targeting GPCR interfaces. Overall, this manuscript represents a field-advancing contribution at the intersection of AI-based ligand discovery and GPCR signaling regulation.</p><p>Strengths:</p><p>The paper presents a comprehensive and well-structured workflow combining cavity identification, de novo ligand generation, statistical validation, and graph neural network-based classification. Notably, the authors use Gcoupler to identify endogenous intracellular sterols as allosteric modulators of the GPCR-Gα interface in yeast, with experimental validations extending to mammalian systems. The ability to systematically explore intracellular metabolite modulation of GPCR signaling represents a novel and impactful contribution. This study significantly advances the field of GPCR biology and computational ligand discovery.</p></disp-quote><p>We thank and appreciate Reviewer #3 for vesting time and efforts in reviewing our manuscript and for appreciating our efforts.</p><disp-quote content-type="editor-comment"><p><bold>Recommendations for the authors:</bold></p><p><bold>Reviewing Editor Comments:</bold></p><p>We encourage the authors to address the points raised during revision to elevate the assessment from &quot;incomplete&quot; to &quot;solid&quot; or ideally &quot;convincing.&quot; In particular, we ask the authors to improve the justification for their methodological choices and to provide greater detail and clarity regarding each computational layer of the pipeline.</p></disp-quote><p>We are grateful for the editors' suggestions. We have incorporated significant revisions into the manuscript, providing comprehensive technical details to prevent any misunderstandings. Furthermore, we meticulously explained every aspect of the computational workflow.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #2 (Recommendations for the authors):</bold></p><p>Query: Would it be possible to make the package itself pip installable?</p></disp-quote><p>Yes, it already exists under the testpip repository and we have now migrated it to the main pip. Please access the link from here: <ext-link ext-link-type="uri" xlink:href="https://pypi.org/project/gcoupler/">https://pypi.org/project/gcoupler/</ext-link></p><disp-quote content-type="editor-comment"><p>Query: I am confused by the binding free energies reported in Supplementary Figure 8. Is the total DG reported that of the protein-ligand complex? If that is the case, the affinities of the ligands would be extremely high. They are also very far off from the reported -7 kcal/mol active/inactive cut-off.</p></disp-quote><p>We thank Reviewer #2 for this query. We would like to mention that we have provided a detailed explanation in the point-by-point response to Reviewer #2's original comment. Briefly, to clarify, the -7 kcal/mol active/inactive cutoff mentioned in the manuscript refers specifically to the docking-based binding free energies (ΔG) calculated using AutoDock or AutoDock Vina, which are used for compound classification or validation against the Gcoupler framework.</p><p>In contrast, the binding free energies reported in Supplementary Figure 8 are obtained through the MM-GBSA method, which provides a more detailed and physics-based estimate of binding affinity by incorporating solvation and enthalpic contributions. It is well-documented in the literature that MM-GBSA tends to systematically underestimate absolute binding free energies when compared to experimental values (10.2174/1568026616666161117112604; Table 1).</p><fig id="sa3fig4" position="float"><label>Author response image 4.</label><caption><title>Scatter plot comparing the predicted binding affinity calculated by Docking and MM/GBSA methods, against experimental ΔG (10.1007/s10822-023-00499-0).</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-106397-sa3-fig4-v1.tif"/></fig><p>Our use of MM-GBSA is not to match experimental ΔG directly, but rather to assess relative binding preferences among ligands. Despite its limitations in predicting absolute affinities, MM-GBSA is known to perform better than docking for ranking compounds by their binding potential. In this context, an MM-GBSA energy value still reliably indicates stronger predicted binding, even if the numerical values appear extremely higher than typical experimental or docking-derived cutoffs.</p><p>Thus, the two energy values, docking-based and MM-GBSA, serve different purposes in our workflow. Docking scores are used for classification and thresholding, while MM-GBSA energies provide post hoc validation and a higher-resolution comparison of binding strength across compounds.</p><disp-quote content-type="editor-comment"><p>To corroborate their findings, can the authors include direct binding affinity assays for yeast and human Ste2p? This will help in establishing whether the observed phenotypic effects are indeed driven by binding of the metabolites.</p></disp-quote><p>We thank Reviewer #2 for raising these insightful questions. During the experimental design phase, we carefully accounted for validating the impact of metabolites in the rescue response by pheromone.</p><p>We would like to mention that we performed an array of methods to validate our hypothesis and observed similar rescue effects. These assays include:</p><p>a. Cell viability assay (FDA/PI Flourometry- based)</p><p>b. Cell growth assay</p><p>c. FUN1-based microscopy assessment</p><p>d. Shmoo formation assays</p><p>e. Mating assays</p><p>f. Site-directed mutagenesis-based loss of function</p><p>g. Transgenic reporter-based assay</p><p>h. MAPK signaling assessment using Western blot.</p><p>i. And via computational techniques.</p><p>Concerning the in vitro interaction studies of Ste2p and metabolites, we made significant efforts to purify Ste2p by incorporating a His tag at the N-terminal. Despite dedicated attempts over the past year, we were unsuccessful in purifying the protein, primarily due to our limited expertise in protein purification for this specific system. As a result, we opted for genetic-based interventions (e.g., point mutants), which provide a more physiological and comprehensive approach to demonstrating the interaction between Ste2p and the metabolites.</p><p>Furthermore, in addition to the clarification above, we have added the following statement in the discussion section to tone down our claims: “A critical limitation of our study is the absence of direct binding assays to validate the interaction between the metabolites and Ste2p. While our results from genetic interventions, molecular dynamics simulations, and docking studies strongly suggest that the metabolites interact with the Ste2p-Gpa1 interface, these findings remain indirect. Direct binding confirmation through techniques such as surface plasmon resonance, isothermal titration calorimetry, or co-crystallization would provide definitive evidence of this interaction. Addressing this limitation in future work would significantly strengthen our conclusions and provide deeper insights into the precise molecular mechanisms underlying the observed phenotypic effects.”</p><p>We request Reviewer #2 to kindly refer to the assays conducted on the point mutants created in this study, as these experiments offer robust evidence supporting our claims.</p><disp-quote content-type="editor-comment"><p>Did the authors perform expression assays to make sure the mutant proteins were similarly expressed to wt?</p></disp-quote><p>We thank reviewer #2 for this comment. We would like to mention that:</p><p>(1) In our mutants (S75A, T155D, L289K)-based assays, all mutants were generated using integration at the same chromosomal TRP1 locus under the GAL1 promoter and share the same C-terminal CYC1 terminator sequence used for the reconstituted wild-type (rtWT) construct, thus reducing the likelihood of strain-specific expression differences.</p><p>(2) Furthermore, all strains were grown under identical conditions using the same media, temperature, and shaking parameters. Each construct underwent the same GAL1 induction protocol in YPGR medium for identical durations, ensuring uniform transcriptional activation across all strains and minimizing culture-dependent variability in protein expression.</p><p>(3) Importantly, both the rtWT and two of the mutants (T155D, L289K) retained α-factor-induced cell death (PI and FUN1-based fluorometry and microscopy; Figure 4c-d) and MAPK activation (western blot; Figure 4e), demonstrating that the mutant proteins are expressed at levels sufficient to support signalling.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #3 (Recommendations for the authors):</bold></p><p>My comments that would enhance the impact of this method are:</p><p>(1) While the authors have compared the accuracy and efficiency of Gcoupler to AutoDock Vina, one of the main points of Gcoupler is the neural network module. It would be beneficial to have it evaluated against other available deep learning ligand generative modules, such as the following: 10.1186/s13321-024-00829-w, 10.1039/D1SC04444C.</p></disp-quote><p>Thank you for the observation. To clarify, our benchmarking of Gcoupler’s accuracy and efficiency was performed against AutoDock, not AutoDock Vina. This choice was intentional, as AutoDock is one of the most widely used classical techniques in computer-aided drug design (CADD) for obtaining high-resolution predictions of ligand binding energy, binding poses, and detailed atomic-level interactions with receptor residues. In contrast, AutoDock Vina is primarily optimized for large-scale virtual screening, offering faster results but typically with lower resolution and limited configurational detail.</p><p>Since Gcoupler is designed to balance accuracy with computational efficiency in structure-based screening, AutoDock served as a more appropriate reference point for evaluating its predictions.</p><p>We agree that benchmarking against other deep learning-based ligand generative tools is important for contextualizing Gcoupler’s capabilities. However, it's worth noting that only a few existing methods focus specifically on cavity- or pocket-driven de novo drug design using generative AI, and among them, most are either partially closed-source or limited in functionality.</p><p>While PocketCrafter (10.1186/s13321-024-00829-w) offers a structure-based generative framework, it differs from Gcoupler in several key respects. PocketCrafter requires proprietary preprocessing tools, such as the MOE QuickPrep module, to prepare protein pocket structures, limiting its accessibility and reproducibility. In addition, PocketCrafter’s pipeline stops at the generation of cavity-linked compounds and does not support any further learning from the generated data.</p><p>Similarly, DeepLigBuilder (10.1039/D1SC04444C) provides de novo ligand generation using deep learning, but the source code is not publicly available, preventing direct benchmarking or customization. Like PocketCrafter, it also lacks integrated learning modules, which limits its utility for screening large, user-defined libraries or compounds of interest.</p><p>Additionally, tools like AutoDesigner from Schrödinger, while powerful, are not publicly accessible and hence fall outside the scope of open benchmarking.</p><table-wrap id="sa3table1" position="float"><label>Author response table 1.</label><caption><title>Comparison of de novo drug design tools.</title><p>SBDD refers to Structure-Based Drug Design, and LBDD refers to Ligand-Based Drug Design.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="bottom">Tools</th><th valign="bottom">Drug design Type</th><th valign="bottom">Open Source</th><th valign="bottom">Code Availability</th><th valign="bottom">End-to-End Solution</th><th valign="bottom">Command Line support</th></tr></thead><tbody><tr><td align="left" valign="bottom">Gcoupler</td><td align="left" valign="bottom">SBDD+LBDD</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td></tr><tr><td align="left" valign="bottom">Pocket Crafter</td><td align="left" valign="bottom">SBDD</td><td align="left" valign="bottom">Partially</td><td align="left" valign="bottom">Partially</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">Yes</td></tr><tr><td align="left" valign="bottom">DeepLigBuilder</td><td align="left" valign="bottom">SBDD</td><td align="char" char="hyphen" valign="bottom">--</td><td align="left" valign="bottom">No</td><td align="char" char="hyphen" valign="bottom">--</td><td align="char" char="hyphen" valign="bottom">--</td></tr><tr><td align="left" valign="bottom">AutoDesigner</td><td align="left" valign="bottom">LBDD</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">No</td><td align="char" char="hyphen" valign="bottom">--</td><td align="left" valign="bottom">Yes</td></tr></tbody></table></table-wrap><p>In contrast, Gcoupler is a fully open-source, end-to-end platform that integrates both Ligand-Based and Structure-Based Drug Design. It spans from cavity detection and molecule generation to automated model training using GNNs, allowing users to evaluate and prioritize candidate ligands across large chemical spaces without the need for commercial software or advanced coding expertise.</p><disp-quote content-type="editor-comment"><p>(2) In Figure 2, the authors mention that IC4 and IC5 potential binding sites are on the direct G protein coupling interface (&quot;This led to the identification of 17 potential surface cavities on Ste2p, with two intracellular regions, IC4 and IC5, accounting for over 95% of the Ste2p-Gpa1p interface (Figure 2a-b, Supplementary Figure 4j-n)...&quot;). Later, however, in Figure 4, when discussing which residues affect the binding of the metabolites the most, the authors didn't perform MD simulations of mutant STE2 and just Gpa1p (without metabolites present). It would be beneficial to compare the binding of G protein with and without metabolites present, as these interface mutations might be affecting the binding of G protein by itself.</p></disp-quote><p>Thank you for this insightful suggestion. While we did not perform in silico MD simulations of the mutant Ste2-Gpa1 complex in the absence of metabolites, we conducted experimental validation to functionally assess the impact of interface mutations. Specifically, we generated site-directed mutants (S75A, L289K, T155D) and expressed them in a ste2Δ background to isolate their effects.</p><p>As shown in the Supplementary Figure, these mutants failed to rescue cells from α-factor-induced programmed cell death (PCD) upon metabolite pre-treatment. This was confirmed through fluorometry-based viability assays, FUN1 staining, and p-Fus3 signaling analysis, which collectively monitor MAPK pathway activation (Figure 4c–e).</p><p>Importantly, the induction of PCD in response to α-factor in these mutants demonstrates that G protein coupling is still functionally intact, indicating that the mutations do not interfere with Gpa1 binding itself. However, the absence of rescue by metabolites strongly suggests that the mutated residues play a direct role in metabolite binding at the Ste2p–Gpa1p interface, thus modulating downstream signaling.</p><p>While further MD simulations could provide structural insight into the isolated mutant receptor–G protein interaction, our experimental data supports the functional relevance of metabolite binding at the identified interface.</p><disp-quote content-type="editor-comment"><p>(3) While the experiments, performed by the authors, do support the hypothesis that metabolites regulate GPCR signaling, there are no experiments evaluating direct biophysical measurements (e.g., dissociation constants are measured only in silico).</p></disp-quote><p>We thank Reviewer #3 for raising these insightful comments. We would like to mention that we performed an array of methods to validate our hypothesis and observed similar rescue effects. These assays include:</p><p>a. Cell viability assay (FDA/PI Flourometry- based)</p><p>b. Cell growth assay</p><p>c. FUN1-based microscopy assessment</p><p>d. Shmoo formation assays</p><p>e. Mating assays</p><p>f. Site-directed mutagenesis-based loss of function</p><p>g. Transgenic reporter-based assay</p><p>h. MAPK signaling assessment using Western blot.</p><p>i. And via computational techniques.</p><p>Concerning the direct biophysical measurements of Ste2p and metabolites, we made significant efforts to purify Ste2p by incorporating a His tag at the N-terminal, with the goal of performing Microscale Thermophoresis (MST) and Isothermal Titration Calorimetry (ITC) measurements. Despite dedicated attempts over the past year, we were unsuccessful in purifying the protein, primarily due to our limited expertise in protein purification for this specific system. As a result, we opted for genetic-based interventions (e.g., point mutants), which provide a more physiological and comprehensive approach to demonstrating the interaction between Ste2p and the metabolites.</p><p>Furthermore, in addition to the clarification above, we have added the following statement in the discussion section to tone down our claims: “A critical limitation of our study is the absence of direct binding assays to validate the interaction between the metabolites and Ste2p. While our results from genetic interventions, molecular dynamics simulations, and docking studies strongly suggest that the metabolites interact with the Ste2p-Gpa1 interface, these findings remain indirect. Direct binding confirmation through techniques such as surface plasmon resonance, isothermal titration calorimetry, or co-crystallization would provide definitive evidence of this interaction. Addressing this limitation in future work would significantly strengthen our conclusions and provide deeper insights into the precise molecular mechanisms underlying the observed phenotypic effects.”</p><disp-quote content-type="editor-comment"><p>(4) The authors do not discuss the effects of the metabolites at their physiological concentrations. Overall, this manuscript represents a field-advancing contribution at the intersection of AI-based ligand discovery and GPCR signaling regulation.</p></disp-quote><p>We thank reviewer #3 for this comment and for recognising the value of our work. Although direct quantification of intracellular free metabolite levels is challenging, several lines of evidence support the physiological relevance of our test concentrations.</p><p>- Genetic validation supports endogenous relevance: Our genetic screen of 53 metabolic knockout mutants showed that deletions in biosynthetic pathways for these metabolites consistently disrupted the α-factor-induced cell death, with the vast majority of strains (94.4%) resisting the α-factor-induced cell death, and notably, a subset even displayed accelerated growth in the presence of α‑factor. This suggests that endogenous levels of these metabolites normally provide some degree of protection, supporting their physiological role in GPCR regulation.</p><p>- Metabolomics confirms in vivo accumulation: Our untargeted metabolomics analysis revealed that α-factor-treated survivors consistently showed enrichment of CoQ6 and zymosterol compared to sensitive cells. This demonstrates that these metabolites naturally accumulate to protective levels during stress responses, validating their biological relevance.</p></body></sub-article></article>